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ABSTRACT 
Transplantation is currently the only form of treatment for many blinding diseases 
caused by opacity of the cornea. Corneal graft rejection is the single most important 
reason for corneal graft failure and survival rates have not improved over the decades.  
 
Alternative investigative interventions have been studied in experimental models of 
corneal transplantation for many years. IDO catabolises tryptophan and as a 
consequence of this and the production of tryptophan catabolites (kynurenines) 
downregulates T cell responses. Overexpression of IDO by virus-mediated cDNA 
transfer to donor cornea ex vivo prior to transplantation prolongs graft survival.  
 
As the overall objective of this project was to develop IDO or kynurenines as 
potential therapeutic targets for preventing corneal allograft rejection, the first part of 
this thesis examined potential methods of upregulation of IDO expression in the 
cornea, concentrating on the effect of UVB exposure on IDO expression. 
Upregulation of IDO at the mRNA level but not the protein or functional level was 
demonstrated in response to UVB exposure. 
The second part of this thesis examined whether kynurenines could mimic the effect 
of IDO in prolonging corneal graft survival. It was demonstrated that the effect of 
IDO overexpression in delaying graft rejection could be replicated by both the 
systemic and local administration of kynurenines. Furthermore the potential 
mechanism of action of this observed effect was investigated at the in vitro and in 
vivo levels with kynurenines demonstrating selective T cell cytotoxicity in vitro as 
well as local and systemic depletion of lymphocyte counts after both local and 
systemic administration of kynurenines respectively. 
 
Given the potential of using kynurenines as a therapeutic strategy in patients, the third 
part of this thesis examined the effect of a commercially available tryptophan 
metabolite- Tranilast- on allograft survival. Significant prolongation in graft survival 
was observed and the potential mechanisms of action of this drug were analysed. 
Tranilast inhibited T cell proliferation through cell cycle arrest as a result of 
upregulation of p21 and p15 (cell cycle inhibitors) and downregulation of Cyclin E. 
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An associated reduction in IL-2 production was also observed allowing us to 
characterise a novel mechanism for Tranilast induced CD4+ T cell anergy. 
 
Further to emerging evidence indicating a role for the aryl-hydrocarbon receptor 
(AhR) in CD4 T cell differentiation and a tryptophan photo-product as a ligand of the 
AhR, the fourth part of this thesis examined the potential of kynurenines (3-
hydroxykynurenine-3HK) as well as Tranilast as agonists of the AhR. 3HK and 
Tranilast were found to activate the AhR and the downstream signalling pathway. 
 
Collectively, the data represented in this thesis helps to explain the effects of IDO and 
kynurenines in prolonging corneal allograft survival and helps to shed light on the 
direct immunoregulatory mechanism of IDO and kynurenines. The identification of a 
commercially available drug effective in prolonging corneal allograft survival may 
prove a useful adjunct or alternative to topical corticosteroids that can be transferred 
from the laboratory to clinical practice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 7 
TABLE OF CONTENTS 
 
Title   2 
Acknowledgements   3 
Statement of originality   4 
Abstract   5 
Table of contents   8 
List of figures   20 
List of tables   23 
Abbreviations   24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 8 
CHAPTER 1  GENERAL INTRODUCTION 27 
1.1  Corneal Transplantation 28 
1.2  Corneal Structure and Anatomy 29 
1.3  Immune Privilege in Corneal Transplantation 30 
 
1.3.1 Immunological ignorance 31 
 
1.3.2 Immune deviation 33 
 
1.3.3 Suppression of immune responsiveness 33 
1.4  Corneal Graft Rejection 34 
 
1.4.1 Site of antigen presentation in corneal 
transplantation 
35 
 
1.4.2 Presentation of cornea-derived alloantigen 36 
 
1.4.3 T cell recognition of a corneal allograft 37 
 
1.4.4 Contribution of direct and indirect T cell 
alloreactivity during corneal allograft rejection 
38 
 
1.4.5 Histocompatibility antigen matching in corneal 
transplantation 
44 
 
1.4.6 Effector mechanisms in corneal allograft rejection 45 
 
1.4.7 Role of Th17 cells in allograft rejection 49 
 
1.4.7.1 Defining T cell subets 49 
 
1.4.7.2 Transcriptional regulation of Th17 cell 
differentiation 
50 
 
1.4.7.3 AhR and Th17 cells 51 
 
1.4.7.4 Effector function of IL-17 52 
 
1.4.7.5 Evidence for role of Th17 cells in allograft 
rejection 
52 
 
1.4.8 Therapeutic immune modulation in corneal 
transplantation 
55 
1.5  Indoleamine 2,3-dioxygenase (IDO) 57 
 
1.5.1 Tryptophan 58 
 
1.5.2 The kynurenine pathway 60 
 
1.5.3 Discovery of IDO 62 
 
1.5.3.1 The INDO gene 62 
 
1.5.3.2 Induction of expression by IFNγ 62 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 9 
 
1.5.3.3 Induction of expression by CTLA-4 63 
 
1.5.3.4 Cytokine inhibitors 64 
 
1.5.4 Structure and expression of IDO 64 
 
1.5.5 Regulation of enzyme activity 65 
 
1.5.6 IDO-mediated immunoregulatory effects 67 
 
1.5.6.1 Tryptophan depletion 67 
 
1.5.6.2 Immune modulation by tryptophan catabolites 69 
 
1.5.7 IDO2 71 
 
1.5.7.1 The INDOL1 gene 71 
 
1.5.7.2 Structure and expression of IDO2 72 
 
1.5.8 IDO and the eye 73 
 
1.5.9 IDO in allograft rejection 74 
 
1.5.10 Kynurenines and their therapeutic application 76 
 
1.5.10.1 Tranilast 77 
1.6  Aims, Approaches and Hypotheses of study 79 
 
1.6.1 Does ultraviolet light influence IDO expression in 
the cornea? 
79 
 
1.6.2 What is the effect of tryptophan catabolites on 
corneal allograft survival and how do they 
prolong survival? 
80 
 
1.6.3 The effect of IDO expression and kynurenines on 
corneal endothelial cell function? 
81 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 10 
CHAPTER 2  MATERIALS AND METHODS 83 
2.1  Cell Lines 84 
 
2.1.1 Murine corneal endothelial cell lines, MCEC 84 
 
2.1.2 Canine osteosarcoma cells, D17 84 
 
2.1.3 293 Human embryonic kidney cells, 293 HEK 84 
 
2.1.4 Chinese hamster ovary cells (CHO) cells 85 
 
2.1.5 Freezing cells 85 
 
2.1.6 Thawing cells 85 
2.2  Exogenous Treatment of MCEC 85 
 
2.2.1 Cytokine stimulation of MCEC 85 
 
2.2.2 Induction of apoptosis 86 
 
2.2.3 EIAV lentiviral transduction of MCEC 86 
 
2.2.4 UVB irradiation of MCEC 86 
2.3  RNA extraction, cDNA synthesis and Real 
time RT-PCR 
86 
 
2.3.1 RNA extraction from mouse corneas 86 
 
2.3.2 Use of quantitative real time RT-PCR for 
determination of viral titre 
87 
2.4  Immunoblot Analysis 89 
 
2.4.1 Protein extraction and SDS treatment 89 
 
2.4.2 SDS Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
89 
 
2.4.3 Western blotting 90 
 
2.4.4 Immunodetection 90 
2.5  L-Kynurenine Assay 91 
2.6  Flow Cytometry 91 
 
2.6.1 Cell surface staining 91 
 
2.6.2 Intracellular staining 93 
 
2.6.3 Calculation of absolute cell counts from spleen, 
peripheral blood and draining lymph node (DLN) 
94 
 
2.6.4 Annexin V and 7-Amino-Actinomycin (7AAD) 
staining 
94 
2.7  Bacterial Transformation 94 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 11 
2.8  Plasmid Isolation 95 
2.9  Replication-Defective Lentivirus Production, 
Titration and Transduction 
95 
 
2.9.1 Titration of lentiviral stocks 96 
2.10  Fluorescence Microscopy 96 
2.11  Generation and Culture of Murine Bone 
Marrow-derived Dendritic cells 
97 
 
2.11.1 Culture of GM-CSF-producing hybridoma 98 
2.12  Murine T cell Proliferation Assays and DC:T 
cell cocultures 
98 
 
2.12.1 Murine CD4+ T cell proliferation 98 
 
2.12.2 Preparation of splenocytes 99 
 
2.12.3 T cell proliferation assays 99 
 
2.12.4 Two-stage MLR (Rechallenge assays) for 
induction of anergy 
99 
2.13  Peripheral Blood Collection from Mouse Tail 
Vein 
100 
2.14  Tryptophan Metabolites 100 
2.15  Kynurenine Treatment of Graft Recipients 100 
2.16  Tranilast (3,4-DAA) 100 
2.17  Animals 101 
2.18  Orthotopic Corneal Transplantation 101 
2.19  Grading of Clinical Findings Used in Diagnosis 
of Graft Rejection 
102 
2.20  Preparation of Mouse Corneas for Histological 
Sections 
102 
2.21  Haematoxylin and Eosin (H&E) 102 
2.22  Immunohistochemistry 103 
2.23  Preparation of Mouse Corneas for Flow 
Cytometry 
103 
2.24  ELISA for IL-2 Cytokine Production 103 
2.25  Th17 Polarisation of Naïve CD4 T cells 104 
 
2.25.1 Isolation of Naïve CD4 T cells 104 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 12 
 
2.25.2 Th17 polarisation 104 
2.26  Skin Transplantation 105 
2.27  Statistical Analysis 106 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 13 
CHAPTER 3  EFFECT OF UVB IRRADIATION ON IDO 
EXPRESSION IN THE CORNEA 
107 
3.1  Introduction 108 
 
3.1.2 Chapter aims 109 
3.2  Results 110 
 
3.2.1 Upregulation of IDO mRNA in corneal 
endothelial cells post UVB irradiation 
110 
 
3.2.2 UVB irradiation of MCEC did not upregulate 
IDO expression an the protein level 
111 
 
3.2.3 UVB irradiation of MCEC did not result in any 
functional activity of IDO 
112 
 
3.2.4 Effect of UVB irradiation of MCEC on T cell 
proliferation 
115 
 
3.2.5 Effect of UVB irradiation on MCEC phenotype 116 
 
3.2.6 Determination of corneal IDO2 expression 117 
3.3  Discussion 118 
 
3.3.1 Chapter summary 119 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 14 
CHAPTER 4  MURINE CORNEAL TRANSPLANTATION 
MODEL 
120 
4.1  Introduction 121 
 
4.1.1 Animal models of experimental corneal 
transplantation 
121 
 
4.1.2 The mouse model of corneal transplantation 121 
 
4.1.3 Chapter aims 123 
4.2  Results 124 
 
4.2.1 Mouse eyes 124 
 
4.2.2 Histology of the mouse cornea 124 
 
4.2.3 Step-by-step corneal transplantation method 126 
 
4.2.4 Grading of corneal grafts 130 
 
4.2.5 Mouse corneal allograft survival: syngeneic 
versus allogeneic 
132 
 
4.2.6 Histology of syngeneic and allogeneic corneal 
transplants 
133 
4.3  Discussion 134 
 
4.3.1 Development of the mouse model of corneal 
transplantation 
134 
 
4.3.2 Grading of corneal transplantation 134 
 
4.3.3 Definition of irreversible graft rejection 135 
 
4.3.4 Allograft survival 135 
 
4.3.5 Histology of rejection 135 
 
4.3.6 Chapter summary 136 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 15 
CHAPTER 5  EFFECT OF TRYPTOPHAN 
METABOLITES ON CORNEAL GRAFT 
SURVIVAL 
137 
5.1  Introduction 138 
 
5.1.1 Chapter aims 138 
5.2  Results 139 
 
5.2.1 Isolation of CD4+ T cells 139 
 
5.2.2 T cell stimulation and expansion using anti 
CD3/CD28 beads 
140 
 
5.2.3 The trytophan metabolites 3HK and 3HAA 
inhibit murine T cell proliferation in vitro 
141 
 
5.2.4 3HK and 3HAA induce CD4+ T cell death 142 
 
5.2.5 Tryptophan metabolites induce a T regulatory 
cell phenotype from the whole CD4+ T cell 
population 
144 
 
5.2.6 Tryptophan metabolites do not alter DC 
function or phenotype 
147 
 
5.2.7 Effect of IDO expression and kynurenines on 
corneal endothelial cell biology 
150 
 
5.2.7.1 Effect of kynurenines on MCEC viability 150 
 
5.2.7.2 Effect of IDO expression on MCEC viability 155 
 
5.2.7.2.1 Self-inactivating lentivirus production using a 
three-plasmid cotransfection technique and 
highly efficient transduction of an immortalised 
cell line 
155 
 
5.2.7.2.2 Lentivirus titration by real time (quantitative 
PCR) and fluorescence microscopy 
157 
 
5.2.7.2.3 Confirmation of functional IDO activity 160 
 
5.2.7.2.4 Effect of IDO expression on MCEC viability 161 
 
5.2.7.3 Effect of kynurenines and IDO expression on 
MCEC phenotype 
162 
 
5.2.8 Systemic administration of 3HK prolongs 
murine corneal allograft survival 
164 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 16 
 
5.2.9 Systemic administration of 3HK results in 
depletion of both splenic and peripheral blood 
lymphocytes 
165 
 
5.2.10 Topical administration of 3HK results in 
prolongation of corneal allograft survival 
167 
5.3  Discussion 171 
 
5.3.1 Chapter summary 174 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 17 
CHAPTER 6  EFFECT OF N-(3,4-
DIMETHOXYCINNAMONYL) 
ANTHRANILIC ACID (TRANILAST) ON 
CORNEAL ALLOGRAFT SURVIVAL 
175 
6.1  Introduction 176 
 
6.1.1 Chapter aims 176 
6.2  Results 177 
 
6.2.1 Tranilast inhibits murine T cell proliferation in 
vitro 
177 
 
6.2.2 Tranilast does not induce T cell death 178 
 
6.2.3 Tranilast can induce Treg development from the 
whole CD4+ T cell population 
179 
 
6.2.4 Cell cycle arrest in T cells cultured with 
Tranilast 
180 
 
6.2.5 Cell cycle arrest in CD4+ T cells cultured with 
Tranilast is associated with reduced IL-2 
production 
185 
 
6.2.6 Tranilast does not induce donor alloantigen 
specific tolerance in vivo 
186 
 
6.2.6.1 Optimisation of rechallenge assays for the 
detection of in vivo generated allogeneic T cell 
responses 
186 
 
6.2.6.2 Tranilast fails to induce donor alloantigen 
specific T cell anergy in vivo 
188 
 
6.2.7 Systemic administration of Tranilast results in 
prolongation of corneal allograft survival 
190 
 
6.2.8 Systemic administration of Tranilast results in 
prolongation of skin allograft survival 
193 
6.3  Discussion 195 
 
6.3.1 Chapter summary 197 
 
   
 
   
 
   
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 18 
CHAPTER 7  KYNURENINES, THE ARYL-
HYDROCARBON RECEPTOR AND Th17 
CELLS 
198 
7.1  Introduction 199 
 
7.1.1 Chapter aims 200 
7.2  Results 201 
 
7.2.1 Corneal IL-17 expression is upregulated in 
corneal allograft rejection 
201 
 
7.2.2 Kynurenines and Tranilast act as AhR agonists, 
inducing AhR signalling transduction pathwyas 
204 
7.3  Discussion 211 
 
7.3.1 Chapter summary 213 
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
 
   
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 19 
CHAPTER 8  GENERAL DISCUSSION 214 
8.1  Introduction 215 
8.2  Summary of Major Findings 216 
8.3  Discussion of the Major Findings 216 
 
8.3.1 The effect of kynurenines on corneal graft 
survival 
216 
 
8.3.2 The effect of Tranilast on allograft survival 218 
 
8.3.3 Kynurenines, the Aryl-hydrocarbon receptor and 
Th17 cells 
219 
8.4  Future Strategies 220 
 
8.4.1 Future possibilities with kynurenines in corneal 
transplantation 
220 
 
8.4.2 Future possibilities with Tranilast 221 
 
8.4.3 Evolving understanding of the AhR pathway and 
its ligands 
221 
 
8.4.4 Conclusion 221 
Presentations and 
Publications 
  223 
 
   
CHAPTER 9  REFERENCES 226 
 
   
 
   
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 20 
LIST OF FIGURES 
 
Figure 1 Anatomical representation of the eye 30 
Figure 2 Direct and indirect pathway of allorecognition 38 
Figure 3 The semi-direct pathway of allorecognition 43 
Figure 4 The CD4+ T cell is the key cell for inducing corneal graft rejection 48 
Figure 5 AhR ligands 54 
Figure 6 The B7.1/B7.2/CTLA-4 superfamily members 57 
Figure 7 Catabolic pathways of Trp 59 
Figure 8 The Kyn pathway of trp metabolism 61 
Figure 9 Structure of Tranilast and selected kynurenines 76 
Figure 10 Validation of IDO real time RT-PCR 110 
Figure 11 IDO mRNA expression in UVB exposed MCEC samples 111 
Figure 12 IDO protein expression in UVB exposed MCEC samples 112 
Figure 13 Effect of UVB exposure on IDO activity 24 hrs post exposure 113 
Figure 14 Effect of UVB exposure on IDO activity at varying time points post 
exposure 
114 
Figure 15 Effect of single and repeated doses of UVB exposure on IDO 
activity 
114 
Figure 16 Effect of UVB irradiation of MCEC on T cell proliferation 115 
Figure 17 Effect of UVB irradiation on MCEC phenotype 116 
Figure 18 Corneal IDO2 expression 117 
Figure 19 Photograph of a rejected corneal allograft in a BALB/c mouse 122 
Figure 20 Histological appearance of a normal human eye 125 
Figure 21 Histological appearance of a normal BALB/c mouse eye 125 
Figure 22 Histological appearance of a normal BALB/c cornea 126 
Figure 23 Orthotopic mouse corneal allograft at day 7 129 
Figure 24 Clinical scoring system for orthotopic corneal grafts 131 
Figure 25 Kaplan-Meier survival of mouse syngeneic and allogeneic corneal 
transplants 
132 
Figure 26 Histology of corneal transplants 133 
Figure 27 Purification of murine spleen-derived CD4+ T cells 139 
Figure 28 Capacity of anti CD3/CD28 beads to stimulate CD4+ T cells 140 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 21 
Figure 29a Effect of kynurenines on T cell proliferation 141 
Figure 29b Effect of kynurenines on T cell proliferation in a mixed lymphocyte 
response 
142 
Figure 30 Effect of kynurenines on T cell viability 143 
Figure 31 FoxP3 expression in CD4+ T cells cultured with kynurenines 145 
Figure 32 FoxP3 expression in CD4+ T cells cultured with kynurenines 146 
Figure 33 Effect of 3HK on the phenotype of both immature and mature bone 
marrow-derived dendritic cells 
147 
Figure 34 Effect of kynurenines on the phenotype of both immature and 
mature bone marrow-derived dendritic cells 
148 
Figure 35 Effect of kynurenines on capacity of dendritic cells to stimulate 
allogeneic CD4+ T cells in a mixed lymphocyte response 
149 
Figure 36 Effect of kynurenines on DC viability 150 
Figure 37 Effect of kynurenines on MCEC viability 152 
Figure 38 Effect of kynurenines on apoptosis of stressed MCEC 153 
Figure 39 Effect of kynurenines on apoptosis of stressed MCEC 154 
Figure 40 IDO EIAV Lentiviral construct (pSMART2G) 155 
Figure 41 Self-inactivating EIAV Lentivirus production 156 
Figure 42 Lentivirus titration by real time (quantitative) PCR and fluorescence 
microscopy 
159 
Figure 43 Expression of functional IDO in transduced cells 160 
Figure 44 Effect of IDO and GFP expression on MECE viability 161 
Figure 45 Effect of kynurenine administration on MCEC phenotype 162 
Figure 46 Effect of IDO expression on MCEC phenotype 163 
Figure 47 Effect of systemic 3HK administration on corneal allograft survival 165 
Figure 48 Splenic and peripheral blood analysis after daily i.p. administration 
of 3HK 
166 
Figure 49 Effect of daily topical administration of 3HK on murine corneal 
allograft survival 
168 
Figure 50 FoxP3 mRNA expression in rejected corneal grafts 169 
Figure 51 Splenic, peripheral blood and draining lymph node analysis after 
daily topical administration of 3HK 
170 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 22 
Figure 52 Effect of Tranilast on CD4+ T cell proliferation 177 
Figure 53 Effect of Tranilast on T cell viability 178 
Figure 54 FoxP3 expression in CD4+ T cells cultured with Tranilast 179 
Figure 55 Relative FoxP3 expression in CD4+ T cells cultured with Tranilast 180 
Figure 56 Cell cycle arrest in CD4+ T cells cultured with Tranilast 184 
Figure 57 Production of IL-2 in Tranilast treated T cell assays 185 
Figure 58 Optimisation of rechallenge assays for the detection of in vivo- 
generated allogeneic T cell responses 
187 
Figure 59 Tranilast fails to induce donor-alloantigen specific T cell anergy in 
vivo 
189 
Figure 60 Effect of systemic Tranilast administration on corneal allograft 
survival 
190 
Figure 61 Tranilast treatment delays onset of allograft rejection as well as 
delaying the onset of vascularisation of recipient and donor corneas 
192 
Figure 62 Effect of systemic Tranilast administration on skin allograft survival 194 
Figure 63 IL-17A expression in cornea 202 
Figure 64 Corneal IL-17A expression in IL-17 KO vs WT mice 203 
Figure 65 Th17 polarisation of Naïve CD4+ T cells 206 
Figure 66 3HK and Tranilast act as AhR agonists utilising the AhR signalling 
pathway 
210 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 23 
LIST OF TABLES 
Table 1 Immunoregulatory elements that contribute to the immune 
privileged status of the eye 
34 
Table 2 Primers used in real time RT-PCR analysis 88 
Table 3 List of primary antibodies for cell surface staining 92 
Table 4 List of secondary antibodies for cell surface staining 93 
Table 5 List of fluorochrome-conjugated antibodies used for intracellular 
staining 
93 
Table 6 Clinical scoring system for corneal allografts 130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 24 
ABBREVIATIONS 
ACAID: Anterior chamber associated immune deviation 
AhR: Aryl-hydrocarbon receptor 
APC: Antigen presenting cell 
bHLH-PAS: Basic helix loop helix- Per-Ant-Sim 
BM-DC: Bone marrow-derived dendritic cell 
α-MSH: α-melanocyte stimulating hormone 
bp: Base pair (of DNA) 
BSA: Bovine serum albumin 
BSS: Balanced salt solution 
CD: Cluster of differentiation 
cDNA: Complimentary deoxyribonucleic acid 
CGRP: Calcitonin gene-related peptide 
CHO: Chinese hamster ovary cell 
CIA: Collagen induced arthritis 
cpm: Counts per minute 
CRP: Complement regulatory proteins 
DC: Dendritic cell 
D17: Canine osteosarcoma cell 
DMEM: Dulbecco’s modified eagle medium 
DMSO: Dimethyl sulfoxide 
dNTP: Deoxyribonucleoside triphosphate 
dsRNA: double-stranded RNA 
EAE: Experimental autoimmune encephalomyelitis 
EDTA: Ethylene-diamine-tetracetic-acid 
EIAV: Equine infectious anaemia virus 
ELISA: Enzyme linked immunoabsorbent assay 
FACS: Fluorescence activated cell sorting 
Fc: Fragment of crystallisation 
FCS: Foetal calf serum 
FITC: Fluorescein isothiocyanate 
GM-CSF: Granulocyte-macrophage colony stimulating factor 
HEPES: N-(2-hydroxyethyl) piperazine-N-(2-ethanesulphonic acid) 
3HK: 3-hydroxykynurenine 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 25 
3HAA: 3-hydroxyanthranilic acid 
293-HEK: Human embryonic kidney cell 
HLA: Human leucocyte antigen 
HRP: Horseradish peroxidase 
IDO: Indoleamine 2,3-dioxygenase 
IFNγ: Interferon gamma 
Ig: Immunoglobulin 
IMDM: Iscove’s modified dulbecco’s medium 
IL: Interleukin 
IU: International units 
kDa: Kilodaltons 
KO: Knockout 
Kyn: L-Kynurenine 
LPS: Lipopolysaccharide 
mAb: Monoclonal antibody 
M: Molar 
MCEC: Murine corneal endothelial cells 
MHC: Major histocompatability (H) complex 
MIP: Macrophage inflammatory protein 
MLR: Mixed lymphocyte reaction 
mRNA: Messenger ribonucleic acid 
MW: Molecular weight 
N-(3,4 DAA): N-3,4-dimethoxycinnamonyl anthranilic acid (Tranilast) 
NK: Natural Killer cell 
OD: Optical density 
PAGE: Polyacrylamide gel electrophoresis 
PBS: Phosphate buffered saline 
PCR: Polymerase chain reaction 
QA: Quinolinic acid 
RNA: Ribonucleic acid 
rpm: Revolutions per minute 
RT-PCR: Reverse transcriptase polymerase chain reaction 
SD: Standard deviation 
SDS: Sodium dodecyl sulphate 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 26 
SOM: Somatostatin 
TCR: T cell receptor 
TNFα: Tumour necrosis factor alpha 
Tris: Tris (hydroxymethyl) aminomethane 
Tween 20: Polyoxyethylene-sorbitan monolaurate 
µg: Microgram 
µM: Micromolar 
UV: Ultraviolet radiation 
VIP: Vasoactive intestinal peptide 
TGFβ: Transforming growth factor beta 
Trp: Tryptophan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 27 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1: GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 28 
1.1. Corneal Transplantation 
The concept of being able to replace an opaque cornea has been the aspiration of 
surgeons for as long as the practice of ophthalmology has existed. The first historical 
records of techniques describing the treatment of corneal scars were found in 
Egyptian manuscripts dating over 4000 years ago (Albert and Edwards, 1996). In 130-
200AD, Galen was the first to describe a surgical procedure for the treatment of ulcers 
and scars on the ‘transparent membrane’ suggesting superficial keratectomy and 
‘abrasio corneae’ as procedures to restore the transparency of an opaque cornea 
(Albert and Edwards, 1996). It was not until the first microscopic observations 
became available in the 18th century, resulting in better understanding of corneal 
anatomy and physiology that any progress was made in the treatment of corneal 
disorders. Interestingly, it was an idea put forward by Erasmus Darwin, the 
grandfather of Charles Darwin where he suggested the complete removal of an 
opaque cornea by trephination: ‘Could not a small piece of cornea be cut out by a kind 
of trephine about the size of a thick bristle, or a small crow quill, and would it not heal 
with a transparent scar?’ that has led to a procedure almost similar to the modern 
technique of corneal transplantation (Albert and Edwards, 1996). It took decades of 
trial and error before the first successful human corneal graft was performed by Dr. 
Eduard Zirm in 1905 (Moffatt et al., 2005). Despite this significant milestone, it was 
several more decades before Zirm’s success was finally achieved this mainly being 
due to parallel advances in anaesthesia and aseptic techniques.  
Several reports on large series of corneal grafts in the early 1930s indicated success 
rates of 20-40% despite the lack of any form of immunosuppressive treatment 
(Moffatt et al., 2005). With the introduction of topical glucocorticoid treatment, the 
one year graft survival rate increased to over 90% (Williams et al., 1995, Price et al., 
1993, Thompson et al., 2003, Randleman and Stulting, 2006). Corneal transplantation 
has become the most commonly performed surgical procedure in transplantation 
medicine with estimates of more than 60,000 transplants performed world-wide every 
year (1988). The excellent one–year graft survival rate, the fact that corticosteroid 
drops are not often perceived as an immunosuppressive treatment and the 
indiscriminate use of the term ‘immune privilege’ have led to a common 
misconception that corneal grafts do not or only rarely undergo transplant rejection. 
However, the reality is quite different. In a large corneal graft follow-up study the 
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Australian Corneal Graft registry, which now contains prospectively-collected data 
from more than 10,000 patients with corneal grafts has shown that the five and ten 
year corneal graft survival rates are only 74% and 62%, respectively (Coster and 
Williams, 2005). As elegantly put by Coster and Williams; ‘we have now amassed 
more than a century’s worth of experience in transplantation of the cornea, making it 
the oldest procedure in transplant surgery and representative of a milestone in human 
medicine. However, there are still limitations to corneal transplantation, of which 
corneal allograft rejection poses the greatest challenge’ (Coster and Williams, 2005). 
 
1.2. Corneal Structure and Anatomy 
The cornea is the clear, dome shaped structure at the front of the eye, lying between 
the environment-protective conjunctiva and the aqueous humour of the anterior 
chamber (Figure 1a). The tissue’s main function is to refract light as it passes into the 
eye to the retina. Its avascularity contributes to the corneas transparency and is a vital 
component in maintaining clarity of vision. The cornea, which is usually 0.5-0.7 mm 
in thickness, can expand to > 1 mm during rejection-induced inflammation or 
damage, and is indicative of graft failure. 
The cornea consists of five layers- the epithelium, Bowman’s layer, the stroma, 
Descemet’s membrane and the endothelium (Figure 1b). The epithelium comprises a 
6-7 cell thick stratified squamous layer on the exterior of the cornea and provides a 
protective barrier against the environment and pathogens. Epithelial cell loss and 
damage can be recovered by migration and replacement of epithelial cells from the 
peripheral limbus. The stroma forms the majority of the tissue and is composed of a 
highly organised arrangement of collagen fibrils and differentiated fibroblasts or 
keratocytes aligned parallel to the corneal surface. The orderly arrangement of stromal 
components and the state of corneal hydration are both essential for determining the 
transparency and visual clarity of the cornea. Similar to the epithelium, fibroblast 
migration, replication and differentiation replace keratocyte loss upon stromal 
damage. Immune mediated rejection of corneal allografts can occur in the epithelial, 
stromal and endothelial cell layers. While epithelial rejection involves the anterior 
layer of the cornea, stromal rejection is associated with the migration of leucocytes 
through this layer. In endothelial rejection, endothelial cells are destroyed as a result 
of alloreactive cells passing through the anterior chamber and adhering to the 
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endothelial surface. This mechanism of rejection has the greatest impact on stability 
and function of the graft as any damage to endothelial cells is irreversible due to the 
cells being non-replicative (George and Larkin, 2004). Immune-mediated rejection of 
the corneal endothelial cell layer is the most common pathological cause of corneal 
allograft failure (Bourne et al., 2001). 
 
 
 
Figure 1. Anatomical representation of the eye 
(a) A simple anatomical description of the eye, depicting the structural location of the 
cornea. Image courtesy of www.wuphysicians.wustl.edu accessed 16.03.10. (b) Cross 
sectional view of the corneal cellular layers- Epithelium, Bowman’s membrane, 
Stroma, Descemet’s membrane and the corneal endothelial monolayer. Image 
courtesy of www.bu.edu/histology/p/08002loa.htm accessed 16.05.11. 
 
1.3 Immune Privilege in Corneal Transplantation 
The fact that 20-30% of human corneal allografts survived in the 1930’s without any 
form of immunosuppressive treatment (Price et al., 1993, Williams et al., 1995) is an 
immunological feature which is unparalleled in other fields of transplantation. 
Therefore, a corneal graft is commonly referred to as an immune-privileged tissue 
transplanted to an immune privileged site. Immune-privileged tissues, such as the 
cornea, testis, ovary, cartilage and tumours are tissues which, when grafted to non-
privileged sites of the body, experience prolonged survival (Thiel et al., 2003). 
Immune privileged sites are organs or tissues such as the eye, the brain, the pregnant 
uterus or tumours, in which non-privileged tissue grafts experience prolonged survival 
(Streilein, 2003a, Streilein, 1993).  
(a) 
 
(b) 
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Many factors contribute to the immune privilege of the ocular site and at the same 
time contribute to the immune privilege of the corneal tissue. However, it is also 
important to note that immune privilege does not prevent immune responses and can 
be overstated (Williams and Coster, 1997). Nevertheless it is clear that there are 
mechanisms present that prevent or attenuate the allogeneic response to donor cornea. 
These include mechanisms that contribute to privilege by making the immune system 
ignorant of the presence of a graft, mechanisms that deviate the immune response into 
a non-destructive pathway and those that suppress immune mechanisms that do 
manage to penetrate the graft (George and Larkin, 2004). 
 
1.3.1 Immunological ignorance 
The concept of ocular immune privilege and the importance of the absence of blood 
vessels in maintaining privilege originated from Medawar’s famous experiments 
(Billingham et al., 1951). In these experiments he showed that skin grafts, which 
would otherwise have become rejected quickly, survived after being transplanted into 
a corneal pocket or into the anterior chamber of the eye, as long as grafts did not 
become vascularised.  
Maumenee, then went on to demonstrate that rabbits with long-surviving avascular 
corneal grafts rejected secondary skin grafts in the same time frame as rabbits without 
corneal grafts, indicating that corneal grafts transplanted into avascular corneal beds 
did not sensitise recipient animals (Maumenee, 1951). In the same experiment, he 
showed that corneal avascularity did not result in immune ignorance, as long term 
surviving corneal grafts became rejected when recipients rejected their skin grafts. 
Together his findings suggested that corneal avascularity enabled a local immune-
modulating mechanism (this lack of blood inflow prevents immune effector cells from 
accessing corneal antigens) to enhance acceptance of corneal grafts, but that this 
immune privilege could be broken even without the presence of blood vessels in the 
host cornea. Blood vessels in the recipient cornea are easy to detect clinically but the 
same stimuli that result in neovascularisation also result in proliferation of lymph 
vessels and migration of APC into the host central cornea, which is normally devoid 
of lymph vessels and APC (Rodrigues et al., 1981, Jager, 1992). More recently, 
Cursiefsen et al. have demonstrated that in addition to corneal haemangiogenesis in 
high-risk corneas, the presence of pathological and clinically non-invisible corneal 
lymphatic vessels in human vascularised high-risk corneas (Cursiefen et al., 2002). 
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Immunologically, these lymphatic vessels act as the afferent arm of the immune reflex 
circle enabling direct access of donor-derived APC and antigenic material to the 
regional lymph node, where an immune response is mounted. It has been shown that 
corneal haem- and lymphangiogenesis occurring before or after keratoplasty 
significantly increase the risk of immune rejection (Bachmann et al., 2008, Cursiefen 
et al., 2004). 
Specific markers to identify lymphatic vessels in the cornea were, until recently 
unknown. A number of studies have identified several molecular markers with good 
lymphatic specificity helpful in studies of corneal lymphangiogenesis (Baluk and 
McDonald, 2008). Hong et al. showed that one of the first signs that indicated 
lymphangiogenesis had begun and which induced the transformation of venous 
endothelial cells to a lymphatic phenotype is expression of the prospero-related 
homeobox-1 (Prox 1) gene (Hong et al., 2002), which lymph vessels continue to 
express in their nuclei. Karpanen et al. demonstrated that the vascular endothelial 
growth factor receptor 3 (VEGFR-3) gene, also important in lymphangiogenesis, 
remains present in lymphatic endothelial cells, and although present in early 
development of blood vessels, its expression becomes more lymphatic specific with 
further development (Karpanen et al., 2006). VEGF-C, The ligand of VEGFR-3, has 
been shown to be present in the lining of the corneal lymphatics (Karkkainen et al., 
2004). However, like other VEGF species, its expression is not confined to haem and 
lymph vessels; being present also in inflammatory cells that may infiltrate the cornea. 
Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE-1) has been used 
extensively as a marker for lymphatic endothelium in the cornea (Cursiefen et al., 
2002). Its expression is not as specific in larger collecting lymphatics and can be 
expressed by other immune cells, such as dendritic cells and macrophages. Therefore, 
it appears that corneal lymphangiogenesis is very much linked to haemangiogenesis 
but each process has its own partially distinct molecular mechanisms. Together they 
serve as a significant means of disrupting the corneal immune privilege, however a 
very recent study showed the greater influence of lymphangiogenesis in mediating 
immune rejection after corneal transplantation (Dietrich et al., 2010). Studies 
investigating the effects of inhibitors of lymphangiogenesis, such as VEGF-tyrosine 
kinase inhibitor- ZK 261991, result in improved corneal allograft survival (Hos et al., 
2008). 
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The lack of conventional dendritic cells in normal cornea is a component of ocular 
immune privilege and if for example, the number of dendritic cells in the graft is 
increased, by experimental induction of APC migration into donor cornea prior to 
transplantation, or by transplantation of peripheral donor cornea, then rejection is 
more rapid (Ross et al., 1991).  
 
1.3.2 Immune deviation 
Immune deviation, frequently termed anterior chamber acquired immune deviation 
(ACAID), describes the phenomenon whereby introduction of antigen into the 
anterior chamber of the eye can induce systemic, antigen-specific immune deviation 
towards suppression of a delayed-type hypersensitivity reaction (DTH). This was 
shown by the elegant experiments of Streilin and coworkers (Streilein et al., 1980, 
Niederkorn, 1999). ACAID is the product of a complex series of cellular interactions 
that begin in the anterior chamber of the eye where antigen is captured and processed 
by F4/80+ APCs, which, under the influence of aqueous humour cytokines, 
demonstrate a unique array of cytokines and cell surface molecules (Niederkorn, 
2002, Streilein, 2003b). The F4/80+ ocular APCs then migrate to the thymus and 
spleen where they promote the generation of CD4+CD25+ Tregs and CD8+ Tregs. 
Other cells involved include, B cells, NKT cells and gamma delta T cells (Lin et al., 
2005, Sonoda et al., 1999, Sonoda et al., 2001, Sonoda and Stein-Streilein, 2002a, 
Wang et al., 2001, Skelsey et al., 2003a, Skelsey et al., 2003b, Ashour and 
Niederkorn, 2006).  
ACAID has been shown to prolong graft survival in mice mismatched for their major 
and minor histocompatibility antigens (Niederkorn and Mellon, 1996, Dana et al., 
1997). 
 
1.3.3 Suppression of immune responsiveness 
The cornea constitutively expresses certain molecules that can inhibit the effector 
immune response. These include soluble molecules that prevent complement 
activation as well as the constitutive expression of Fas ligand on corneal epithelium 
and endothelium (Wilson et al., 1996). Fas ligand interacts with Fas on infiltrating 
leucocytes, inducing their apoptosis. It has been shown that apoptosis induced by Fas 
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ligand results in antigen specific tolerance in the eye; but this is not seen when T cells 
undergo Fas ligand independent necrosis (Griffith et al., 1995). Blockade of Fas/ Fas 
ligand interaction (using FasL KO mice) results in rejection of corneal allografts, 
which otherwise would have survived (Stuart et al., 1997, Yamagami et al., 1997). 
Table 1 summarises the most important soluble components that contribute to 
immune privilege of the eye. 
 
Element Function Reference 
CRP Inhibits complement activation (Goslings et al., 1998) 
FasL Induces apoptosis on activated T cells and neutrophils (Griffith et al., 1995) 
TGFβ2 Suppresses T cells and macrophages; promotes 
tolerance-inducing APCs 
(Xu et al., 2003) 
MIP Suppresses NK cell activity (Apte et al., 1998) 
Il-10 Suppresses antigen presentation and cytokine 
synthesis; induces tolerance-inducing APCs 
(Sonoda and Stein-Streilein, 
2002b) 
VIP Inhibits T cell activation and proliferation; inhibits 
DTH 
(Taylor et al., 1994) 
CGRP Inhibits elaboration of pro-inflammatory factors by 
macrophages 
(Taylor, 1999) 
α-MSH Inhibits DTH and the release of inflammatory factors 
by macrophages; inhibits activation of neutrophils; 
induces CD4+ CD25+ regulatory T cells 
(Taylor, 2003) 
SOM Suppresses IFN-γ production and NK-cell activity (Taylor, 2003) 
 
Table 1- Immunoregulatory elements that contribute to the immune privileged status 
of the eye (Vallochi et al., 2007) 
 
1.4 Corneal Graft Rejection 
Transplant rejection is the most important reason for corneal graft failure in humans. 
Integrity of the corneal endothelium is the single most important factor for the 
survival of a transparent corneal graft. In humans, corneal endothelial cells are 
terminally-differentiated and once damaged by transplant rejection they are incapable 
of proliferation and regeneration by mitosis (Tuft and Coster, 1990). 
Experimental orthotopic corneal transplantation in animal models has provided much 
of what is currently understood about the immunology of corneal allograft rejection. 
The rabbit (Khodadoust, 1968) and the domestic cat (Bahn et al., 1982) were two of 
the first species to be used as the clinical picture of corneal graft rejection in both 
these species is very similar to the corresponding process in humans. However, the 
recipient must be sensitised to the donor (by induction of neovascularisation and 
inflammation in the grafted eye), before rejection will occur. The sheep however, has 
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been shown to be an excellent experimental model, as rejection consistently occurs 
without the need for any manipulation, this being due to the fact that normal sheep 
cornea is already slightly vascularised (Williams et al., 1999). The development of 
orthotopic corneal transplantation in rats (Williams and Coster, 1985) and mice (She 
et al., 1990a) was a valuable advance, but has its limitations, mainly due to 
differences in the anatomy and physiology of the rodent and human eye. However, 
with the large range of transgenic and gene targeted strains of rodents currently 
available, valuable information on the potential mechanisms of corneal graft rejection 
has been gained.  
 
1.4.1 Site of antigen presentation in corneal transplantation 
While many molecular aspects of antigen processing and presentation are well 
understood in general, less is known about local factors involved in antigen 
presentation in corneal transplantation. Studies have shown that there are several 
distinct groups of APC in the anterior segment of the eye. McMenamin et al. 
demonstrated the presence of macrophages and MHC class II+ dendritic cells located 
within the iris and the trabecular meshwork of rat and human eyes (McMenamin et 
al., 1994). Furthermore, Camelo and Steptoe et al. showed that APCs present in the 
iris and ciliary body were able to capture and internalise soluble antigen introduced 
into the anterior chamber (Camelo et al., 2003), and that iris macrophages could 
efficiently stimulate primed T cells, playing a role in local antigen presentation during 
secondary responses (Steptoe et al., 2000). In 2004, Camelo et al. further 
demonstrated that in addition to internalisation of antigen introduced into the anterior 
chamber by APCs in the anterior segment tissues; internalisation of antigen occurred 
by macrophages present in mesenteric lymph nodes as well as spleen (Camelo et al., 
2004). As described previously in section 1.3.2, foreign antigen introduced into the 
anterior chamber results in a phenomenon called ACAID (systemic, antigen-specific 
suppression of DTH responses) (Dullforce et al., 2004). However, ACAID does not 
prevent  active sensitisation to corneal alloantigen as it is an active regulatory process 
that requires time to develop (Sonoda et al., 1995). 
MHC class II+ APCs, expressing macrophage markers have also been located in the 
conjunctiva (Baudouin et al., 1997). MHC class II- APCs have been found in murine 
corneal stroma which become MHC class II+ after migration to the draining lymph 
node. However, this finding has not been reproduced by others and instead it has been 
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shown that there are two subset populations of leukocytes in the central corneal 
stroma: an MHC class II+ population (approximately 40%) that are CD11b+ CD11c- 
(i.e. macrophages) and an MHC class II- population that are CD34+ and are probably 
myeloid precursor cells. There is also a small population of B220+CD11clo cells 
which appear to be plasmacytoid DCs (Forrester et al., 2010). What is more 
interesting, is recently Maruyama et al., demonstrated CD11b+ cells (but not CD11c- 
cells) to contribute to lymphangiogenesis as demonstrated by the expression of 
lymphatic endothelial markers when the cornea is inflamed (Maruyama et al., 2005). 
This has implications in our understanding of local antigen presentation and T cell 
recruitment.  
 
1.4.2 Presentation of cornea-derived alloantigen 
Traditionally it is assumed that APC, having captured an antigen, migrate to regional 
lymphoid tissue where they mature and present antigen to naïve T cells. When 
transgenic cornea expressing green fluorescent protein (GFP) were transplanted into 
wild type mice, GFP was detected in the cervical lymph nodes within 6 hours (Liu et 
al., 2002). Another study has shown that after corneal transplantation, the number of 
CD4 and CD8 positive cells increases only in the cervical lymph nodes (Okada et al., 
1997). 
Other studies indicate that the actual site of antigen presentation may be even further 
upstream within the ocular structures. It has been shown that the conjunctiva contains 
a mucosa-associated lymphoid tissue with all components necessary for a complete 
immune response (Knop and Knop, 2000). Antigen presentation can occur in such 
mucosa-associated lymphoid tissue (Porgador et al., 1998). In the eye it has been 
demonstrated that a localised blockade of the costimulatory signals CD80 and CD86 
within the conjunctiva but outside of the cervical lymph nodes prevented a CD4+ T 
cell mediated herpetic keratitis (Chen and Hendricks, 1998). Local antigen 
presentation is further suggested by an experiment in which expression of 
recombinant IL-10 by corneal endothelial cells prevented corneal graft rejection 
(Klebe et al., 2001). IL-10 downregulates antigen presentation but its half-life is too 
short to account for modulation of antigen presentation outside the eye. After corneal 
graft rejection, dendritic cells are found in high frequency in the basal epithelium and 
stroma of human grafts (Morris, 1996). 
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Kuffova et al. recently demonstrated unequivocal evidence for the central role of 
recipient antigen-presenting cells in corneal allogeneic responses in which host APC-
associated cornea-derived antigen was transported to the draining lymph node 
(submandibular) and induced antigen-specific T-cell activation (Kuffova et al., 2008). 
 
1.4.3 T cell recognition of a corneal allograft 
There are two distinct pathways by which alloantigens expressed in solid organ 
transplants are recognised by recipient T cells, the indirect and direct pathways 
(Figure 2). In the direct pathway, the recipient T cells through their receptor (TcR) 
bind to the intact donor MHC molecules which are displayed on the surface of the 
donor cells. Alternatively, in the indirect pathway the TcR of recipient T cells require 
processing and presentation of donor derived peptides from MHC and minor 
transplantation antigens on self-MHC molecules at the surface of the hosts APCs 
(Lechler and Batchelor, 1982). 
When donor and recipient share no MHC class I or class II molecules, the two 
pathways of allorecognition are induced by two different types of APCs: the donor 
APCs serve the direct pathway while the indirect pathway is mediated by the recipient 
APCs. Both pathways have been implicated in the rejection of solid organ transplants 
(Benichou et al., 1999), however the direct pathway of allorecognition maybe 
preferentially involved in acute rejection of allografts, and the indirect pathway seems 
to be involved in chronic allograft rejection although it could also mediate acute 
rejection (Fluck et al., 1999). 
The most obvious source of alloantigen in a transplanted tissue is its MHC protein. 
MHC class I is expressed abundantly on the corneal epithelium and sparsely on the 
stroma and corneal endothelium (Khodadoust, 1968). In contrast MHC class II is not 
expressed on the epithelium or stroma and is absent on healthy endothelium. 
Cytokines TNF, GM-CSF and IL-1 can alter MHC class II expression following 
corneal transplantation, with rapid upregulation of MHC class II induced as a result of 
inflammation and cellular activation (Pepose et al., 1985). Thus with respect to graft 
self or non-self MHC antigen recognition, MHC class II donor antigens present 
themselves as direct targets for immune attack following transplantation. 
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Figure 2- Direct and indirect pathway of allorecognition 
In the direct pathway of allorecognition the TCR on the recipient alloreactive T cell 
directly recognises peptide antigen presented in the context of allogeneic MHC 
molecules on donor-derived APCs. In indirect presentation, allogeneic antigens are 
released from the donor cells (e.g. by death or shedding), these are then taken up by 
recipient APCs, processed and presented in the context of recipient MHC molecules.  
 
 
1.4.4 Contribution of direct and indirect T cell alloreactivity during corneal allograft 
rejection. 
Recipients of corneal transplants fall into two rejection risk categories. In 
approximately two thirds of graft recipients, ocular surface blood vessels do not 
extend beyond the corneal-conjunctival junction (the limbus). Thus, the recipient 
peripheral cornea, which provides the ‘bed’ for the graft, has no blood or lymphatic 
vessels and is therefore at a low risk of a rejection episode. However, the remaining 
third will have had a prior inflammatory episode, such as chemical trauma or infection 
(e.g. herpes simplex virus) or a previously rejected graft. These conditions promote 
corneal vascularisation and local infiltration of MHC class II-expressing APC 
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(Williams et al., 1985). In addition, recipients of multiple grafts may become 
sensitised to shared donor antigens. A breach of immunological privilege by any of 
these ways leads to a high chance of rejection and graft failure, which is as at least 
similar to that seen after renal transplantation (Nicholls and Williams, 2001).  
It has been well documented that the indirect pathway plays a significant role in 
corneal transplantation as will become evident later, especially when transplants are 
grafted onto uninflamed host beds. In this setting, the lack of constitutive expression 
of MHC class II by corneal tissues and the lack of passenger bone marrow-derived 
cells of the dendritic cell lineage, which basally express class II MHC molecules 
(Streilein et al., 1979, Whitsett and Stulting, 1984) are believed to be the main reasons 
for the minimal involvement of the direct pathway in low rejection risk (LR) 
transplantation. Indeed, Boisergault and co-workers, (Boisgerault et al., 2001) and 
others (Sano et al., 1997), have compellingly demonstrated that indirectly primed 
allospecific CD4+ T-cells produced against minor transplantation antigens (by 
comparing indirect T cell responses in MHC-disparate and fully allogeneic corneal 
transplant models) are essential in initiating the alloimmune response in LR corneal 
transplantation in mice.  
Huq et al. reported data to further support the concept that the direct pathway is not 
operative in rejection of LR allografts. They showed, using LR responder T-cells 
isolated from transplanted hosts, they were unable to detect any direct response in LR 
graft recipients and that by eliminating the class II-mediated direct response (by using 
class II KO mice as donors); this had no effect on the survival of LR grafts (Huq et 
al., 2004). While data suggest that the indirect pathway is operative in the HR setting 
(Sano et al., 1997, Dana et al., 1997) inhibiting it (by blockade of host APC 
infiltration into grafts) consistently fails to completely prevent graft rejection (Dana et 
al., 1997). 
Boisergault et al. also showed that an allograft naturally free of MHC class II+ APCs 
at the time of grafting is able to activate T-cells through both indirect and direct 
allorecognition pathways. Each pathway mediated by different T cell subsets with 
varying phenotypes and alloantigen specificities. Although the direct CD8 response 
can induce graft destruction when full costimulation is provided, the CD4 indirect 
response is vital in the rejection observed under normal circumstances. This provides 
further evidence that the indirect alloresponse remains the main driving force in the 
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rejection process, in the absence of MHC class II on the graft and most likely in the 
case of MHC-matched transplants (Boisgerault et al., 2001). 
Illigens et al. again showed that in corneal transplantation, the T-cell response was 
mediated by two T-cell subsets: i) CD4+ T-cells that recognise alloantigens 
exclusively through the indirect pathway and secrete IL-2 and ii) IFN-γ producing 
CD8+ T-cells recognising donor MHC in a direct fashion. In addition they observed 
that the vast majority of alloreactive CD4+ T-cells activated indirectly was directed 
towards mH, but not MHC proteins (using MHC deficient mice) (Illigens et al., 
2002). Yamada et al. when using BALB/c mice as recipients of orthotopic corneal 
allografts, revealed that mice with rejected grafts (but not mice with accepted grafts) 
acquired primed mH specific T-cells. However, none of the mice displayed 
cytotoxicity directed at target cells bearing donor MHC alloantigens (Yamada et al., 
2001). Thus showing, in BALB/c mice, direct alloreactive T-cells (either CD4+ or 
CD8+) specific for donor MHC alloantigens are not activated. Instead, donor mH-
specific DH and T-cells are readily detectable, especially in mice in which grafts are 
rejected. Combined with evidence that sensitisation of cornea allograft recipients to 
donor alloantigens correlates temporarily with infiltration of recipient Langerhans’ 
cells into the graft (Sano et al., 2000b), they deduced that only the indirect pathway of 
allorecognition is activated by orthotopic corneal allografts.  
Similarily, Neiderkorn and co-workers  and Sano et al. showed that it is mH antigens, 
rather than MHC, alloantigens that offer the greatest barrier to successful orthotopic 
corneal transplantation in mice and that these antigens will evoke an immune rejection 
reaction to the extent that recipient APCs migrate into the graft and capture donor-
derived alloantigens for processing and presentation on recipient MHC molecules 
(Peeler et al., 1988) ,(Sano et al., 1999). 
Sano et al. show that in high rejection risk corneal transplantation, it is the direct 
pathway of allorecognition that comes to the fore. They reported that C57BL/6 
corneal grafts placed in high risk eyes are capable of sensitising recipient T-cells 
through the ‘direct pathway of allorecognition’, but that this was not the case for graft 
rejection in normal eyes. Graft rejection in this case being mediated by T cells that 
recognise donor alloantigens presented by recipient MHC molecules (Sano et al., 
2000a).  
However, Dana and co-workers showed that contrary to current belief, donor graft 
cells that acquire MHC class II expression migrate from the corneal transplant to 
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draining lymph nodes, and the traffic of these donor cells to draining lymph nodes is 
significantly enhanced in inflamed high risk host beds compared with low risk hosts 
(with avascular recipient beds). Moreover, they demonstrated that these trafficking 
cells are CD45+CD11c+ cells that are normally universally MHC class II- when 
resident in the uninflamed cornea but rapidly become MHC class II+ after 
transplantation or when placed in culture. They also demonstrated that in culture 
corneal CD11c+ cells spontaneously migrate out of the cornea and progressively 
acquire MHC class II expression, but have modest allostimulatory capacity compared 
with dendritic cells derived from the spleen (Liu et al., 2002). 
In summary, under normal circumstances, i.e. transplantation of a cornea into an 
uninflamed host (LR), allorecognition occurs through the indirect pathway mediated 
by CD4+ cells. Where the immune privilege is abolished by inflammation, or 
vascularisation, allorecognition occurs through the indirect and direct pathway 
mediated by both CD4+ and CD8+ T-cells respectively. A question that remains 
unanswered however is how CD4+ T-cells with indirect donor allospecificity regulate 
CD8+ T-cells with direct anti-donor allospecificity. The induction of an antigen 
specific cytotoxic CD8+ T lymphocyte (CTL) response usually requires helper CD4+ 
T cells activated by the same APC to be effective (Ridge et al., 1998): often described 
as ‘linked’ help or the ‘three-cell’ model. However, several studies from Lee et al. 
showed that CD4+ cells (sensitised indirectly by recipient APCs) can provide help for 
CD8+ CTLs (sensitised directly by donor cells). They did this by examining T cell 
responses in mice that had been treated with anti-CD8 antibody in vivo and that had 
rejected class II deficient but class I mismatched grafts. They found that despite the in 
vivo treatment with anti-CD8 antibody, CD8+ CTLs were present in these mice after 
graft rejection and that these CTLs were specific for donor class I antigens and 
depended on CD4+ helper cells that had been sensitised by donor peptides presented 
by recipient class II molecules (Lee et al., 1994). This suggests ‘unlinked’ help by 
which CD8+ T cells, activated directly by donor APCs, receive help from CD4+ T 
cells that are primed indirectly by recipient APCs. This has been described as the 
‘four cell problem’ (Jiang et al., 2004).  
Lechler and co-workers showed that DCs are capable of acquiring significant levels of 
MHC class I and II molecules from other DCs and from endothelial cells; and that the 
DCs were then able to present these acquired MHC complexes efficiently to antigen-
specific and alloreactive T cells (Jiang et al., 2004). With these reports, Lechler 
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proposed a third mode of allorecognition which he termed the ‘semi-direct’ pathway 
and which would provide a solution to the ‘four cell problem’. ‘Recipient DCs could 
acquire and present intact donor MHC class I molecules to direct pathway CD8+ T 
cells, and simultaneously could present internalised and processed donor MHC 
molecules as peptides to CD4+ T cells with indirect anti-donor allospecificity’ (Figure 
3) (Jiang et al., 2004). 
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Figure 3- The semi-direct pathway of allorecognition:  
In corneal allograft rejection, recipient CD8+ T cells, stimulated directly by donor 
DCs or parenchymal cells, receive help from CD4+ T cells primed indirectly by 
recipient DCs after processing of donor antigens. Thus, in the semi-direct pathway of 
allorecognition, recipient DCs  could acquire and present intact donor MHC class I 
molecules to direct pathway CD8+ T cells, and simultaneously present internalised 
and processed donor MHC molecules as peptides to CD4+ T cells with indirect 
allospecificity. 
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1.4.5 Histocompatibilty antigen matching in corneal transplantation 
Human leucocyte antigen (HLA) matching is not routinely carried out for corneal 
transplants. Over the past thirty years, clinical HLA-matching studies have produced 
inconsistent and conflicting results. Boisjoly et al. found a close association between 
HLA-A and –B incompatibility and  the  incidence of graft rejection in both high and 
low rejection risk patients (Boisjoly et al., 1990). The US Collaborative Corneal 
Transplantation Study (CCTS) found no beneficial effect of HLA matching in high 
risk patients (1992) (although an aggressive  post-grafting topical immunosuppressive 
protocol was used), whereas the UK Corneal Transplant Follow-up Study (CTFS) 
found a small increased risk of rejection with HLA-A and –B mismatching but a 
reduced risk of rejection with HLA-DR mismatching (Vail et al., 1997). Another 
study, using molecular typing methods concluded that DR matching was beneficial 
(Baggesen et al., 1991). 
The variable results obtained from HLA-matching in corneal transplantation, which is 
in contrast from those of other organs, such as kidney, can only be explained by the 
unique characteristics of the cornea. These in turn influence the mechanisms of T-cell 
activation and the antigens that are targeted (Nicholls, 1996). 
Murine models of corneal transplantation have confirmed a prominent role for non-
MHC antigens in corneal graft rejection (Sonoda and Streilein, 1992). The antigens 
themselves remain largely uncharacterised, although the chromosomal locations of 
some 50 or more have been determined in mice. The best known non-MHC antigens 
in humans are blood group antigens, but these are atypical in that they are targeted by 
antibody, rather than by T lymphocytes. Their role in corneal graft rejection is 
equivocal. The CCTS group showed that ABO compatibility resulted in fewer 
rejection associated graft failures and rejection episodes, however results were not 
statistically significant (1992), and recent work has shown improved survival if 
matched for the H-Y minor H antigens (Bohringer et al., 2006). Batchelor et al 
however, showed ABO incompatibility or ABO phenotype of recipient did not 
influence graft prognosis (Batchelor et al., 1976). The question of MHC matching 
remains controversial and there is currently a randomised, multicentre trial underway 
to address this question (Williams and Coster, 2007). 
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1.4.6 Effector mechansims in corneal allograft rejection 
The effector phase of corneal graft rejection involves multiple and redundant 
mechanisms. Using KO mice, graft rejection in the face of the selective exclusion of a 
single effector mechanism does not necessarily mean that mechanism does not have a 
role in a different situation. CTL and DTH responses are the two main T cell 
dependent immune effector mechanisms that are believed to be involved in the 
rejection of vascularised organ grafts. CTLs are characterised by their expression of 
the CD8 cell surface marker, whereas cells mediating DTH classically express the 
CD4 surface marker (Qian and Dana, 2001).  
The majority of existing evidence indicates that CD4+ T -cells play a crucial role in 
corneal allograft rejection. In vivo depletion of CD4+ T-cells using neutralising 
antibodies or by gene deletion results in a significant reduction in corneal graft 
rejection in both rat and mouse models (Ayliffe et al., 1992, He et al., 1991, 
Niederkorn et al., 2006, Yamada et al., 1999a). Furthermore, several groups have 
shown that long-term corneal allograft survival is closely associated with abolition of 
CD4+ T-cell dependent DTH responses to the donor’s histocompatibility antigens 
(Yamada et al., 1999a, Niederkorn and Mellon, 1996, She and Moticka, 1993, She et 
al., 1990a, Sonoda and Streilein, 1992). CD4+ Th1 cells were previously believed to 
be the sole mediator of corneal allograft rejection (Nickerson et al., 1994). However, 
results from studies examining survival of corneal allografts transplanted to Th2-
deviated hosts have yielded results ranging from complete acceptance of corneal 
allografts to rejection (Yamada et al., 1999b, Hargrave et al., 2004). Various groups 
have shown that patients with severe allergic eye disease are at a higher risk of 
corneal transplant rejection thus providing support to the idea that Th2 immune 
responses might be harmful, rather than beneficial (Easty et al., 1975, Ghoraishi et al., 
1995, Lyons et al., 1990, Hargrave et al., 2003). Recent reports by Beauregard et al. 
have shown that atopic conjunctivitis promotes systemic Th2 immune responses to 
the alloantigens expressed on the corneal allograft; that corneal allografts transplanted 
to atopic hosts display an increased incidence and a more rapid onset of rejection and; 
that corneal allograft rejection in atopic recipients does not require the direct 
involvement of infiltrating eosinophils (Beauregard et al., 2005). This was later 
confirmed by Flynn et al. who again showed an increased incidence of rejection in 
mice with allergic conjunctivitis (Flynn et al., 2007).  
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Hargrave et al. provided further evidence that corneal allograft rejection is not solely 
mediated by CD4+ Th1 cells.  They showed that corneal allograft rejection in IFN-γ 
KO mice or mice treated with neutralising anti-IFN-γ antibody ranged from 0% 
(MHC matched, multiple minor H-mismatched) to 100% (full MHC and multiple 
minor H mismatches) (Hargrave et al., 2004). This suggests therefore, that both Th1-
dependent and Th2-dependent pathways are essential for corneal allograft rejection. 
Although it is thought that CTLs play a central role in the rejection of different types 
of allografts, the evidence is not as clear in the case of corneal allografts. Corneal 
graft rejection occurs readily in mice with defective CTL function, such as perforin 
KO mice, β2-microglobulin KO mice and CD8 KO mice (Yamada et al., 2001, Hegde 
and Niederkorn, 2000). Furthermore, rejection of corneal allografts in normal mice 
still occurs if CD8+ T-cells are depleted with  neutralising anti-CD8 mAb, suggesting 
that CD8+ T cells are not obligatory for rejection (Yamada et al., 2001).  
It has become apparent that macrophages play an important role in corneal allograft 
rejection. They are a principal inflammatory cell in DTH lesions and as mentioned 
previously, DTH responses to donor histocompatibility antigens are the effector 
mechanism that most commonly result in corneal allograft rejection (Williams et al., 
1989, Hegde et al., 2005, Dvorak et al., 1986, Brissette-Storkus et al., 2002, 
Yamagami et al., 2006, Slegers et al., 2000). 
Macrophages have not only been found in rejected allografts but also in the 
conjunctiva and central corneal stroma in both humans and mice (Brissette-Storkus et 
al., 2002, Yamagami et al., 2006). 
Studies involving depletion of periocular macrophages (by subconjunctival injection 
of liposomes containing the macrophagicidal drug, clodronate) resulted in rejection of 
corneal allografts in rats (Slegers et al., 2000) and mice (Hegde et al., 2005) further 
confirming their important role in corneal allograft rejection.  Furthermore, Flynn 
showed that CD45+ monocyte/macrophage lineage cells are the predominant cell type 
in the aqueous humour of rejecting corneal grafts in humans (Flynn et al., 2008). 
Using rodent models of corneal transplantation, numerous studies have confirmed that 
the mammalian immune system provides multiple mechanisms for the destruction of 
the corneal allograft. These studies have shown that CD4+ T cells are the most 
important T cell population, but a wide range of molecules and immune cells may 
also contribute in different extents to corneal allograft rejection, but are not necessary 
for rejection to occur. These include 1) CD4+ T cells, 2) CD8+ T cells, 3) B cells 4) 
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perforin, 5) FasL, 6) TNF-α, 7) complement, and 8) interferon-γ, (Table 3). It seems 
therefore, reasonable to conclude that multiple and redundant immune effector 
elements can contribute to corneal allograft rejection (Niederkorn, 2007). 
Figure 4 illustrates the pivotal role that the CD4+ T-cell plays in inducing corneal 
graft rejection. In a typical DTH reaction, CD4+ T-cells, especially Th1 cells, secrete a 
variety of chemokines, cytokines, and toxic molecules including IFN-γ, nitric oxide, 
superoxide radicals, and tumour necrosis factor-α (TNF-α). Each of these molecules is 
capable of inflicting injury to the corneal allograft. As an example, it is possible to 
induce apoptosis of corneal endothelial cells both in isolation and in intact corneas in 
a NO-dependent manner (produced by endothelial cells) using combinations of 
cytokines (Sagoo et al., 2004). 
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Figure 4- The CD4 + T cell is the key cell for inducing corneal graft rejection.  
CD4 + T cells could contribute to corneal graft rejection in multiple ways. They 
provide help for the activation of B cells and CD8 + T cells. CD4 + T cells also 
produce IFNγ and tumor necrosis factor-alpha (TNFα), which can directly induce 
apoptosis of corneal cells in a NO dependent manner. IFNγ can also activate 
macrophages, which in turn, elaborate apoptosis-inducing factors, including nitric 
oxide (NO), hydrogen peroxide (H2O 2), oxygen radicals, and TNFα. Antibody can 
produce corneal cell death by complement-mediated cytolysis, antibody-dependent 
cellular cytotoxicity via natural killer cells or by inducing apoptosis. 
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1.4.7 Role of Th17 cells in allograft rejection 
 
1.4.7.1 Defining T cell subsets 
As mentioned previously, CD4+ T helper (Th) cells are essential mediators of the 
immune response, helping to coordinate other cellular components of the immune 
system. The existence of two distinct effector Th populations, Th1 and Th2, was first 
demonstrated over two decades ago (Mosmann et al., 1986). These populations differ 
in the cytokines they produce and thus in their function. The decision on which path 
the progeny of a naïve CD4+ T cell will take is made during the clonal expansion 
phase that takes place after the first encounter with antigen. 
Th1 cells, characterised by the secretion of IFNγ and expression of T-bet as well as 
STAT4 are essential for the clearance of intracellular bacteria (Reiner, 2007). Th2 
cells are controlled by master regulator GATA-3 and play an essential role in humoral 
immunity by producing IL-4, IL-5, and IL-13 (Reiner, 2007). It has become clear only 
recently that IL-17 producing T cells form a separate T cell effector subset, termed 
Th17, distinct from Th1 and Th2 cells. Th17 cells do not produce the “classical” 
Th1/Th2 cytokines, and the Th1/Th2 signature cytokines IFNγ and IL-4 suppress 
Th17 cell differentiation (Harrington et al., 2005). Th17 cells produce large amounts 
of IL-17, IL-17F, IL-21 and IL-22, contributing to mucosal immunity (Mangan et al., 
2006, Zhou et al., 2007). In the presence of TGFβ, IL-6 and IL-21, naïve T cells 
differentiate into Th17 cells under control of housekeeper gene RORγt (Ivanov et al., 
2006). In addition, although essential for Th17 commitment, IL-23 is also required for 
expansion of Th17 cells (Veldhoen et al., 2006, Aggarwal et al., 2003). Regulatory T 
cells (Treg) are another T cell lineage under transcriptional control of master gene 
FoxP3 (Hori et al., 2003). Th17 cells have various roles; their importance in the 
control or clearance of various pathogens has been demonstrated in several models of 
acute infection (Infante-Duarte et al., 2000, Huang et al., 2004, Ye et al., 2001). They 
also play a key pathological role in several autoimmune diseases, which were 
previously assumed to be mediated by Th1 responses (Fujimoto et al., 2008, Cua et 
al., 2003, Jain et al., 2008). Interestingly, Th17 cells have been shown to be involved 
in allograft rejection of solid organs (Antonysamy et al., 1999, Vanaudenaerde et al., 
2006, Burlingham et al., 2007, Yuan et al., 2008, Burrell et al., 2008).  
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1.4.7.2 Transcriptional regulation of Th17 cell differentiation 
Unlike Th1 and Th2 cells, initial characterisation of Th17 cells has shown that they do 
not express T-bet and GATA3,  the classic transcriptional factors involved in Th1 and 
Th2 differentiation and that their differentiation is independent of STAT1, 4 or 6 
signalling (Harrington et al., 2005, Park et al., 2005). Chen et al. showed that 
deficiency in Socs3 (suppressor of cytokine signalling 3), a negative regulator of 
STAT3 phosphorylation, resulted in greatly enhanced IL-17 expression and that 
Socs3-conditional knockout mice developed systemic autoimmune disease, similar in 
phenotype to that observed in IL-17 and IL-23p19 transgenic mice (Chen et al., 
2006b). Subsequently, it has been shown that STAT3 deficiency results in impaired 
differentiation of Th17 cells (Yang et al., 2007). STAT3 is involved in the expression 
of RORγt, a critical transcription factor required for Th17 differentiation. STAT3 
mediated signals also suppress Th1 and T reg associated transcription factors, T-bet 
and FoxP3 respectively (Laurence et al., 2007).  
RORγt was identified as the first lineage specific transcription factor expressed in 
Th17 cells by the demonstration of a lack of IL-17 expressing cells in RORγt deficient 
mice (Ivanov et al., 2006). Furthermore, even in the presence of TGFβ and IL-6, 
RORγt deficiency has been shown to greatly reduce the differentiation of Th17 cells, 
establishing RORγt as a master transcriptional regulator of Th17 differentiation. 
However, mice lacking T cell expression of RORγt can still develop EAE and residual 
Th17 cells (compared with STAT3 deficient cells) are still present in the absence of 
RORγt, which indicates the involvement of other factors. Recently, it has been 
reported that RORα is also expressed by Th17 cells; however, compared with RORγt, 
it seems to have a minor role in Th17 cell differentiation (Yang et al., 2008). 
Furthermore, the interferon regulatory factor-4 (IRF4), known to be involved in Th2 
differentiation, was recently identified as a transcription factor necessary for Th17 cell 
differentiation. T cells from IRF4 deficient mice exhibit reduced RORγt expression 
and fail to diferentiate into Th17 cells (Brustle et al., 2007). Recently it has been 
shown that both T regs and Th17 cells express the aryl hydrocarbon receptor (AhR), 
as discussed later in section 1.4.7.3. (Veldhoen et al., 2008, Quintana et al., 2008).  
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1.4.7.3 AhR and Th17 cells 
The AhR belongs to the bHLH-PAS protein family. These are proteins that have been 
shown to control vascular and haemopoietic development aswell as a range of 
physiological events including circadian rhythms, toxin metabolism and stress 
responses to hypoxia, among others (Kewley et al., 2004). Environmental pollutants 
such as dioxin are the most extensively characterised classes of AhR ligands, 
however, the fact that the AhR is highly conserved in evolution supports the idea of 
there being other more naturally occurring ligands that drive its functions (Nguyen 
and Bradfield, 2008). An example of such a ligand is the tryptophan photo-product 6-
formylin-dolo (3,2-b) carabazole (FICZ) (Veldhoen et al., 2009). In fact tryptophan 
can be converted by a variety of mechanisms into AhR ligands and inducers of AhR-
dependent gene expression (Denison and Nagy, 2003) (Figure 5). 
There is a large body of evidence supporting a role for AhR signalling in the function 
of the immune system. Th17 cells have been shown to express high levels of AhR 
(Veldhoen et al., 2008). Although there are reports of AhR expression in Tregs 
(Quintana et al., 2008), its level of expression is much lower compared with Th17 
cells. Veldhoen et al. have shown that AhR activation as well as promoting the 
expression of IL-22, enhances Th17 cell development and increases cytokine 
production (Veldhoen et al., 2009). Furthermore, in vivo studies using a model of 
experimental autoimmune encephalomyelitis have shown premature onset of disease 
and more severe pathology, as well as a reduction in the number of Th17 cells, in 
Ahr-null mice in comparison to wild type (Veldhoen et al., 2008). Despite AhR not 
being an essential requirement for Th17 differentiation, its activation promotes further 
functional differentiation in these cells.  
Interestingly, it has been shown that FICZ, an endogenous AhR ligand mentioned 
above affects Th17 differentiation. FICZ has been shown to markedly increase the 
number of Th17 cells and their production of cytokines through activation of the AhR 
(Veldhoen et al., 2008, Veldhoen et al., 2009). 
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1.4.7.4 Effector function of IL-17 
mIL-17R expression has been revealed in virtually all cells and tissues by northern 
analysis (Yao et al., 1995). This ubiquitous distribution of the IL-17R is in contrast to 
the restricted expression of IL-17 in T cells. Expression of Il-17 was initially detected 
in memory CD4+ T cells from peripheral blood in humans (Yao et al., 1995). In 
addition to CD4+ T cells, IL-17 is expressed by CD8+ T cells, natural killer (NK) T 
cells, γδ T cells, and neutrophils under certain conditions (Dong, 2009). 
The role of IL-17 in autoimmune diseases is well established (Tartour et al., 1999, 
Witowski et al., 2004, Langowski et al., 2006). It has also been found to induce 
activation of the transcription factor NF-κB in a range of cell types and stimulate 
cells, such as endothelial cells, epithelial cells, and fibroblasts to secrete IL-6, IL-8, 
granulocyte CSF (G-CSF), and PGE2, a process that can be blocked by anti-IL-17 
mAb. In addition, IL-17 has been shown in human macrophages to induce the 
secretion of IL-1β and TNFα (Antonysamy et al., 1999). As well as inducing 
proinflammatory cytokine production, IL-17 has been shown to exhibit indirect 
haemopoietic activity by enhancing the ability of fibroblasts to sustain the growth of 
CD34+ haemopoietic progenitors and directing their maturation into neutrophils 
(Antonysamy et al., 1999). Yao et al. demonstrated that an IL-17 antagonist, soluble 
mIL-17R:Fc fusion protein, was able to inhibit IL-2 production and T cell 
proliferation induced by different stimulants, suggesting a key role for endogenously 
produced IL-17 in T cell growth (Yao et al., 1995). 
 
1.4.7.5 Evidence for a role of Th17 cells in allograft rejection 
Since IL-17 producing cells and enhanced IL-17 mRNA have been observed in 
human kidney transplants, investigators have focused on the possible role IL-17 may 
play in allograft rejection (Van Kooten et al., 1998, Loong et al., 2002).  
Antonysamy et al. showed in a rat cardiac allograft transplantation model that 
blocking IL-17 function resulted in significant increases in graft survival 
(Antonysamy et al., 1999). The same group later showed that IL-17 inhibition was 
able to prevent rejection in a murine aortic transplantation model (Tang et al., 2001). 
More recently, Vanaudenaerde et al. have shown IL-17 to be implicated in rejection 
of lung transplants, demonstrating that in patients with acute rejection of lung 
transplantation, IL-17 mRNA and protein levels were increased in bronchoalveolar 
lavages (Vanaudenaerde et al., 2006). Furthermore, Burlingham et al., showed that 
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Th-17 mediated immunity to collagen type V ultimately caused progressive airway 
obliteration in the transplanted lung (Burlingham et al., 2007). A disease promoting 
role for Th17 cells in cardiac allograft rejection was also confirmed, especially in the 
absence of a Th1 response (Burrell et al., 2008, Yuan et al., 2008).  
There has only been one report in the literature which demonstrated a pathogenic role 
of IL-17 at the early stage of corneal allograft rejection. The authors demonstrated 
significantly enhanced Th17 expression in inflamed transplants and draining lymph 
nodes early on in allocorneal rejection, while upregulation of Th1 producing IFNγ 
was seen in the late phase. Furthermore, they showed that IL-17 deficiency led to a 
delay in the onset of allogeneic rejection, but did not affect the overall survival time 
of transplants (Chen et al., 2009).  
The presence of both Th1 and Th17 cells has been demonstrated during allograft 
rejection, although direct evidence representing their specific roles is lacking. Indirect 
evidence as determined by detection of cytokines may even be deceptive in itself, as 
individual cells may co-produce both IFNγ and IL-17. Tackling the clinical problem 
of rejection will require better understanding of the factors that regulate both the 
development of these different cell types and the balance between them, as well as 
their interaction with other cell types such as Tregs. 
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Figure 5- AhR ligands 
Tryptophan can be converted by a variety of mechanisms into AhR ligands and 
inducers of AhR-dependent gene expression (Denison and Nagy, 2003). 
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1.4.8 Therapeutic immune modulation in corneal transplantation 
The goal of transplantation medicine is to improve the patient’s long-term quality of 
life by re-establishing lost organ or tissue function. To achieve this goal it is crucial to 
prevent the occurrence of any form of transplant rejection. This has to be achieved 
with the lowest possible number and severity of side effects.  
Historically, the major strategy for improving long-term graft survival in clinical 
transplantation has always been the suppression of the immune system. 
Immunosuppression comes at a cost of serious side effects and immunosuppressive 
treatment in organ transplantation must usually be given for as long as the graft 
survives. 
One of the major aims in transplantation immunology at large is the induction of 
donor-specific transplantation tolerance in the recipient, where a short-term 
immunomodulatory treatment would induce indefinite graft survival thereby allowing 
discontinuation of treatment. Tolerance, defined as a state of non-aggressive reactivity 
to a specific antigen, is demonstrated by the large number of foreign and self antigens 
that are encountered continuously throughout life without rejection or autoimmunity. 
T cell proliferation, the initial step in any transplant rejection, is induced if a foreign 
antigen is presented by the TCR (signal 1) together with a co-stimulatory signal 
(signal 2), delivered by receptor interactions between CD80 and CD86 on APC and 
CD28 on T lymphocytes. Signal 1 in the absence of signal 2 results in a state of 
anergy. Co-stimulation is of therapeutic interest because the manipulation of co-
stimulatory signals can provide a means to either enhance or terminate immune 
responses. 
The two-signal model oversimplifies the contribution of each signal because the 
strength of the TCR signal also has an influence on the extent of T cell differentiation. 
T cell activation might occur in the absence of signal 2 if the TCR signal is very 
strong. In addition both positive and negative second signals can be delivered to T 
cells. The balance between stimulatory and inhibitory signals is crucial in maximising 
protective immune responses whilst maintaining immunological tolerance and 
preventing autoimmunity. Negative second signals seem to be needed to induce T cell 
tolerance, whereas positive second signals promote T cell activation (Figure 6) 
(Sharpe and Freeman, 2002). 
Topical glucocorticoid treatment is the mainstay of immunosuppression in corneal 
transplant recipients with the exception of those patients with a recognised high risk 
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of rejection (Hill et al., 1991). Although topical steroid treatment has been 
demonstrated to prevent or reverse rejection episodes (Randleman and Stulting, 
2006), it is much less effective in preventing graft failure in high-risk patients. This 
has provided the impetus for the development of immunomodulatory approaches 
which would not involve systemic immunosuppression. There have been no reported 
clinical trials of immunomodulatory proteins in patients with corneal graft rejection, 
mainly due to a lack of clear cut, long term graft survival in animal models (George 
and Larkin, 2004). Modification of corneal endothelial cells by gene therapy is an 
attractive alternative to the systemic use of immunomodulatory proteins (Fu et al., 
2008). Ex vivo transduction of the cornea with viral vectors has been achieved using 
adenoviral, lentiviral, herpes and adeno-associated viral vectors in a range of different 
species (George et al., 2000, King et al., 2000, Larkin et al., 1996, Gong et al., 2006, 
Xie et al., 2003). These vectors have been used for the expression of molecules that 
can prolong the survival of allografts, including IL-10 (Klebe et al., 2001), IL-12 
(Klebe et al., 2005), soluble TNF receptor (Rayner et al., 2000), CTLA4-Ig (Comer et 
al., 2002, Gong et al., 2006) and IL-4 (Pleyer et al., 2000). However, while viral 
vectors can achieve efficient transgene expression, they can be immunogenic and pro-
inflammatory, and in at least one study vector controls have shortened graft survival 
when compared with untreated corneal grafts (George and Larkin, 2004). Therefore, 
there is a need for finding alternative strategies of introducing immunomodulatory 
molecules such that the cornea itself is not transduced, a process which has been 
implicated in the premature destruction of the corneal endothelium, thus overcoming 
the beneficial effects of the transgene. 
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Figure 6- The B7.1/B7.2-CD28/CTLA-4 superfamily members.  
 
 
 
1.5 Indoleamine 2,3-dioxygenase (IDO) 
IDO catabolises the enzymatic degradation of the essential and rarest amino acid 
tryptophan (trp) to kynurenine (kyn) and promotes the formation of kyn pathway 
metabolites. Trp degradation was previously thought to be a mechanism of the innate 
immune system as early literature showed IDO to inhibit the proliferation of 
facultative intracellular pathogens and tumour cells in vitro as a result of consumption 
of the essential amino acid tryptophan (Taylor and Feng, 1991). Since Mellor and 
Munn’s discovery in the late 1990’s of the involvement of IDO in maintaining 
maternal tolerance towards the foetus (Munn et al., 1998), interest in the enzyme has 
focused on its role in the generation of immune tolerance to foreign antigens. 
Currently the importance of the IDO enzyme is well recognised both in immunity and 
the pathogenesis of many diseases. Furthermore, the recent discovery of a novel 
isoform of IDO (IDO2) suggests that the degradation of trp via the kynurenine 
pathway may be involved in more biological processes than previously believed (Ball 
et al., 2009, Metz et al., 2007).  
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1.5.1 Tryptophan 
Trp is the rarest of all 20 essential amino acids. Essential amino acids are those that 
cannot be synthesised de novo and on which we rely on dietary ingestion for supply. 
Although it is the rarest of all 20 essential amino acids, accounting for only 1 to 1.5 % 
of total amino acids in cellular proteins, it is required in many physiological processes 
in addition to protein synthesis (Peters, 1991). It is essential to human metabolism, 
being the metabolic precursor of neuro-hormone melatonin, neurotransmitter 
serotonin and vitamin B3, Niacin. It is found in a variety of foodstuffs including, 
milk, chocolate, bananas and peanuts. The average daily intake is about 1g with the 
minimum recommended intake being approximately 200 mg.  
 Upon ingestion, dietary trp has been shown within minutes to enter the hepatic 
portal system and induce protein synthesis in the liver (Sidransky, 1976). Any excess 
trp is delivered to the bloodstream, where it is absorbed by tissues and used in general 
protein synthesis or in the synthesis of serotonin and melatonin. 
 Free trp in the plasma is derived not only from dietary trp, but also from trp 
released by protein turnover (Brown, 1996). In addition to general protein synthesis 
and serotonin biosynthesis, the third and main fate of trp in the body is catabolism 
through the kynurenine (kyn) pathway (Figure 7). 
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Figure 7- Catabolic pathways of trp. 
Trp is metabolised along various metabolic pathways however, 95% is metabolised 
via the kynurenine pathway. This pathway ultimately produces significant amounts of 
nicotinamide ribonucleotide, a precursor of the coenzyme nicotinamide adenine 
dinucleotide (NAD), thus decreasing the requirement for dietary niacin. 
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1.5.2 The kynurenine pathway  
The kyn pathway represents the major catabolic route of Ltrp in mammals, 95% of trp 
is metabolised via this pathway (Figure 8), (Takikawa et al., 2001). The first and rate-
limiting step in the kyn pathway is the oxidative cleavage of the pyrrole ring of trp 
catalysed by two unrelated enzymes; hepatic trp 2,3-dioxygenase (TDO) or ubiquitous 
and extrahepatic IDO. The end product of this pathway is nicotinamide 
ribonucleotide, a precursor of the coenzyme nicotinamide adenine dinucleotide 
(NAD). The kyn pathway is the only source of endogenous NAD, and therefore trp is 
an important pro-vitamin (MacKenzie et al., 2007).  
 Regulation of the kyn pathway is dependent on the type of tissue or cell in which it is 
expressed. For example, kyn production in the brain in comparison to peripheral 
organs is low; moreover, astrocytes preferentially breakdown kyn to kynurenic acid, 
which is a dead-end side arm of the kyn pathway. Microglial cells, in contrast, 
metabolise trp almost completely to quinolinic acid (QA) (MacKenzie et al., 2007), as 
do dendritic cells (Hill et al., 2007). 
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Figure 8- The Kyn pathway of trp metabolism. 
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1.5.3 Discovery of IDO 
Kotake and Masyama were the first to discover the liver enzyme TDO that catalysed 
the conversion of L-trp to N-formyl-kyn (Kotake and Masyama 1936). It wasn’t until 
1967, that Osamu Hayaishi’s group (Yamamoto and Hayaishi, 1967) discovered IDO, 
as a D-trp degrading enzyme from rabbit intestine. So far, IDO has been found only in 
mammals and yeast whereas TDO has been isolated in mammals as well as different 
insects, scallop and yeast (Yuasa et al., 2007).  
 
1.5.3.1 The INDO gene  
The IDO protein  is encoded by a single gene (INDO), located in a similar region of 
both human and mouse chromosome 8 (8p12-p11) (Najfeld et al., 1993). The cDNA 
clone was originally isolated, and after determination of its nucleotide sequence, the 
protein product identified as IDO in 1990 (Dai and Gupta, 1990). The INDO gene 
spans ~15 kb of DNA with 10 exons, and has been well conserved (Suzuki et al., 
2003). Gene transcription is tightly controlled, responding to specific inflammatory 
mediators and restricted to a limited range of cell types (Fallarino et al., 2002b).   
 
1.5.3.2 Induction of expression by IFNγ 
IDO expression has been shown to increase in response to a variety of inflammatory 
stimuli such as during; wounding, infection, or tumour growth in response to cytokine 
release (Jung et al., 2007). Monocyte-derived macrophages and DCs, endothelial 
cells, fibroblasts and some tumour-cell lines have been shown to express IDO after 
exposure to IFNγ (Fallarino et al., 2002b).  
IFNγ, a type II interferon, is a cytokine with a wide range of functions, including; a 
role in T cell differentiation, in the induction of immune-mediated inflammatory 
responses, in haematopoiesis as well as having antimicrobial, anti-proliferative, and 
anti-tumour functions (Jung et al., 2007).  IFNγ is the main inducer of INDO 
transcription and therefore the promoter region of INDO contains multiple sequence 
elements that confer responsiveness. Two IFN-stimulated response elements (ISRE1 
and ISRE2) and gamma-activated sequence (GAS) binding elements in the promoter 
recognise IFN regulatory factor-1 (IRF-1) and activated signal transducer and 
activator of transcription-1 (STAT-1) respectively (King and Thomas, 2007). STAT1 
and IRF-1 act together to mediate the induction of INDO expression by IFNγ (Chon et 
al., 1996), and both IFNγ and IRF-1 knockout mice have been shown to be deficient 
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in IDO expression during infection (Silva et al., 2002). Type I interferons, IFNα and 
IFNβ, are also able to induce INDO although to a much lesser extent than IFNγ (King 
and Thomas, 2007). This is believed to be as a result of minor differences in the 
nucleotide sequence of the ISRE homolog present in the INDO gene promoter and the 
ISRE consensus sequence characteristic of IFNα (Hassanain et al., 1993). 
There is a strong link between inflammation, IFNγ and induced IDO expression, but 
IFNγ is not essential for IDO induction. Several inflammatory agents and extracellular 
signals, such as lipopolysaccharide (LPS), the inflammatory cytokines IL-1 and TNFα 
act synergistically with IFNγ to enhance IDO expression in vitro (Babcock and 
Carlin, 2000, Platten et al., 2005). The mechanism for synergy may include an 
increase in cytokine receptor expression. 
LPS can also induce INDO expression via an IFNγ independent mechanism, which 
may be mediated by Toll-like receptors (TLRs) (Hayashi et al., 2004) and associated 
with the activities of the p38 mitogen-activated protein kinase (MAPK) and nuclear 
factor (NF)-κB (Jung et al., 2007). Jung et al. showed that the LPS induced expression 
in murine bone marrow derived DCs is mediated by PI3 kinase and c-Jun N-terminal 
kinase (JNK), whereas IFNγ induced expression is regulated by Janus kinase (JAK). 
Their results suggest that LPS and IFNγ belong to different signalling pathway 
responses of INDO induction. 
TNFα on the other hand, is directly dependent upon IFNγ; IFNγ mediated signalling 
is directly responsible for the synergistic transcriptional activation and is independent 
of TNFα specific activator recruitment to the INDO regulatory region (Platten et al., 
2005).  
 
1.5.3.3 Induction of expression by CTLA4 
Cytotoxic T lymphocyte associated antigen 4 (CTLA4), is an important negative 
costimulatory molecule constitutively expressed by Tregs (Scalapino and Daikh, 
2008). Grohmann et al. were the first to show soluble CTLA4-Immunoglobulin 
(CTLA4-Ig) fusion protein to induce INDO expression through the ligation of cell-
surface CD80/CD86 molecules (Grohmann et al., 2002). This role for CD80/CD86 
molecules has subsequently been confirmed in several model systems of both mouse 
and human DCs (Fallarino et al., 2003a, Mellor et al., 2003, Munn et al., 2004b, 
Mellor et al., 2004). Although IFNγ was required for induction of functional IDO 
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expression in some it was not essential as it could also be induced by ligation of 
CD80/CD86 in IFNγ receptor deficient DCs (Mellor et al., 2004).  
 
1.5.3.4 Cytokine inhibitors 
A number of cytokines have been shown to influence IDO activity. TGFβ inhibits 
several of the cellular responses to IFNγ. It mainly inhibits LPS induced IFNγ 
production but Yuan et al. also showed it to inhibit IDO gene expression in IFNγ 
stimulated human skin and synovial fibroblasts (Yuan et al., 1998). 
IL-6 has been shown to inhibit IDO activity; IL-6 results in downregulation of IFNγ 
receptor expression in the mouse CD8+ DC subset and is associated with a reduced 
ability of these cells to metabolise trp and initiate T cell apoptosis in vitro (Grohmann 
et al., 2001). Orobona et al. also showed that blocking the effects of IL-6 in mouse 
DCs resulted in increased trp catabolism (Orabona et al., 2004). 
 
1.5.4 Structure and expression of IDO 
With the use of X-ray crystallography, the tertiary structure of recombinant human 
IDO has recently been identified (Sugimoto et al., 2006). The protein is folded into 
two distinct alpha-helical domains of unequal size with a haem group positioned 
between them (King and Thomas, 2007). Human IDO protein consists of 403 amino 
acids with a molecular weight of ~45 kDa. The primary sequence of human INDO 
shows only 57% identity to that of mouse INDO. IDO is an intracellular enzyme; 
there are no reports of it being secreted or existing in an extracellular form (Mellor 
and Munn, 2004).  
Unlike TDO, whose catalytic activity is not dependent on haem or superoxide, the 
haem of IDO is essential for its enzymatic activity (King and Thomas, 2007). 
IDO and TDO differ in their tissue expression patterns. TDO is principally expressed 
in hepatic cells, is non-inducible and its main role is to regulate homeostatic trp 
concentrations (Mellor and Munn, 2003). IDO, on the other hand is detected in 
various tissues under normal conditions. Constitutive IDO expression has been 
demonstrated in immune privileged sites and in tissues with large mucosal surface 
area, such as the gut and placenta, potentially limiting harmful inflammatory 
responses.  
Functional IDO expression has also been found in the gut (distal ileum and colon), 
lymph nodes, spleen, thymus, lungs and mouse epididymis- which has the highest 
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expression outside the placenta (Takikawa et al., 1986). In the epididymis, IDO acts 
as an antioxidant enzyme, protecting the epithelia from the damaging effect of 
reactive oxygen species (Britan et al., 2006). IDO expression in these tissues might 
function as an anti-inflammatory and immunosuppressive mechanism (Mellor and 
Munn, 2004). In humans, IDO has been detected in lung, stomach, spleen, liver, 
kidney, thymus, epididymis and brain. 
Although most descriptions on the immunoregulatory role of IDO focus on DCs and 
macrophages, i.e. APCs; functional IDO activity can also be expressed by endothelial 
and epithelial cells, fibroblasts, eosinophils, lung cells, vascular smooth muscle cells, 
microglial cells in the central nervous system and, also certain tumour cell lines. Thus 
IDO is a molecule not just confined to the immune system (Terness et al., 2006, King 
and Thomas, 2007). 
 
1.5.5 Regulation of enzyme activity 
Although IDO is ubiquitously expressed, the protein can be present without functional 
enzymatic activity (Mellor and Munn, 2004). This is likely an evolutionary protective 
mechanism as due to its consumption of the essential amino acid (and nutrient) trp, it 
could potentially be very harmful if it were constitutively active and hence activity 
must be strictly regulated. Fallarino et al.  showed that isolated mouse splenic CD8α+ 
DCs catabolised tryptophan when exposed to IFNγ, whereas other CD8α- DCs did 
not, even though both subsets expressed comparable amounts of IDO protein as 
analysed by western blot (Fallarino et al., 2002b). Similarly, human DCs have been 
shown to constitutively express immunoreactive IDO protein as confirmed by flow 
cytometry and western blotting, yet they did not have functional enzymatic activity 
until they were activated by IFNγ and CD80/CD86 ligation (Munn et al., 2004b). The 
possible mechanisms for post-translational regulation are not yet clear, but include; 
controlling the supply of enzyme co-factors and substrates, regulation of protein 
stability, alternative splicing, and the presence of inhibitors of the enzyme active site 
(Thomas et al., 2001). Antioxidants and the cellular redox potential can also affect 
enzyme activity (Thomas et al., 2001). 
Orobana et al. recently investigated the gene expression programs of IDO competent 
DCs and showed that IFNγ stimulation of DCs resulted in downregulation of the 
TYROBP gene, which encodes the membrane protein adapter DAP12; a 
transmembrane signalling adapter which typically associates with activating 
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receptors. They concluded that the downregulation of DAP12 appears to be necessary 
for full IDO enzyme activity, suggesting that the loss of DAP12 expression could be a 
distinctive mark of IDO-competent DCs (Orabona et al., 2006). 
Nitric oxide (NO) has been shown in several studies to inhibit IDO enzyme activity. 
This has been through a direct effect, blocking the haem prosthetic group, thus 
inactivating the active site, or by breaking the Fe-N bond and inducing structural 
changes (Thomas et al., 1994, Alberati-Giani et al., 1997, Aitken et al., 2004). It also 
promotes proteasome-mediated degradation of the IDO protein (Hucke et al., 2004). 
NO is a highly reactive free radical produced by the enzymatic degradation of L-
arginine by nitric-oxide synthase (NOS) (Bogdan, 2001). There are three different 
NOS enzymes but only NOS2 (iNOS) is inducible, responding to IFNγ stimulation. It 
appears that NOS2 and IDO are reciprocally controlled, i.e. the product of one 
pathway regulates the enzyme of the other pathway; e.g. NO inhibits IDO (Thomas 
and Stocker, 1999). Although NOS2 and IDO are able to be induced in the same cell, 
it is uncertain as how one gains dominance over the other. It is unclear whether this is 
in response to the surrounding immunological milieu or directly influenced by the 
infectious organism (King and Thomas, 2007). 
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1.5.6 IDO-mediated immunoregulatory effects 
Early literature showed IDO to inhibit the proliferation of microbes and tumour cells 
in vitro as a result of depletion of the essential amino acid tryptophan (Taylor and 
Feng, 1991). In 1999, Mellor and Munn proposed a further role for IDO, suggesting 
that IDO-dependent suppression of T cell responses might function as a natural 
immunoregulatory mechanism, based on data showing that IDO regulated maternal T 
cell immunity during pregnancy (Munn et al., 1998). To date, there have been several 
studies supporting a role for IDO in immune regulation, including: as an effector 
mechanism for the immunosuppressive molecule CTLA4-Ig fusion protein 
(Grohmann et al., 2002); in T cell tolerance to tumours (Fallarino et al., 2002b, 
Friberg et al., 2002, Uyttenhove et al., 2003, Munn et al., 2004a); as a protective 
negative regulator in autoimmune disorders (Sakurai et al., 2002b, Gurtner et al., 
2003, Swanson et al., 2004); dysfunctional self-tolerance in non-obese diabetic 
(NOD) mice (Grohmann et al., 2003); and inhibition of an induced model of asthma 
(Hayashi et al., 2004). While it is clear that IDO suppresses T cell responses, the exact 
mechanism has not been fully elucidated. 
 
1.5.6.1 Tryptophan depletion 
T cells have been shown to be particularly senisitive to low tryptophan levels (Munn 
et al., 1999).  The in vitro work of Munn et al. demonstrated that IDO induced 
tryptophan depletion arrested cell cycle progression at the mid-G1 phase. Restoration 
of tryptophan to arrested cells, along with a second round of T cell receptor signalling, 
reversed the state of non-reactivity and induced cell cycle progression.  
It has been noted previously that amino acid deprivation exerts an inhibitory effect on 
cell-cycle progression (Dauphinais and Waithe, 1977, Tobey and Ley, 1971). In fact T 
cells may sense reduced levels of free tryptophan by two known amino acid 
responsive signal transduction pathways. The first is the mammalian Target of 
Rapamycin (mTOR) kinase pathway; mTOR signalling controls initiation of 
ribosomal translation. Amino acid starvation has been shown to inhibit this pathway 
by resulting in dephosphorylation of translation initiation regulators (Gao et al., 2002, 
Rohde et al., 2001). The immunosuppressant drug, rapamycin works specifically 
through this pathway (Grolleau et al., 2002). A second amino acid pathway is initiated 
by General Control Non-depressible 2 (GCN2) kinase. Amino acid depletion results 
in phosphorylation and activation of the kinase domain, resulting in phosphorylation 
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of eukaryotic translation-initiation factor-2α (eIF-2α) and inhibition of translation 
(Harding et al., 2000). These and other observations led to the hypothesis that the 
main mechanism by which IDO inhibits T cell proliferation is the depletion of 
tryptophan. However, most of the results suggesting trp depletion as the mechanism 
of IDO-induced immunosuppression have been obtained in vitro, and whether or not 
this is responsible for the immunosuppressive effects of IDO in vivo is open to debate. 
In vivo, a local decrease of trp is rapidly compensated by diffusion from surrounding 
tissues and plasma. In addition, at the site of inflammation, dead cells provide an 
additional source of trp by releasing their intracellular stocks (Terness et al., 2006). 
Thus the trp depletion hypothesis may not be the only explanation for the 
immunomodulatory properties elicited by IDO. 
What is interesting is that from an evolutionary perspective the downregulation of the 
immune system by trp metabolism, i.e. the suppression of T cell proliferation, appears 
to be in direct conflict with the antimicrobial function of IDO. To efficiently clear a 
pathogen, a brisk immune response is required at the infection site. On the one hand 
this IFNγ-induced upregulation of IDO protects against invading pathogens, while on 
the other inhibiting the production of the same IFNγ by T cells. Work carried out by 
MacKenzie et al. may help to explain these contradictory effects. They investigated 
the critical threshold of trp concentration required for survival of both T cells and 
micro-organisms. They found that this concentration is two to three times higher for 
bacteria (staphylococci) than for T cells (MacKenzie et al., 2007). They suggest that 
IDO-mediated trp depletion in the first instance leads to an inhibition in the growth of 
the pathogen and then, at lower concentrations, acts as a negative feedback loop 
downregulating T cell proliferation and hence IFNγ production. This would prevent 
an overshoot of the immune response and thus protect the host tissue from possibly 
damaging trp starvation. Thus IDO would be a ‘late contributor’ to the immune 
reaction, having a role of downregulating a successful response. On the other hand, 
inducers of IDO are clearly present at the start of an inflammatory process. IDO 
present early in the immune response may exist in a functionally inactive form or may 
not reach suppressive concentrations (Terness et al., 2006). The former can be 
achieved by coexpression of IDO inactivators, such as NO (Thomas et al., 1994). 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 69 
1.5.6.2 Immune modulation by tryptophan catabolites 
It is also known that the kynurenines resulting from tryptophan catabolism, which 
include: Kyn, 3-hydroxykynurenine (3HK), 3-hydroxyanthranilic acid (3HAA) and 
QA, can themselves inhibit T cell activation and proliferation (Terness et al., 2002, 
Frumento et al., 2002).  
Kynurenines have pro-apoptotic properties particularly for activated cells and Th1 
lymphocytes (Fallarino et al., 2002a, Fallarino et al., 2003b) and molecular 
mechanisms of apoptosis have been characterised in murine thymocytes (Fallarino et 
al., 2002a). It has been shown that 3HAA induces apoptosis which is independent of 
Fas-/ Fas ligand interactions and is associated with the activation of caspase-8 and 
release of cytochrome c from the mitochondria (Fallarino et al., 2002a). In 
monocyte/macrophage cell lines, 3HAA can also induce apoptosis by production of 
hydrogen peroxide (Morita et al., 2001).  Besides T cells, kynurenines also suppress 
NK cells (Terness et al., 2002, Frumento et al., 2002), whereas B cells are not affected 
(Frumento et al., 2002). Fallarino et al. (2002) exposed T cells, macrophages and DCs 
to trp catabolites, 3HAA and QA, and demonstrated increased apoptosis. 
In the study by Fallarino et al. (2002) the kynurenine concentrations required to affect 
macrophages and DCs were 10-fold those required for lymphocytes, thus IDO-
producing cells seem to display resistance to the effects of IDO. Macrophages have 
been described as possessing a high affinity trp transport system, which may allow 
them to access the scant trp available during increased IDO activity (Seymour et al., 
2006). It may also be partly explained by the findings that some IDO competent cells 
also express the IFNγ-inducible enzyme trp-transfer-RNA ligase (WARS). Keskin et 
al. (2007) demonstrated that macrophages transfected to overexpress IDO had 
reduced superoxide levels in cell culture compared with control macrophages and had 
reduced protein nitration, suggesting that they were protected against oxidative stress 
(Fallarino et al., 2002b). So IDO induction in macrophages is likely to represent a 
host defence mechanism which produces a hostile environment for pathogens while at 
the same time protecting the macrophage itself against this environment. However, 
these findings do not explain DC and macrophage resistance to trp catabolites. It may 
be that specific kynurenines have a particular affinity for certain cell types owing to 
cell-specific uptake mechanisms or the differential expression of enzymatic 
breakdown pathways (Frumento et al., 2002). It is known that DCs metabolise 
tryptophan through the kynurenine pathway as demonstrated by 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 70 
immunohistochemical staining of the presence of quinolinic acid, the penultimate 
product of the kynurenine pathway (Hill et al., 2007). Furthermore, it has been shown 
that 3HAA induced T cell death is as result of inhibition of NF-κB activation upon T 
cell antigen receptor engagement by specifically targeting PDK1 (Hayashi et al., 
2007). The same authors showed that inhibition of NFκB and induction of apoptosis 
is specific to CD4+ T cells as 3HAA did not inhibit NFκB activation or induce cell 
death upon Toll-like receptor 4 (TLR-4) stimulation in dendritic cells (Hayashi et al., 
2007). While DCs and macrophages appear to be resistant to the apoptotic effects of 
IDO, it is not known whether the phenotype of these cells is altered by trp deficiency 
or excess catabolites (Mulley and Nikolic-Paterson, 2008). 
The combined effect of tryptophan degradation and increasing concentration of 
kynurenines has been shown to be responsible for GCN2 kinase mediated down-
regulation of the TCRζ-chain in CD8+ cells reducing their cytotoxic effector function 
(Fallarino et al., 2006b). In addition, long term tryptophan depletion with increased 
production of tryptophan metabolites promotes conversion of naïve CD4+CD25- T 
cells into a regulatory phenotype (Fallarino et al., 2006b).  
In conclusion, the available evidence suggests a synergistic role of both trp depletion 
and production of trp catabolites in regulating adaptive immunity. They do not appear 
mutually exclusive and each could be active in varying degrees in different tissues or 
cells.  
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1.5.7 IDO2 
Until recently it was believed that the first and rate-limiting step in the kyn pathway 
was performed by either of the two enzymes, TDO or IDO, depending on the tissue 
and cell type. This was until the discovery of a gene with homology to INDO in 2007 
by a group in Boston (Murray, 2007) and subsequently demonstrated by three other 
groups to encode a trp catabolising enzyme (Metz et al., 2007, Ball et al., 2007, Yuasa 
et al., 2007). This new enzyme has been referred to as IDO-like protein (INDOL1) or 
IDO2 due to similarities in structure and enzymatic activity to IDO. The discovery of 
IDO2 suggests that the kyn pathway of trp metabolism may be involved in more 
biological processes than previously thought (Ball et al., 2009). 
The exact biological role of IDO2 is yet to be defined as its discovery is only recent. 
However, its predominant expression in kidney, followed by epididymis, ovary, 
uterus and also in DCs suggests that it has a role in kidney function, fertility and 
immunomodulation (Ball et al., 2009). Its ability to catabolise trp has been 
demonstrated in intact mammalian cells expressing IDO2 (Ball et al., 2009, Metz et 
al., 2007), with IDO2  catabolising a similar range of substrates to IDO but with much 
lower efficiency (Ball et al., 2009). 
 
1.5.7.1 The INDOL1 gene 
The INDOL1 gene is located on chromosome 8p12 just downstream of the IDO gene 
INDO. The primary human transcript is derived from 11 exons encompassing a 74 kb 
region of chromosome 8p12 (Metz et al., 2007). Transcripts are initiated only 5 to 7 
kb downstream of the INDO gene. The mouse gene differs in its lack of the alternate 
exon 1a found in the human gene; otherwise, exon positions are conserved, indicating 
gene duplication during evolution of this region of the genome (Metz et al., 2007). 
Alignments between IDO and IDO2 sequence have revealed highly conserved 
features that mediate haem and substrate binding, although the overall level of 
sequence conservation in humans is not particularly high (43% identical) (Metz et al., 
2007).  
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1.5.7.2 Structure and expression of IDO2 
IDO and IDO2 proteins share significant identity at the amino acid level (43% for 
humnas and mouse) but are not structurally related to the TDO protein. Human and 
mouse IDO2 proteins consist of 420 and 405 amino acids respectively, and are more 
conserved (72% identical) than IDO proteins (62% identical). Significantly, certain 
catalytically important residues determined by IDO mutagenesis and crystallographic 
analysis are highly conserved in IDO2 (Metz et al. 2007, Ball et al. 2009). 
Metz et al. (2007) showed IDO2 expression to be more restricted than IDO using RT-
PCR. Primers spanning the complete human coding region detected full length 
mRNAs only in placenta and brain, whereas primers specific to exon 10 (found in all 
human INDOL1 cDNAs) detected INDOL1 mRNAs in liver, small intestine, spleen, 
placenta, thymus, lung, brain, kidney and colon. A more restricted expression pattern 
was detected in mouse, revealing INDOL1 transcripts only in liver and kidney.  
Ball et al. found IDO2 protein in mice to be predominantly expressed in the kidney 
followed by epididymis, testis and liver as well as the ovary, uterus and placenta (Ball 
et al., 2009).  
Lӧb et al. showed that human DCs express both IDO and IDO2, but that only IDO 
mediates tryptophan catabolism. IDO and IDO2 differ also in their response to the 
competitive IDO-inhibitor 1-methyl-trp (1MT). 1MT exists in two forms, the levo and 
dextro isomer. It has been shown that D-1MT is selective for inhibition of IDO2, 
whilst its stereoisomer L-1MT is more selective for IDO (Metz et al. 2007, Lӧb et al. 
2008).  
Although IDO has shown to be expressed in murine corneas at the mRNA level 
(Serbecic and Beutelspacher, 2006), there have been no previous reports on IDO2 
expression in the cornea. 
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1.5.8 IDO and the eye 
Both murine and human corneas constitutively express IDO, albeit at low levels. This 
expression is markedly upregulated during rejection in response to the release of pro-
inflammatory cytokines. IDO was found in the endothelium of rejecting mouse 
corneas whereas it was found in corneal endothelial cells or in the corneal epithelial 
layer (Beutelspacher et al., 2006) and in rejecting human corneas depending on the 
underlying corneal disease and predominant site of immune reaction (Serbecic et al., 
2009). Furthermore, it was demonstrated that this upregulation of IDO in human 
(HCEC) and mouse (MCEC) corneal endothelial cells could inhibit T cell 
proliferation in vitro. This represents therefore an innate mechanism of both HCEC 
and MCEC for immunological modulation. More significantly, Serbecic et al. (2009) 
demonstrated that an L-amino acid transporter protein (LAT1) is upregulated in 
HCEC by pro-inflammatory cytokines. This transporter is known to exchange 
tryptophan for kynurenine. The authors conclude that the inhibition of T cell 
proliferation might depend on rapid delivery of L-kynurenine to the local corneal 
environment and that LAT1 is responsible for this mechanism. Moreover, Ryu et al. 
showed that amongst the three types of human corneal cells (fibroblasts, epithelial 
cells, andothelial cells), IDO mRNA and protein expression were observed in corneal 
fibroblasts and epithelial cells, with higher levels in the fibroblasts. They showed that 
human CD4+ T cells cultivated in conditioned medium derived from human corneal 
fibroblasts resulted in decreased cell proliferation and increased apoptosis, concluding 
that human corneal fibroblasts are relatively immunoresistant and that the IDO 
expression can act as one of the factors for the maintenance of immune privilege in 
the cornea (Ryu and Kim, 2007). 
IDO has also been shown to be involved in promoting the development of ACAID 
(Chen et al., 2006a). These authors showed that an increased expression of IDO 
correlates with the formation of ACAID and that inhibiting IDO activity with 1-MT 
prevented its development.  
As well as the role of IDO in the immune privilege of the eye, IDO has also been 
demonstrated as having a protective role in the eye, mainly as an antioxidant by its 
direct scavenging of superoxide radicals (Malina and Martin, 1996). IDO has also 
been shown to protect corneal endothelial cells from UV mediated damage (Serbecic 
and Beutelspacher, 2006). 
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1.5.9 IDO in allograft rejection 
Manipulation of the expression of IDO offers an important possibility for preventing 
graft rejection. Increased IDO activity has been demonstrated to suppress T cell 
activity in vitro in a variety of cell lines, whether by overexpression by ex-vivo 
transduction with IDO cDNA or upregulated endogenous IDO (Logan et al., 2002, 
Munn et al., 1999, Beutelspacher et al., 2006). IDO has also been shown to be 
upregulated in rejecting grafts as a result of IFNγ induction and increased IDO 
activity has been seen in studies of human kidney, cardiac and corneal transplant 
rejection (Brandacher et al., 2007, Guillonneau et al., 2007, Beutelspacher et al., 
2006)). 
Although IDO is upregulated during rejection, inhibition of function with 1-MT did 
not lead to significant increases in the speed of graft rejection in a variety of animal 
transplant models including skin, cornea and pancreas (Moffett and Namboodiri, 
2003, Grohmann et al., 2002, Sakurai et al., 2002a, Beutelspacher et al., 2006), with 
liver transplantation being the exception to this (Miki et al., 2001, Pan et al., 2000). 
This suggests that the level of IDO upregulation during rejection is not sufficient to 
prevent or significantly delay this process. Whether this is due to the rejection process 
being too strong to be overcome by IDO or simply that insufficient IDO is being 
induced in these models is unclear. The latter possibility has been addressed by using 
gene transfection strategies to overexpress IDO at levels higher than can be achieved 
endogenously (Mulley and Nikolic-Paterson, 2008). 
Ex-vivo transduction of transplanted tissue with IDO cDNA has generally resulted in 
prolongation of graft survival. In a mouse model of corneal transplantation, IDO 
transduction resulted in a significant prolongation in graft survival (median survial of 
21 days) in comparison to 11 days for controls (Beutelspacher et al., 2006). 
Alexander et al. investigated the effect of IDO overexpression on islet cell allograft 
survival. Diabetic NODscid mice (using streptozocin) were used as recipients. After 
islet transplantation the mice were reconstituted with diabetogenic NOD splenocytes. 
IDO-transfected islets exhibited significant prolongation of graft survival (median of 
15 days longer) in comparison to controls (Alexander et al., 2002). 
Li et al. demonstrated a significant reduction in CD3+ T cell infiltration of skin 
xenografts receiving IDO-transduced fibroblasts at days 14 and 28 post transplant 
relative to controls (Li et al., 2006). 
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Most recently, Yu et al. demonstrated prolongation of cardiac allograft survival after 
transfection of allografts with IDO. Furthermore, they showed that hearts treated with 
IDO had significantly reduced transcript levels of IL-2, IFNγ and IL-17 and T cells 
isolated from allografts pre-treated with IDO displayed a dramatic reduction of 
proliferation capacity to alloantigen stimuli and had a significant higher proportion of 
Tregs in comparison to controls (Yu et al., 2008). It appears therefore that IDO has an 
effect on both naïve and sensitised alloresponses as well as on xenogeneic responses 
in vivo. 
Although some work has been undertaken to understand the mechanism of IDO-
induced prolongation in graft survival, little is known about the effects of kynurenines 
in allograft rejection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 76 
1.5.10 Kynurenines and their therapeutic applications 
Kynurenines may also be used in pharmacotherapy (Inglis et al., 2007). Several 
groups have looked at the effects of kynurenine administration mainly in animal 
models of allergic airway inflammation (Taher et al., 2008), mouse model of collagen 
induced arthritis (CIA) (Criado et al., 2009) and there has been one report in a rat 
model of skin transplantation (Bauer et al., 2005). Taher et al. (2008) showed that 
intraperitoneal administration of L-kyn, 3HK, 3HAA, QA and Xanthurenic acid in a 
mouse model of allergic asthma resulted in reduced eosinophilia as well as Th2 
cytokine production. Similarily, Criado et al. showed in a mouse model of CIA that 
IDO was induced in lymph node dendritic cells after collagen immunisation and that 
if tryptophan catabolism was inhibited by a systemic IDO inhibitor during active 
arthritis it resulted in increased severity. Conversely, bypassing the requirement for 
tryptophan degradation by the intrapeitoneal administration of L-kyn resulted in 
amelioration of the disease (Criado et al., 2009). 
Bauer et al. showed moderate prolongation in graft survival in a rat model of skin 
transplantation after the subcutaneous adminstration of L-kyn and 3HAA (Bauer et 
al., 2005). Currently, there is one commercially available drug, Tranilast :N-(3,4-
dimethoxycinnamonyl) anthranilic acid (3,4-DAA) that shares a common core of the 
anthranilic acid with other kynurenines- 3HAA and 3HKA respectively (Platten et al., 
2005) Figure 9. Studies in mice with experimental autoimmune encephalomyelitis 
(EAE) (Platten et al. 2005) or with CIA (Criado et al. 2007) have proved that 
Tranilast effectively ameliorates the clinical and histological manifestations of both 
diseases. 
 
 
Figure 9- Structure of Tranilast and selected kynurenines. Anthranilic acid core is 
highlighted in the black rectangle. 
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1.5.10.1 Tranilast 
 
Tranilast, an anti-inflammatory drug, has several mechanisms of action and is 
currently approved for use in Japan as an anti-allergic drug. It was first found to 
inhibit mast cell degranulation and thereby their antigen-induced release of histamine 
(Azuma et al., 1976),  but since, other biological effects have been suggested, such as 
inhibition of leukotrienes, cytokines, prostaglandins, oxygen radicals, and 
cycloxygenase-2 expression (Komatsu et al., 1988a, Komatsu et al., 1988b). Tranilast 
has also been shown to have anti-proliferative effects as well as inhibiting collagen 
deposition in several models of inflammatory disease (Tanaka et al., 1994, Miyazawa 
et al., 1996, Nie et al., 1996). Based on this, Tranilast has been used to inhibit keloid 
formation (Suzawa et al., 1992). More recently, in small clinical studies it has been 
shown to inhibit restenosis after percutaneous transluminal coronary angioplasty 
(Tamai et al., 1999) but not in a large clinical trial (SoRelle, 2001). It has also been 
shown to inhibit cardiac allograft vasculopathy by inhibiting neo-intimal smooth 
muscle cell proliferation (Izawa et al., 2001). Tranilast induced inhibition of vascular 
inflammation is believed to be as a result of its inhibition of vascular chymase, 
platelet-derived growth factor (PDGF)- and transforming growth factor β1 (TGF-β1)- 
induced smooth muscle cell proliferation as well as a result of upregulation of p21, a 
universal inhibitor of cyclin-dependent kinases (Izawa et al., 2001). Furthermore, it 
has been shown to inhibit NF-κB dependent transcriptional activation of endothelial 
cell adhesion molecules (Spiecker et al., 2002).   
As mentioned previously, Tranilast is an anthranilic acid derivative that shares the 
anthranilic acid core with both 3-HAA and 3-HK. Platten et al. have shown it to 
suppress antigen specific T cell proliferation and IFNγ and TNFα production and to 
increase production of IL-4 and IL-10 in a manner comparable with the structurally 
related kynurenines (Platten et al., 2005). They also showed Tranilast to reverse 
paralysis in mice with established experimental autoimmune encephalomyelitis (EAE) 
at least partly by inhibiting the activation of myelin-specific T cells (Platten et al., 
2005). Similarily, Tranilast has been shown to ameliorate the clinical and histological 
manifestations of arthritis in a mouse model of collagen induced arthritis (CIA), a T 
cell mediated disease that displays many pathological, genetic and immunological 
similarities to human rheumatoid arthritis (RA) (Inglis et al., 2007). In summary, 
Tranilast has anti-inflammatory, antiproliferative as well as immunomodulatory 
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effects. The exact mechanism for Tranilast’s immunosuppressive activities remains 
unknown and its role in preventing allograft rejection has not been previously 
investigated.  
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1.6 Aims, Approaches and Hypotheses of study 
The overall objective of this study was to harness IDO and particularly kynurenines as 
potential regulatory mechanisms to prolong allograft survival. 
In order to do this there were four specific aims: 
1) To determine whether UV irradiation could result in upregulation of IDO 
activity and if so, what effect this had on corneal allograft survival 
2) To determine if the effect of IDO in delaying graft rejection could be 
replicated by the administration of tryptophan metabolites and if so to 
determine the effect of the synthetic tryptophan metabolite 3,4-DAA on 
allograft survival 
3) To determine if IDO expression, or the administration of kynurenines, had a 
deleterious effect on corneal endothelial biology 
4) To examine how kynurenines prolong graft survival. 
 
Plan of investigation: 
 
1.6.1 Does ultraviolet light influence IDO expression in the cornea? 
The first report of IDO in ocular tissue was in the lens: Takikawa and co-authors 
demonstrated its role in protecting the lens from ultraviolet (UV) damage (Takikawa 
et al., 2001). It is therefore likely that a physiological function of IDO is to protect 
endothelial cells from UV-mediated cell injury, and there is data that it can be 
upregulated in endothelial cells by UVB (Serbecic and Beutelspacher, 2006). This 
study compared the effect of UVB irradiation on IDO mRNA and protein expression 
in murine corneal endothelial cells by real time RT-PCR and western blotting. UVB 
irradiation was administered according to protocols previously described (Harned et 
al., 2003). Functional activity was quantified by L-kynurenine production. 
One potential long-term strategy for therapeutic intervention would be to develop 
approaches to upregulate IDO activity in corneas. If increased levels of IDO were 
confirmed following irradiation, the effect of UV irradiation on allograft survival was 
to be examined. 
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1.6.2 What is the effect of tryptophan metabolites on corneal allograft survival and 
how do they prolong graft survival? 
Progressing from preliminary research undertaken with ex-vivo IDO viral 
transduction of the donor cornea significantly prolonging allograft survival 
(Beutelspacher, Pillai et al. 2006), the study assessed whether kynurenines could 
replicate the effect of IDO in prolonging graft survival, this would be a far simpler 
therapeutic approach than gene therapy. While on the one hand, the prolongation in 
graft survival obtained with IDO over-expression in the cornea, is explained by the 
accepted effect of IDO-induced tryptophan depletion in arresting replication of 
activated T lymphocytes, it is also known that the catabolites resulting from 
tryptophan breakdown, including Kyn and its further breakdown products 3HK, 
3HAA and QA can inhibit T cell activation (Terness et al., 2002, Frumento et al., 
2002). The study assessed how effective the kynurenines were in inhibiting T cell 
proliferative responses. This was tested using mixed lymphocyte responses consisting 
of stimulator C3H strain dendritic cells and responder BALB/c T cells as well as anti-
CD3 and anti-CD28 stimulated T cells. It was important to assess the effect of the 
kynurenines on T cell viability and on the induction of regulatory cells. This would 
allow us to determine which of the kynurenines is the most potent. Little is known 
about the effect of the kynurenines on dendritic cells. This study investigated the 
effect of individual kynurenines on DC phenotype, function and viability.  
As mentioned previously, in section 1.4.7.5, emerging evidence indicates a role for Th 
17 cells in allograft rejection. Recently it has been shown that Th17 cells express high 
levels of AhR as discussed in section 1.4.7.3. AhR activation results in expansion of 
Th17 cells, as well as increased cytokine production. FICZ is formed upon exposure 
of solutions of trp, cell culture medium or cells to UVR and is a high affinity AhR 
ligand. FICZ increases the proportion of Th17 cells and their production of IL-22 by 
activating the AhR. Given that a tryptophan photo-product is an AhR ligand, this 
study investigated whether or not kynurenines act as AhR ligands and induce AhR 
signalling transduction pathways, namely cytochrome p450 and 1A1. This was 
investigated by looking at gene upregulation of certain molecules of the AhR 
signalling pathway using quantitative real time RT-PCR.  
 
The known ability of kynurenines to inhibit T cell activation and proliferation offers, 
in the context of corneal transplantation, the opportunity for systemic or local 
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administration of these molecules with a view to blocking rejection. Using 
kynurenines identified from the first part of this project and using quantities estimated 
from the in vitro dose-response curves, this study investigated the effect of both 
systemic and topical administration on graft survival.  The effect of both systemic and 
topical treatment on lymphocyte counts in spleen, peripheral blood and in the case of 
topical treated animals, DLN lymphocyte counts were assessed. The induction of 
regulatory T cells after in vivo administration was also assessed.  
As there is a commercially available tryptophan metabolite (Tranilast), this study 
assessed the effect of Tranilast again on T cell function, namely proliferation, 
apoptosis and induction of regulatory cells and tried to understand further its 
mechanism of action. Experiments performed in a mouse in vitro system have shown 
Tranilast to inhibit T cell proliferation as a result of cell cycle arrest at the G1/S phase 
(Platten et al., 2005). This study determined whether Tranilast treated CD4+ T cells 
express specific cell cycle associated kinase inhibitors such as, p21 and underlined a 
potential signalling pathway by which T cells are rendered anergic. The effect of 
Tranilast on graft survival was also determined. 
 
These experiments offer an attractive and potentially rapidly applicable strategy for 
reducing T cell responses during allograft rejection. In addition, it might also find 
application in other settings such as autoimmune or inflammatory disorders of the 
anterior chamber. 
 
1.6.3 The effect of IDO expression and kynurenines on corneal endothelial cell 
function 
Clearly any strategies that aim at modulating or mimicking IDO activity have the 
potential of altering the behaviour of non-immunological cells, in this instance corneal 
endothelial cells. High levels of IDO activity, for example in the placenta, are 
compatible with the function and survival of normal tissues. Preliminary work, with 
different cell types over-expressing IDO has shown no obvious non-specific effects of 
the enzyme. However, it is important to systematically investigate this. This study 
investigated the effects of increased expression of IDO by both pathophysiological 
processes (IFNγ stimulation) and by gene transfer. The effect of addition of 
kynurenines directly to corneal endothelial cells was also examined. 
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The most likely consequence of IDO activity is death of the cells. In the first instance 
the effect of IDO and kynurenine administration on apoptosis of the cells was 
investigated. It has been previously shown that it is possible to induce apoptosis of 
corneal endothelial cells in a NO dependent manner using combinations of cytokines 
(Sagoo et al., 2004). Using dose response experiments in the presence or absence of 
IDO expression or kynurenines it was determined whether the cells became more 
sensitive to apoptosis by this pathway. Other functions of the corneal endothelial 
cells, namely their ability to upregulate chemokine and adhesion molecule expression, 
and MHC class II expression was also investigated (Arancibia-Carcamo et al., 2004). 
These experiments will allow determination of any toxic effect of IDO activity. 
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2.1 Cell Lines 
Four cell lines, detailed below, were used during the study. All cell lines were tested 
for Mycoplasma organisms using the gel-based PCR Mycoplasma Test Kit (MD 
Biosciences, Glasgow, UK) and were confirmed to be free of contamination before 
use. 
 
2.1.1 Murine corneal endothelial cells, MCEC 
Much of the in vitro work performed was carried out using a transformed endothelial 
cell line derived from murine (BALB/c) corneal endothelium, MCEC. MCEC were 
immortalised using a recombinant viral construct pLXSN16 E6/E7 containing the E6 
and E7 genes of human papilloma virus (Wilson et al., 1995). This was a kind gift 
from Prof. J. Neiderkon, (U.T. Southwestern Medical Centre, Dallas). Cells were 
maintained in DMEM supplemented with 100 u/ml penicillin:streptomycin, non-
essential amino acids (Gibco-BRL, Paisley, UK) and 10% heat inactivated foetal 
bovine serum (FBS) (Gibco-BRL). Cells were routinely grown at 37°C in 5% CO2 
within 75-cm2 flasks (T75; Corning Inc., Acton, MA, USA). Adherent cells were 
passaged routinely using trypsin treatment (0.02% EDTA and 0.05% trypsin solution- 
Gibco-Invitrogen) to remove them from the dish.  
 
2.1.2 Canine osteosarcoma cells, D17 
The D17 tumour cell line is derived from dog osteosarcoma tissue. They are 
characterised by their ease of transfection with a retroviral vector (Gilmore et al., 
2003). Cells were maintained in DMEM supplemented with 100 u/ml penicillin: 
streptomycin, non-essential amino acids and 10% heat inactivated FBS. Adherent 
cells were passaged routinely using trypsin treatment (0.02% EDTA and 0.05% 
trypsin solution) to remove them from the dish.  
 
2.1.3 293 Human embryonic kidney cells, 293HEK 
These cells are an immortalised epithelial cell type derived from human embryonic 
kidney (Graham et al., 1977) (ECACC 85120602). Cells were maintained in DMEM 
supplemented with 100 u/ml penicillin:streptomycin, non-essential amino acids and 
10% heat inactivated FBS. Adherent cells were passaged routinely using trypsin 
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treatment (0.02% EDTA and 0.05% trypsin solution- Gibco-Invitrogen) to remove 
them from the dish.  
 
2.1.4 Chinese Hamster Ovary (CHO) cells 
A CHO cell line stably transduced with IDO was used a positive control (generated in 
the laboratory) when assessing IDO protein expression using western blotting. Cells 
were maintained in DMEM supplemented with 100 u/ml penicillin: streptomycin, 
non-essential amino acids and 10% heat inactivated FBS. Adherent cells were 
passaged routinely using trypsin treatment (0.02% EDTA and 0.05% trypsin solution) 
to remove them from the dish.  
 
2.1.5 Freezing cells 
Cells were removed from a confluent flask using trypsin and washed with PBS. Cells 
were resuspended at 1x 106/ ml in 10% DMSO and 90% foetal calf serum (FCS) and 
1 ml aliquotted into 2 ml cryovials. The cells were placed in an isopropanol cooling 
chamber that had been cooled to 4°C and placed at -80°C. Frozen cells were stored in 
liquid nitrogen. 
 
2.1.6 Thawing cells 
To thaw cells, the cryovial was placed in a 37°C water bath. The cells were then 
transferred to a 50 ml conical tube containing 10 ml of warmed medium, pelleted and 
the medium discarded. The cells were then resuspended in medium and transferred to 
a tissue culture flask at the appropriate volume. 
 
2.2 Exogenous Treatment of MCEC 
 
2.2.1 Cytokine stimulation of MCEC 
When assessing the effect of cytokine stimulation on MCEC phenotype, the 
recombinant murine pro-inflammatory cytokine IFN-γ (PeproTech EC, London, UK) 
was added directly to cell cultures at final concentrations of 100 ng/ml and 
subsequently cultured for 48 h. Cells were cultured to 70% confluence during routine 
culture and prior to stimulation. 
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2.2.2 Induction of apoptosis 
Recombinant murine pro-inflammatory cytokines TNF, IL1-α and IFN-γ (PeproTech 
EC, London, UK) were added directly to cell cultures at final concentrations of 10 
ng/ml and 100 ng/ml in combination and subsequently cultured for 48 h (Sagoo et al., 
2004). Cells were cultured to 70% confluence prior to stimulation. 
 
2.2.3 EIAV lentiviral transduction of MCEC 
MCEC were seeded in 6-well culture plates at 2x105 cells/ well. After 24 hours and at 
approximately 60% confluence, EIAV-IDO (described later in section 2.9) or EIAV-
GFP (9.5 x106 TU/ml) was added at a final MOI of 100 and subsequently cultured for 
72 h.  
 
2.2.4 UVB irradiation of MCEC 
Cells were plated in 6-well plates (2x105 cells/well) and grown to confluence. Cells 
were exposed to UVB radiation at doses ranging from 0 to 1000 j/m2 from the UV 
source (Fisher Scientific, EL Series; 8 W, 302 nm, typical peak intensity at 7.5 cm- 
1300 µW/cm2 with a UV dose equivalent of 13 j/s). This lamp has a filter that blocks 
out all other wavelengths. Before irradiation, the media was removed from cells in 6-
well plates. Immediately after UV exposure, the media was replaced (Harned et al., 
2003). 
 
2.3 RNA extraction, cDNA synthesis and Real time RT-PCR  
Total RNA from corneal endothelial cells was extracted using the RNA isolation 
reagent Trizol (Invitrogen, UK) which uses the single step method for RNA isolation 
(Chomczynski and Sacchi, 1987). Briefly, corneal endothelial cells were homogenised 
in 1 ml Trizol and incubated at RT for 5 minutes. RNA was extracted by the addition 
of 200 µl of chloroform and precipitated with 500 µl of isopropanol. Total RNA was 
then washed with 70% ethanol and dissolved in RNA free molecular graded water. 
RNA concentration was determined by spectrophotometry and used when ratio of 
OD260 toOD280 was greater than 1.7. 
 
2.3.1 RNA extraction from mouse corneas 
For optimal RNA preparation from mouse corneas, corneas were removed from mice 
within 1 hr of sacrifice and snap-frozen in an eppendorf tube in liquid nitrogen. 
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Corneal tissue was ground using the beads and reagent supplied with the Fast RNA 
Pro Green Kit (QBiogene, Carlsbad, CA). Briefly, 1 ml of RNApro™ solution was 
added to one vial of beads from the Fast RNA kit. 4-6 corneas were thawed on ice and 
added to the bead mixture and the corneas ground using a FastPrep instrument for 40 
sec at 60 vibrations/ second and repeated 2-3 times until no tissue fragments were 
visible. The RNA was extracted as per manufacturer’s instructions. The final step was 
to DNAse treat the RNA by adding 1 µl DNAse, 1 µl Rnasin and 2.5 µl of 10xDNAse 
buffer (Promega, Southampton, UK) in a final volume of 25 µl. This was incubated 
for 30 min at 37°C in a waterbath. The reaction was stopped by heating for 10 min at 
70°C on a heat block. 
Prior to reverse transcription, RNA was treated with RNAse-free DNAse (RQ RNase-
free DNAse, Promega, Madison, WI, USA) for 30 minutes to eliminate potentially 
contaminating genomic DNA. The first strand cDNA was synthesised from 15.25 µl 
of RNA with 1 µl of oligo dT primer (10 µg/ml) heated at 65°C for 10 minutes and 
then cooled on ice for 2 minutes. To this 5 µl of 5x RT buffer, 1 µl of M-MLV reverse 
transcriptase, 1 µl of dNTP’s and 0.75 µl of RNAsin RNAse inhibitor. cDNA was 
stored at -20°C. 
The PCR protocol comprised an initial denaturation step at 95°C for 10 minutes 
followed by 40 cycles of amplification. The conditions were denaturation at 95°C for 
15 seconds, annealing at 60°C for 1 minute, elongation at 72°C for 30 seconds and a 
final dissociation stage. Amplification was performed using a LightCycler machine 
(Roche Molecular Biochemicals, Hertfordshire, UK) and the HotStart SYBR-Green 
mastermix (Roche), according to the manufacturer’s protocols. Specificity of the 
amplification was assessed by the melting temperature of the product determined 
using the LightCycler. Quantitative, real-time PCR data were analysed with 
LightCycler software (Roche). Table 2 lists the primer pair sequences used in real-
time PCR analysis. 
 
2.3.2 Use of quantitative real-time RT-PCR for determination of viral titre 
In order to determine titres for EIAV IDO lentiviral stocks, quantification of a DNA 
sequence found in the woodchuck hepatitis postregulatory element (WPRE) of the 
lentiviral constructs had to be undertaken as a reporter gene is not present in the 
constructs to allow for direct visualisation (Lizee et al., 2003a). The following   
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primers were used for the detection by real-time PCR of WPRE in RNA extracted 
from EIAV-transduced D17 cells- forward 5’-3’ CCGTTGTCAGGCAACGTG; 
reverse 5’-3’ AGCTGACAGGTGGTGGCAAT. 
Gene amplified 
(mouse) 
Amplicon size 
(bp) 
Primers (sequence given 5’-3’) Temp (°C) 
IDO1 197 Forward 
TGGCAAACTGGAAGAAAAAG 
Reverse 
AATGCTTTCAGGTCTTGACG 
60 
IDO2 188 Forward 
AATATGGAGCCTCAAAGTCAG 
Reverse 
TGAGCTCGGAGCTGGCGGTTC 
60 
HPRT 196 Forward 
GTAATGATCCAGTCAACGGGGGAC 
Reverse 
CCAGCAAGCTTGCAACCTTAACCA 
60 
FoxP3 314 Forward 
CACCCAGGAAAGACAGCAACC 
Reverse 
GCAAGAGCTCTTGTCCATTGA 
60 
p21 103 Forward 
CCTGGTGATGTCCGACCTG 
Reverse 
CCATGAGCGCATCGCAATC 
60 
p15 169 Forward 
CCCTGCCACCCTTACCAGA 
Reverse 
CAGATACCTCGCAATGTCACG 
60 
AhR 110 Forward 
CTCCTTCTTGCAAATCCTGC 
Reverse 
GGCCAAGAGCTTCTTTGATG 
60 
ARNT 101 Forward 
CAGCTCCTCCACCTTGAATC 
Reverse 
GGCGACTACAGCTAACCCAG 
60 
CYP1A1 110 Forward 
AGAATACGGTGACAGCCAGG 
Reverse 
TTTGGGAGGAAGTGGAAGG 
60 
IL-17A 141 Forward 
CTCCAGAAGGCCCTCAGACTA 
Reverse 
AGCTTTCCCTCCGCATTGACACAG 
60 
RORγt 232 Forward 
CCACTACGGGGTTATCACCTG 
Reverse 
CACTTCTGCATGTAGACTGTCC 
60 
 
Table 2- Primers used in real time RT-PCR analysis 
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2.4 Immunoblot Analysis 
 
2.4.1 Protein extraction and SDS treatment 
Cells ready for extraction of proteins were harvested and washed three times in cold 
PBS prior to counting. The cells were then pelleted by centrifugation at 350g for 5 
minutes and the supernatant removed. Cell lysates were prepared by resuspending 
1x106-2x106 cells in 130 µl lysis buffer (1% NP-40, 150 mM NaCl, 5 mM MgCl2, 10 
mM Hepes Buffer) supplemented with Protease Inhibitor Cocktail (PIC) (Sigma-
Aldrich). Once resuspended the cell/lysis buffer mixture was incubated on ice for 30 
minutes and the resulting cell debris was pelleted by centrifugation at 7500g in a 
bench-top microcentrifuge for 5 minutes. The supernatant containing the cell lysate/ 
extracted proteins was used for the subsequent stage. The cell lysate was diluted with 
an equal volume of 2X concentrated Laemmlli sample buffer (125 mM Tris HCL pH 
6.8, 10% 2-mercaptoethanol, 4% SDS, 0.004% bromophenol blue, 20% glycerol ) 
(Sigma-Aldrich) and boiled for 5 minutes. The 2-mercaptoethanol in the sample 
buffer reduces the intra- and intermolecular disulphide bonds of proteins. Thus 
reducing gels were used to carry out western blots in this study. SDS is a detergent 
that serves to denature the proteins and subunits and give an overall negative charge  
that is roughly proportional to the size of the proteins. The bromophenol blue serves 
as a dye front that runs ahead of the proteins whilst the glycerol increases the density 
of the sample so that it will layer in the sample well. 
 
2.4.2 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Gels containing varying percentages of acrylamide were prepared from a 30% (w/v) 
acrylamide. 0.8% (w/v) N-N’-methylene bisacrylamide stock (Sigma-Aldrich). A 
12% SDS-PAGE gel was used in the separation of IDO, cyclin E and β-actin. 
The resolving polyacrylamide gels were produced by mixing the following 
reagents prior to pipetting the resulting solution into casting modules: 4.3 ml of 30% 
acrylamide, 3 ml of H2O, 2.5 ml of 1.5M Tris (pH 8.8) and 100 µl of 10% (w/v) SDS. 
100 µl of 10% (w/v) ammonium persulphate and 4 µl of Tetramethyltheylenediamine 
(TEMED) were added immediately prior to pipetting 4 ml of the resulting solution 
into the casting module. After polymerisation of the resolving gel, a 4% 
polyacrylamide stacking gel was produced. Each stacking gel was prepared by mixing 
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500 µl of 30% acrylamide, 2.1 ml of H2O, 380 µl of 1M Tris (pH 6.8) and 30 µl of 
10% (w/v) SDS. Similar to the production of the resolving gel, 30 µl of 10% (w/v) 
ammonium persulphate and 3 µl of TEMED were added just prior to pipetting 3 ml of 
acylamide solution over the polymerised resolving gel. Protein was loaded into pre-
formed wells of the stacking gel, which together with the resolving gel was immersed 
in a running buffer (25 mM Tris-base, 192 mM glycine, 0.1% SDS) during 
electrophoresis. 
 
2.4.3 Western blotting 
Following electrophoresis, SDS-polyacrylamide gels were equilibrated in a transfer 
buffer (25 mM Tris-base, 192 mM glycine, 20% (w/v) methanol). Proteins separated 
by electrophoresis on the resolving gel were then electro-transferred onto Protran™ 
nitrocellulose membrane (Schleicher and Schuell Bioscience GmbH, Germany) using 
the Biorad Protean II™ electrotransfer equipment (Biorad Laboratories Ltd, UK). 
Electro-transfer was carried out for 1 hour at 200 mA and 4°C. The temperature of the 
transfer buffer, which immersed the cassette (containing the SDS-PAGE gel and 
membrane) during electro-transfer, was preventing from increasing in temperature by 
the applied current using an iceblock/compartment in the transfer tank. 
 
2.4.4 Immunodetection 
Following electro-transfer, the protein-blotted nitrocellulose membrane was rinsed 
with PBS Tween (0.1% (w/v) Tween 20). In order to block non-specific binding sites, 
the membrane was then immersed in newly prepared blocking solution (5% non-fat 
powdered milk in PBS Tween) for 1 hour at room temperature with constant agitation. 
After blocking the membrane was incubated with primary antibody diluted in 
blocking solution (at a dilution recommended by the manufacturer) at 4°C overnight 
with constant agitation. This was followed by three 15 minute washes in PBS Tween 
and further incubation with a secondary/HRP-conjugated antibody for 1 hour at room 
temperature at a dilution recommended by the manufacturer. Another 3x 20 minute 
washes in PBS Tween were carried out following the incubations with secondary 
antibody. 
Specific proteins labelled indirectly with HRP-conjugated secondary antibodies were 
visualised by enhanced chemiluminesence using the ECL™ plus western blotting 
detection system (Amersham Biosciences-GE Healthcare, UK) according to 
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manufacturer’s instructions. ECL™ plus-treated membranes were exposed to an 
autoradiography film- Hyperfil ECL™ (Amersham Biosciences-GE Healthcare)- that 
was then processed using a standard developer (AGFA, UK) after an optimal 
exposure time. The BenchMark™ pre-stained protein ladder (Invitrogen), were used 
to determine molecular weights of proteins and were treated in accordance with 
manufacturer’s instructions. After washing of the nitrocellulose membrane, the 
membranes were re-probed, after immunodetection of the primary protein of interest, 
with antibodies specific for the ubiquitous murine β-actin cytoskeletal protein and a 
secondary HRP-conjugated antibody as described earlier. The primary antibodies used 
for western blotting were: 
- Indoleamine 2,3-dioxygenase, Rabbit polyclonal IgG, Cosmo Bio Co. (USA). 
- Cyclin E, Rabbit polyclonal IgG, Upstate/Millpore 
- Β-actin, (AC-15) Mouse IgG1, Sigma-Aldrich 
The secondary antibodies used were: 
- Rabbit IgG- polyclonal goat  anti-rabbit IgG HRP, Dakocytomation 
- Mouse IgG-polyclonal rabbit anti-mouse IgG HRP, Dakocytomation 
 
2.5 L-kynurenine Assay 
The biological activity of IDO was evaluated by measuring levels of the tryptophan 
metabolite L-Kynurenine in culture supernatant as previously described (Takikawa et 
al., 1988, Feng and Taylor, 1989, Damonte et al., 1990). Briefly, 100 µl of tissue 
culture medium was incubated with 100 µl of 30% trichloracetic acid to precipitate 
the proteins for 30 minutes at 50°C. After centrifugation, 50 µl of supernatant was 
incubated with 50 µl Ehrlich’s reagent (1.2 ml H2O, 2.6 ml Perchloric acid, 6.2 ml 1-
propranolol, 1.5 g dimethylaminobenzaldehyde) for 15 minutes at 65°C. Absorption 
of the resulting solution was measured at 490 nm by a spectrophotometer. The values 
of kynurenine in conditioned medium were calculated by a standard curve with 
defined levels of kynurenine (Sigma-Aldrich) concentrations. 
 
2.6 Flow Cytometry 
2.6.1 Cell surface staining 
Prior to staining, cells harvested for analysis were pelleted by centrifugation at 300  g 
for 5 minutes at 4°C and washed twice with cold PBS, followed by counting and 
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assessment of viability, a minimum of 0.5x106 were stained with antibody per test 
sample for the flow cytometric detection of cell surface markers. After counting, the 
cells were then pelleted again by centrifugation at 350g for 5 minutes at 4°C and 
resuspended in 100 µl of cold PBS supplemented with 5% FCS (FACS buffer). 
Staining of cells for the detection of surface markers was performed either directly, 
using flourochrome-conjugated antibodies, or indirectly using a combination of 
unconjugated/purified primary antibodies (listed in Table 3) and FITC- or PE-
conjugated secondary antibodies (listed in Table 4). Cells were incubated with a 
fluorochrome-conjugated/unconjugated antibody in 100 µl of FACS buffer for 30 
minutes at 4°C (on ice). 1 µg of antibody was added per 0.5x106 cells. After 30 
minutes of incubation, cells were washed three times in 200 µl of FACS buffer and 
resuspended in 200 µl of PBS for analysis. If unconjugated primary antibodies were 
used, the cells were incubated for a further 30 minutes at 4°C with a fluorochrome- 
conjugated secondary antibody. This was followed by three subsequent washes in 
FACS buffer as described above and resuspension in 200 µl of PBS as described 
above. 
Determinant (Clone) Isotype-Conjugate Source (Company) 
CD3 
CD4 
CD8 
I-A/I-E (MHC II) 
CD16/32 
CD19 
CD80 (B7.1) 
CD86 (B7.2) 
ICOSL 
PDL-1 
ICAM-1 
Isotype Control 
Isotype Control 
Isotype Control 
(17A2) Rat IgG2b-Purified 
(RM4-5) Rat IgG2a-Purified 
(53-6.7) Rat IgG2a-Purified 
(M5/114.15.2) Rat IgG2a-Purified 
(93) Rat IgG2a-Purified 
(ID3) Rat IgG2a-Purified 
(RMMP-1) Rat IgG2a-Purified 
(RMMP-2) Rat IgG2a-Purified 
(HK5.3) Rat IgG2a-Purified 
(MIH5) Rat IgG2a-Purified 
(3E2) Hamster IgG1-Purified 
(A19-3) Hamster IgG1-Purified 
(54447) Rat IgG2a-Purified 
(141945) Rat IgG2b-Purified 
eBioscience/Insight 
eBioscience/Insight 
eBioscience/Insight 
BD Biosciences 
eBioscience/Insight 
eBioscience/Insight 
Catlag/Invitrogen 
Catlag/Invitrogen 
eBioscience/Insight 
BD Biosciences 
BD Biosciences 
BD Biosciences 
R&D systems 
R&D systems 
 
Table 3- List of primary antibodies for cell surface staining 
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Determinant Conjugate Source (Company) 
Rat IgG 
Hamster IgG 
Goat anti-Rat IgG-PE 
Goat anti-Hamster IgG-PE 
BD Biosciences 
BD Biosciences 
 
Table 4- List of secondary antibodies for cell surface staining 
 
2.6.2 Intracellular staining 
Intracellular staining for FoxP3, IL-17A and IFNγ was carried out in this study. 
Briefly, 100 µl of 1x106 cells were first stained for relevant surface markers such as 
CD4 using the surface staining protocol described above, and washed in cold FACS 
buffer. Cells were then fixed, permeabilised and stained using the intracellular 
staining set (eBioscience, USA) in accordance with manufacturer’s instructions. 1x106 
cells were resuspended in 100 µl of cold fixation/permeabilisation solution 
(eBioscience), vortexed and incubated at 4°C for 30 minutes in the dark. Cells were 
then washed twice in cold permeabilisation buffer (eBioscience) followed by staining 
with directly-conjugated antibody in the presence of 100 µl permeabilisation buffer at 
4°C for 30 minutes in the dark. Cells were washed twice again in cold 
permeabilisation buffer, centrifuged and resuspended in 200 µl of FACS buffer. 
Samples were then analysed within 24 hours by flow cytometry. All fluorochrome-
conjugated antibodies used for intracellular staining are listed in Table 5. 
 
Determinant (Clone) Isotype-Conjugate Source (Company) 
FoxP3 
IL-17A 
IFNγ 
Isotype control 
Isotype control 
Isotype control 
(FJK-16s) Rat IgG2a-APC 
(eBio17B7) Rat IgG2a-FITC 
(XMG1.2) Rat IgG1-eFlour®450 
Rat IgG2a-APC 
Rat IgG1-eFlour®450 
Rat IgG2a-FITC 
eBioscience/Insight 
eBioscience/Insight 
eBioscience/Insight 
eBioscience/Insight 
eBioscience/Insight 
eBioscience/Insight 
 
Table 5- List of fluorochrome –conjugated antibodies used for intracellular staining 
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2.6.3 Calculation of absolute cell counts from spleen, peripheral blood and draining 
lymph node (DLN) 
Splenocytes, PBMC and lymphocytes (from the DLN) taken from mice following 
systemic and topical 3HK administration (or controls) were stained with rat anti-
mouse CD4-FITC, CD8- Peridinin chlorophyll protein (PerCP) and CD19-
Phycoerythrin (PE) (Abcam, UK). For absolute cell counts, cell counting beads 
(Perfect-count Microspheres, Cytognos, Spain) were used according to 
manufacturer’s instructions. 
 
2.6.4 Annexin V and 7-Amino-Actinomycin (7AAD) staining 
This assay is based on identifying apoptotic cells by the asymmetrical composition of 
the cellular membrane. Annexin V binds specifically to phosphatidylserine, which 
becomes translocated from the inner membrane leaflet to the outer lipid layer when 
cells enter early apoptosis. 7-AAD, normally actively excluded by viable cells, allows 
for the further discrimination of necrotic cells. This assay was used to assess apoptosis 
and cell death in T cells, DC’s and MCEC. Cells were stained with FITC-conjugated 
Annexin V and 7-AAD. The reagents were obtained from BD Bioscience and used 
according to the manufacturer’s instructions. Cells were stained with annexin-V in a 
buffer containing 0.01 M HEPES (pH 7.4); 0.14 M NaCl; 2.5 mM CaCl. Annexin V-
FITC was detected on the FL-1 channel and 7-AAD on the FL-3 channel of a 
FACSCALIBUR flow cytometry instrument equipped with a 488 nm Argon laser 
(BD Biosciences. 
 
2.7 Bacterial Transformation 
 
To insert a plasmid into a bacterial strain, DH5α E. coli competent cells were quickly 
thawed and transferred to an ice-bath for 10 minutes. 50 µl of the cell suspension were 
then transferred to a chilled polypropylene tube and stored in ice. 1ng of the plasmid 
of interest was then added to the competent cells and mixed. The tube was stored on 
ice for 30 minutes. The tube was then incubated at 42°C for 90 seconds and 
transferred to ice for a further 2 minutes. 
 450 µl of LB media without antibiotic was added to the tube and placed in a shaking 
incubator at 37°C. After one hour the transformed competent cells were plated onto 
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LB agar plates containing the appropriate antibiotic. The plates were incubated 
overnight at 37°C and checked for positive single colonies. 
 
2.8 Plasmid Isolation 
Plasmids were isolated from bacteria using the QIAfilter® Plasmid Purification Kit 
(QIAGEN Inc, Valencia, CA) according to manufacturer’s instructions. Briefly, a 
single colony was inoculated in 5 ml of LB medium containing the appropriate 
antibiotic, typically ampicillin 50 µg/ml and incubated for 8 hours at 37°C in a 
shaking incubator. The starter culture was then diluted 1:1000 and incubated at 37°C 
overnight in a shaking incubator. The bacteria were then harvested by centrifugation 
at 6000g in a Sorvall GSA rotor for 15 minutes at 4°C. 
The supernatant was removed and the bacterial pellet resuspended in 50 ml of 
Tris/EDTA (suspension buffer) with 100 mg/l of RNase. 50 ml of NaOH/1% SDS 
(lysis buffer) were then added and mixed gently. The mixture was then incubated at 
room temperature for 5 minutes after which the lysis reaction was stopped by the 
addition of 50 ml of potassium acetate (neutralising buffer). The lysate was then 
poured into the QIAfilter cartridge and incubated for 10 minutes at room temperature, 
this allows for a precipitate containing proteins, genomic DNA and detergents to float. 
The QIAGEN column was equilibrated by applying a buffer containing 
NaCl/MOPS/Triton (equilibration buffer) and the content of the QIAfilter cartridge 
was filtered and added to the equilibrated QIAGEN column. 
After the lysate passed through, the column was washed twice with a solution 
containing NaCl/MOPS (wash buffer). The DNA was then eluted with 30 ml of 
NaCl/Tris.Cl (elution buffer). The plasmid DNA was then precipitated by adding 21 
ml of isopropanol to the eluted DNA. The mixture was then centrifuged at 5000g for 
60 minutes, and the DNA pellet was washed with 7 ml of 70% EtOH. After further 
centrifugation at 5000g for 60 minutes the supernatant was decanted and the pellet air-
dried. The DNA was then resuspended in water and stored at -20°C. 
 
2.9 Replication-Defective Lentivirus Production, Titration and 
Transduction 
The EIAV-based constructs were propagated by a 3 plasmid cotransfection technique 
in 293T as described elsewhere (Naldini et al., 1996). All plasmids were a kind gift of 
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Oxford Biomedica (Oxford, United Kingdom). Transfections were performed using 
polyethylenimine (PEI; Sigma) on 14 cm tissue-culture plates. The 293T cells were 
transfected at a confluency of approximately 70%. For each plate to be transfected, a 
DNA mixture consisting of 24 µg of an EIAV gag/pol-expressing plasmid 
(pONY3.1), 12 µg of a viral envelope-expressing plasmid (pRV67), 24 µg of the 
vector constructs pSMART2G (EIAV with eGFP and IDO), were added to 7.5 ml 
serum-free DMEM;. A 10mM PEI solution was diluted 1:1000 in serum-free DMEM, 
of which 500 µl was added to 7.5 ml serum-free DMEM. The DNA and PEI solutions 
were mixed vigorously by vortexing for 30 seconds and then kept for 15 minutes at 
room temperature to allow complex formation. A quantity of 15 ml of the DNA/PEI 
solution was added to each 14 cm plate and left at 37°C for 4 hours; this was then 
replaced with full tissue culture medium. At 72 hours after transfection, supernatant 
was collected, cleared by low speed centrifugation (1200 g, 5 minutes) and filtered 
through 0.45 µm filters. Vector particles were then concentrated by ultracentrifugation 
at 17 000 g for 100 minutes at 4°C. The virus pellet was resuspended on ice in serum-
free DMEM, snap-frozen and kept in liquid nitrogen. 
 
2.9.1 Titration of lentiviral stocks 
To calculate lentiviral titres, canine osteosarcoma (D17) cells were seeded on 24-well 
plates at 2x104 cells per well in 400 µl of medium. 40 µl of EIAV GFP stock was 
added to the seeded wells in triplicate and serially diluted 10-fold (10-1 -10-7). The 
D17 cells were subsequently visualised by fluorescence microscopy 72 hours after 
transduction. Quantitative (real-time) PCR was carried out (see section 2.3) in 
conjunction with fluorescence microscopy (see section 2.10) in order to determine 
titres of stocks of EIAV IDO, as the construct of this virus did not encode a reporter 
gene that would have allowed for direct visualisation of transduction of a reporter cell 
line (Lizee et al., 2003b). 
Titres calculated were of the order 1.5x106-1.5x108 infectious particles/ml. 
 
2.10 Fluorescence Microscopy 
Accurate determination of viral titres after each cycle of replication-defective EIAV 
production (EIAV GFP and EIAV IDO) relied, in part, upon the counting of the 
number of foci of infection present after transduction of canine osteosarcoma (D17) 
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cells by serial dilutions of EIAV GFP stocks. As described in section 2.9.1, 
fluorescence microscopy was used in conjunction with real-time PCR in order to 
determine titres for EIAV IDO, the DNA construct of which did not encode a reporter 
gene that would have allowed for direct visualisation of transduction like EIAV GFP 
stocks. Counting of the number of foci of infection in the GFP-transduced D17 cells 
was undertaken using a Nikon Eclipse TE2000-S (Nikon, UK) and Olympus CK40 
(Olympus, UK) fluorescence microscope. 
 
 
2.11 Generation and Culture of Murine Bone Marrow-derived 
Dendritic cells 
DCs were generated from the bone marrow (BM) obtained from the hind limbs (both 
tibia and femur) (Inaba et al., 1992, Lutz et al., 1999) of C3H mice used in this study. 
The hind limbs were collected in phosphate buffered saline (PBS) and the BM cavities 
flushed out with a 25G needle to obtain a homogenous cell suspension. The cells were 
pelleted by centrifugation and red blood cells lysed with Red Blood Cell (RBC) lysis 
solution (Flowgen, UK). After termination of lysis by dilution, cells were transferred 
through a 70 µM cell strainer, centrifuged again, and put in culture in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Gibco-Invitrogen, Paisley, UK) 
supplemented with 10% heat-inactivated FCS (PAA, UK), 100 units/ml penicillin, 
100 µg/ml streptomycin (Cambrex Biosciences, Wokingham, UK), 2 mM L-
glutamine (Cambrex biosciences) and 50 µM β-mercaptoethanol (Gibco-Invitrogen) 
in the presence of a 1:30 dilution of culture medium obtained from a GM-CSF-
producing hybridoma (Zal et al., 1994)- see culture protocol of hybridoma below. 
DCs were cultured in T75 flasks at 37°C in a humidified atmosphere with 5% CO2 
until day 7. The DC culture medium was replaced with fresh GM-CSF-containing 
medium (1:30 hybridoma supernatant dilution) on day 3, and half of the culture 
medium was replaced with fresh GM-CSF-containing medium (1:60 hybridoma 
supernatant dilution) on day 6. In order to generate mature DCs, the cultures were 
stimulated for 16 hours with 1 µg/ml lipopolysaccharide (LPS) (Sigma-Aldrich). 
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2.11.1 Culture of GM-CSF-producing hybridoma 
The GM-CSF-producing hybridoma-Hypoxanthine-aminopetrin-thymidine-sensitive 
Ag8653 myeloma cells transfected with murine GM-CSF cDNA (Zal et al., 1994)- 
was cultured in DMEM that was purchased with supplemented glucose (Gibco-
Invitrogen), in the presence of 10% heat-inactivated FCS, 100 units/ml penicillin, 100 
µg/ml streptomycin, 2 mM L-glutamine and 1 mg/ml of G418 to ensure selection until 
GM-CSF-containing supernatant was ready to be collected. Cells were grown at 37°C 
in a humidified atmosphere with 5% CO2 to approximately 500 ml in volume in G418, 
centrifuged, washed twice in PBS and resuspended in medium without G418. The 
cells were then split every 2-3 days until 2 litres were attained, at which point the cells 
were grown to exhaustion in roller bottles (Falcon, UK) in order to achieve the highest 
activity. 
 
2.12 Murine T cell Proliferation Assays and DC : T cell cocultures 
2.12.1 Murine CD4+ T cell purification 
A single-cell suspension was obtained by passing spleens and lymph nodes 
(mesenteric and inguinal), derived from BALB/c mice, through 70 µM cell strainers 
into cold RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 100 
units/ml penicillin, 100 µg/ml streptomycin, 2 mM L-glutamine  and 50 µM β-
mercaptoethanol and 10 units/ml DNAse-Pulmozyme/Dornase Alfa (Roche, UK). The 
cells were pelleted by centrifugation and red blood cells lysed with RBC lysis solution 
(for experiments using splenocytes the purification process was terminated at this 
step, see section 2.12.2). Subsequent to lysis of erythrocytes, splenocytes were 
incubated on a horizontal roller at 4°C with supernatants of rat anti-mouse hybridoma 
cultures containing antibodies specific for murine CD45R/B220 (RA3-3A1, ATCC, 
Manassas, VA), murine CD8 (53.67, ATCC), H2-E k,d/Ab,d (M5/114.2, ATCC) and 
murine CD16/32 (2.4G2, ATCC). After treatment with the hybridoma supernatants, 
the cells were washed twice in serum free/unsupplemented RPMI 1640 medium and 
incubated with sheep anti-rat IgG Dynabeads® (Dynal Biotech, Bromborough, UK) 
for 30 minutes on a horizontal roller at 4°C before separation in a magnetic field for 
negative selection of CD4+ T cells. Cells expressing CD8, MHC class II, CD16/32 
and B220 were selected and retained in the magnetic column due to Dynabead 
conjugation. The supernatant containing the population of negatively selected CD4+ T 
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cells was removed for another round of selection in a magnetic field (for optimal 
purity of CD4-expressing cells). The purity of the negatively selected CD4 population 
was assessed to be greater than 90% by flow cytometry. 
 
2.12.2 Preparation of splenocytes 
As described above, after red cell lysis of the spleen and lymph node suspension, 
medium was added, the cells centrifuged and then resuspended in 1.5 ml of medium. 
When used in mixed lymphocyte reactions, the cells were activated by incubating 
them with LPS at 10 µg/ml for 48 hours and irradiated (60 Gray) prior to co-culture. 
 
2.12.3 T cell proliferation assays 
Responder CD4+ T cells (1x105 cells/well) were stimulated with anti-mouse CD3 and 
CD28 beads (Dynabeads Mouse CD3/CD28 T cell expander, 1x108/ ml,- 1 bead/cell) 
or allogeneic BM-derived C3H (H-2k) DCs at a ratio of 10:1 (1x105 CD4+ T cells: 
1x104 DCs) in 96-well plates for 3 days. In order to measure proliferation, each well 
of the 96 well plate was pulsed on day 3 with 3H-thymidine that was diluted in serum 
free/unsupplemented-RPMI 1640 to a working concentration of 1 µCi/well 
(Amersham, UK). Plates were harvested 16 hours later and T cell proliferation 
determined using a Wallac MicroBeta TriLux Scintillation counter (Wallac, UK). 
 
2.12.4 Two-stage MLR (Rechallenge assay) for induction of anergy 
Rechallenge assays were optimised from established protocols in the laboratory 
designed to investigate the induction of anergy in vivo. Thus, for the detection of an 
allogeneic T cell response following a primary challenge in vivo, 8x106 C3H/He LPS 
stimulated splenocytes were injected intravenously into BALB/c mice. After 10 days, 
spleen-purified CD4+ T cells from the injected mice were rechallenged in vitro (at a 
1:5 DC: T cell ratio) with donor C3H/He LPS stimulated splenocytes or third-party 
C57BL/6 LPS stimulated splenocytes, and proliferation assessed by thymidine 
incorporation on days 3, 5 and 7. 
 
2.13 Peripheral Blood Collection From Mouse Tail Vein 
Prior to blood collection, mice were placed in a warming chamber for 30 minutes to 
dilate veins. A scalpel was used to make a superficial incision in the tail vein and 7-9 
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droplets of blood collected in an eppendorf containing 100 µl of anticoagulant (3.2% 
buffered trisodium citrate). 1 ml of RBC lysis buffer (Flowgen) was added. Samples 
were centrifuged at 300 g for 5 minutes, the supernatant discarded and resuspended in 
PBS followed by further centrifugation. Cells were then stained for FACS analysis as 
described in section 2.6.1. 
 
2.14 Tryptophan Metabolites 
The main metabolites resulting from IDO-induced degradation of tryptophan are 
generally known as kynurenines and comprise N-formyl-kynurenine, kynurenine 
(kyn), 3-hydroxykynurenine (3HK), 3-hydroxyanthranilic acid (3HAA) and quinolinic 
acid (QA).  Kyn, 3HK and, 3HAA were dissolved in 1 M HCl as a carrier and QA 
(Sigma-Aldrich) dissolved in 1 M NaOH. To determine the inhibitory concentration, 
tryptophan metabolites were tested in titration series. Stocks of Kyn, 3HK, 3HAA and 
QA (Sigma-Aldrich) were dissolved in RPMI 1640 medium (Gibco BRL) and added 
to the cell cultures in different concentrations ranging from 0 to 100µM (pH of final 
cell culture medium 7.5-8.5). 
 
2.15 Kynurenine Treatment of Graft Recipients 
Stock 3HK was dissolved in PBS and administered intra-peritoneally (IP) 560 mg/kg 
on a daily basis on day 1-7, day 7-14 or day 1-14 post-operatively. Control animals 
were given the same volume of vehicle from day 1-14. For topical application, a total 
dose of 3HK of 0.165 mg was dissolved in 30 µl 0.9% NaCl eye drops (final pH 2.5-
3.0) and administered twice daily on days 3-14 post-operatively after removal of the 
protective eyelid suture. This was the highest tolerated topical dose, having been 
tested on unoperated eyes of BALB/c mice for 5 days. This dose is based on 1/3 of the 
total dose used in systemic administration. Control animals were given the same 
volume of vehicle.  
 
2.16 Tranilast (3,4-DAA) 
Tranilast was obtained as a kind gift from Nuon Therapeutics (San Mateo, CA) as 
well as Sigma Aldrich, UK. For in vivo studies, Tranilast was dissolved at a maximum 
concentration of 10 mg/ml in 1% sodium bicarbonate by heating for 1 h at 70°C. 
Upon cooling, an emulsion was formed. Animals received 400 mg/kg of Tranilast, 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 101 
administered by IP injections, on days 1-16 post-operatively for corneal transplants 
and days 1-15 and days 1-30 for skin transplants. Control animals were given the 
same volume of vehicle. 
For in vitro studies, Tranilast was dissolved in dimethyl sulphoxide (DMSO). Stock 
Tranilast was dissolved in RPMI 1640 medium (Gibco BRL) and added to cell 
cultures in different concentrations ranging from 0 to 200µM. 
 
2.17 Animals 
Experiments were conducted using inbred adult female BALB/c mice (H2d, Harlan 
Olac), female C3H/He (H2k, Harlan Olac), male BALB/c mice (Harlan Olac) and 
C57BL/6 (H2b, Harlan Olac). Animals were maintained in a specific pathogen-free 
facility and treated in accordance to the UK regulations for care of experimental 
animals. 
 
2.18 Orthotopic Corneal Transplantation 
Mouse corneal transplantation was performed in the right eye of all animals (age 6-10 
weeks) as originally described by Zhang et al. 1996 with minor modifications 
(described in Ardjomand et al. 2003). To prepare the donor cornea a 2.5mm trephine 
was first used to mark the cornea. The eye was then enucleated and an anterior 
chamber paracentesis performed using a diamond knife (Duckworth & Kent, Baldock, 
UK). The cornea was then excised using curved Vannas scissors (M.I.S.S, Germany). 
This was left in PBS until grafting. Preparation of the recipient required topical 
administration of 2.5% phenylephrine and 1% atropine to the recipient eye to ensure a 
fully dilated pupil. A full anaesthetic was given as a 150 µl IP injection comprising 
25% Hypnorm, 25% Hypnovel in 50% water. A top-up to a maximum total volume of 
200 µl was used if the mouse was not sufficiently anaesthetised. The recipient cornea 
was marked using a 2.0 mm trephine and under a bubble of PBS an anterior chamber 
paracentesis performed and the cornea excised. The bubble of PBS on the ocular 
surface was maintained to prevent the eye from drying and cataract formation. The 
donor was then transferred to the recipient and an initial 11/0 nylon suture placed 
through the donor and recipient cornea. The cornea was fixed with a continuous 
suture with a minimum of 8 bites taken. At the end of the procedure chloramphenicol 
ointment (Martindale Pharmacuticals, Brentwood, UK) was applied to the eye and a 
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7/0 vicryl lid suture placed, which was removed after 48 hours. At that time and every 
2 days thereafter the eye was examined using the operating microscope. 
 
2.19 Grading of Clinical Findings Used in Diagnosis of Graft 
Rejection 
Grading of corneal opacity was as previously described (Sonoda et al. 1993) with 
minor modifications, as follows: grade 0, complete transparent cornea; 1, minimal 
corneal opacity, but iris clearly visible; 2, moderate corneal opacity, iris vessels still 
visible; 3, moderate corneal opacity, only pupil margin visible; 4, complete corneal 
opacity, pupil not visible. Grading of graft transparency was undertaken by an 
examiner masked in respect of treatment group of each animal. Technically 
satisfactory grafts had corneal opacity grade 0 to 1 at all times until corneal suture 
removal on day 7. All other graft recipients, including those with wound dehiscence, 
intraocular haemorrhage or cataract were excluded from further analysis. The onset of 
graft rejection was diagnosed when corneal opacity increased to grade 3 (no iris 
vessels visible) in a graft previously transparent after transplantation. 
 
2.20 Preparation of Mouse Corneas for Histological Sections 
To maintain corneal integrity for preparation of cryostat sections, whole eyes were 
removed from the sacrificed mouse on the day of observed onset of rejection. The 
tissue was placed in OCT embedding matrix (CellPath, Powys, UK) then snap frozen 
in liquid nitrogen and stored at -80°C. 7 µM thick sections were cut using a cryostat 
(Bright, Huntingdon, UK) and transferred onto clean microscope slides (CA Hendley, 
Loughton, UK). Sections were air-dried at room temperature for 30-40 minutes, fixed 
for 10 minutes in cold acetone (Sigma-Aldrich) and then further air-dried for 30 
minutes. Slides were wrapped in foil and stored at -20°C until use. 
 
2.21 Haematoxylin and Eosin (H&E) 
Frozen tissue sections of cornea were allowed to thaw at room temperature and H&E 
staining performed courtesy of Hammersmith Hospital Pathology department.  
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2.22 Immunohistochemistry 
The cryostat sections were thawed at room temperature for 10 minutes. A wax pen 
was used to encircle the sections. The slides were rinsed in PBS first and 2-3 times in 
PBS-T (0.1% Tween, Bio-rad). Sections were blocked with 10% mouse serum 
(Sigma-Aldrich) in PBS-T for 30 minutes. FITC labelled IL-17A Clone: eBio17B7 
was diluted (1:50 dilution; e-Bioscience) in 10% mouse serum/PBST (0.1% Tween) 
and sections incubated with this for 1 hour in a humidified chamber in the dark. 
Sections were washed with PBST (0.1% Tween) once and once with PBS. Excess 
PBS was removed with tissue paper, being careful not to touch the section. 1 drop of 
DAPI mounting medium, non-hard set (Vector Laboratories, UK) was placed on a 
cover slip and the slides carefully placed on the cover slip. Slides were kept in the 
dark for 5-10 minutes and stored at 4°C in the dark until analysis with a fluorescent 
microscope. Negative controls were sections incubated with rat IgG2a as the primary 
antibody. 
 
2.23 Preparation of Mouse Corneas for Flow Cytometry 
Corneas were dissected carefully under a stereo-microscope. All precautions were 
taken to avoid the limbal blood vessels. Single-cell suspensions were prepared from 
three corneas as described (Deshpande et al., 2001), with some modifications. Briefly, 
corneal buttons were incubated with collagenase D (Roche) 2.5 mg/ml for 60 minutes 
at 37°C in a humidified atmosphere at 5% CO2. After incubation, corneas were 
disrupted by grinding with a syringe plunger and passing through a 45 µM cell 
strainer. Cells were washed and suspended in RPMI 1640 with 10% FCS. Prior to 
intracellular staining for IL-17, cells were stimulated with 50 ng/ml PMA, 1 µg/ml 
Ionomycin in the presence of Brefeldin A for 4 hours. Cells were washed and then 
stained with FITC labelled anti IL-17A antibody (eBioscience) and isotype controls as 
described in section 2.6.2. 
 
 
2.24 ELISA for IL-2 Cytokine Production 
IL-2 levels in the supernatants of T cell proliferations assays were detected using the 
Mouse IL-2 Platinum ELISA kit (eBioscience, UK). The IL-2 kit had a sensitivity of 
5.3 pg/ml which allowed for the accurate and precise detection of low levels of IL-2 
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in 50 µl of culture supernatant taken from wells of a 96-well plate T cell proliferation 
assay. All steps were carried out according to the manufacturer’s protocol. After the 
addition of pre-titrated detection enzyme (Streptavidin-HRP), substrate solution 
(tetramethylbenzidine-TMB) and stop solution, ELISA plates were read at 450 nm 
using a microplate spectrophotometer. Samples were assayed in triplicate and were 
quantified by comparison with standard curves obtained with purified recombinant 
cytokines provided with the ELISA kits. Results are presented as the means and 
standard deviations of triplicates. 
 
2.25 Th17 Polarisation of Naïve CD4+ T cells 
 
2.25.1 Isolation of Naïve CD4 T cells 
CD4 T cells from spleens and lymph nodes (mesenteric and inguinal) of BALB/c 
mice were purified as described in section 2.12.1. Naïve CD4 T cells were isolated by 
FACS sorting using a FACSAria sorter of CD4 T cell suspensions for CD44lo(Pacific 
blue, EFlour 450 labelled), CD25-(PE labelled),CD62Lhigh (FITC labelled), CD4+ (PE 
CY5 labelled) cells. A purity of >99.5% was achieved. 
 
2.25.2 Th17 polarisation 
The culture medium used was IMDM (Sigma-Aldrich), supplemented with 2x10-3 M 
L-glutamine, 100 u/ml penicillin, 100 µg/ml streptomycin, 5x10-5 M β-
mercaptoethanol, and 10% FCS. For Th17 polarisation in the presence of 3HK and 
Tranilast, a final concentration of 10 µM of each was used. Th17 cells (2x105 
cells/well) were differentiated on 24 well plates coated with 2µg/ml anti-CD3 and 10 
µg/ml anti-CD28 with a cytokine cocktail of 2 ng/ml TGFβ, 25 ng/ml IL-6 and 10 
ng/ml IL-1β. Neutralising antibodies to IFNγ (50 µg/ml), IL-4 (10 µg/ml) and IL-2 
(10 µg/ml) was added to cultures. For real-time PCR experiments, cells were collected 
at different time points in culture, 0, 18, 24 and 36 hours. For Flow cytometry to 
assess measurement of intracellular cytokines, cells were kept in culture, split 1:2 on 
day 4 in media only and then on day 8 stimulated with 50 ng/ml PMA and 1µg/ml 
Ionomycin in the presence of Brefeldin A for 4 hours, then fixed and stained as 
described in section 2.6.2. 
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2.26 Skin Transplantation 
Skin transplantation was carried out kindly by David Coe of Imperial College 
London. 6-8 week old male BALB/c (H2d) mice were used as recipients and 6-8 week 
old male C57BL/6 (H2b) mice were used as donors.  
Procedure: 
1) Donor skin preparation 
The donor mouse was sacrificed and the mouse positioned on a tail removing board. 
The tail was sterilised with 70% alcohol. Using a #3 scalpel handle fitted with a #11 
blade, a ring incision was made around the base of the tail and continued along the 
dorso mid-line for about two to three inches. The skin was pulled off the tail using a 
pair of toothed forceps. The skin was placed dermis side down on a dry, sterile plastic 
Petri dish. The tail was flattened using a glass “hockey stick” and the tail cut into 1 
cm x 1 cm squares using a #4 scalpel handle fitted with a #22 blade. The grafts were 
moistened with a small volume of sterile saline. 
2) Preparation of the recipient mouse 
The mouse was anaesthetised using induction and maintenance (Face mask) 
inhalational anaesthesia (Isoflourane). The mouse was secured on its side to the 
grafting board using retainers. An area over the chest about 2cm wide, from the base 
of the neck to the last rib was shaved. Loose hair was removed and the area wiped 
with 70% alcohol. 
3) Grafting 
Using fine scissors, the graft bed was prepared by cutting and removing an area of 
skin from the flank of the mouse. This area was made larger than the size of the graft 
to be used, making sure not to cut the underlying tissue. The donor skin was placed 
into position in the graft bed, making sure that the graft did not overlap the bed and 
was not curled. A square of tulle was placed over the graft area. A plaster was 
moistened and placed directly over the tulle and wound round the mouse making sure 
it was tight but comfortable. The plaster was allowed to dry and the retainers released 
from the mouse and the mouse placed in a warming chamber until it recovered from 
anaesthesia. 
4) Scoring the grafts 
8 days after the primary graft, the plaster was removed very carefully to prevent 
damage to the graft. Grafts were scored on day 9 and then daily thereafter. Scoring of 
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grafts was undertaken by an examiner masked in respect of treatment group of each 
animal. Rejection was registered when less than 10% of the original graft remained 
viable. 
 
2.27 Statistical Analysis 
The mean of triplicate values and associated standard deviation (SD) were calculated 
for all T cell proliferation, L-kynurenine assay, flow cytometry and ELISA data. 
Statistical differences were calculated using a two-tailed t-test. A Mann-Whitney U 
test was used for calculating statistical differences in absolute lymphocyte counts of 
peripheral blood. Differences in graft survival were analysed using a log rank test and 
plotted according to the Kaplan-Meyer method. A value of p≤0.05 was regarded as 
statistically significant. 
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CHAPTER 3: RESULTS 
EFFECT OF UVB IRRADIATION ON IDO EXPRESSION 
IN THE CORNEA 
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3.1 Introduction 
As one of the objectives of this study was to develop IDO as a potential therapeutic 
target for preventing corneal allograft rejection, it was of interest to investigate 
different methods of upregulation of IDO expression in the cornea. So far, methods of 
overexpressing IDO in the cornea have included: 
• Gene therapy: 
Lentiviral vectors have been shown to be efficient at transducing human, rabbit 
and mouse corneal endothelial cells (Beutelspacher et al., 2005).  
• Pro-inflammatory cytokine stimulation 
As mentioned in section 1.5.3.2, LPS and the inflammatory cytokines IL-1 and 
TNF act synergistically with IFNγ to enhance IDO expression in vitro (Babcock 
and Carlin, 2000, Robinson et al., 2003). 
 
The first report of IDO in ocular tissue was in the lens, where Takikawa and co-
authors demonstrated its role in protecting lens from UV damage, being the first 
enzyme in the synthesis of UV filters (Takikawa et al., 2001). 3-hydroxykynurenine 
glucoside (3HKG), kyn and 3HK have been shown to be the major short-wave 
absorbing pigments present in human lenses (Wood and Truscott, 1993). On 
absorption of light they reach an excited state, described as a ‘triplet state’ and in this 
state they have been shown to be weakly reactive. Furthermore in the ‘triplet state’ 
they undergo decay rapidly, returning to the ground state. It is these properties- low 
triplet yield and low reactivity of the excited states that make kynurenine and its 
derivatives excellent UV filters (Sherin et al., 2008) (Dillon and Atherton, 1990, 
Dillon et al., 1990, Luthra and Balasubramanian, 1992). It is therefore likely that a 
physiological function of IDO is to prevent endothelial cells from UV-mediated cell 
injury, and there is data in the human that it can be upregulated in endothelial cells by 
UVB (Serbecic and Beutelspacher, 2006).  
UVB and UVC rays are strongly absorbed by all corneal layers. Experimental studies 
have shown that the corneal epithelium, Bowman’s membrane and stroma have the 
highest UV absorption, preventing penetration to the deeper ocular structures and 
hence light induced ocular damage. The significant absorbance of the cornea in the 
UVB and UVC spectra has been attributed to the high amounts of tryptophan residues 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 109 
in the proteins of the stroma (Mitchell and Cenedella, 1995), as well as the high 
ascorbic acid content of the epithelium (Ringvold, 1997). 
As mentioned previously, the condition of the corneal endothelium is essential to the 
normal functioning of the whole cornea due to its restricted regenerative capacity in 
humans. As it is a single-layered structure, it is very susceptible to damage by UV 
irradiation. Dependent on the dose and duration of UV exposure, cell damaging 
effects may vary from minor endothelial changes such as pleomorphism, as observed 
clinically in patients exposed to excess solar radiation (Good and Schoessler, 1988) to 
irreversible DNA damage due to nuclear fragmentation resulting in apoptosis 
(Cejkova et al., 2001). However, experimental studies have shown that the corneal 
endothelium is relatively resistant to repeated radiation damage, with the threshold 
dose for damage not being beyond those used for practical purpose (Ringvold et al., 
1982). The exact mechanism by which the corneal endothelium protects itself from 
environmental UV irradiation has not yet been fully understood. 
 Although IDO has shown to be expressed in murine corneas at the mRNA 
level (Serbecic and Beutelspacher, 2006), there have been no previous reports on 
IDO2 expression in the cornea. 
 
3.1.2 Chapter aims 
The aims of the work presented in this chapter were to: 
 
1. Determine the effect of UVB exposure on corneal endothelial cell IDO 
expression at the mRNA and protein level as determined by real time RT-PCR 
and western blotting respectively.  
2. Determine functional activity of any upregulated IDO by quantification of L-
kynurenine production as well assessing function of irradiated MCEC in 
mixed lymphocyte reactions. 
3. Examine the effect of UVB exposure on murine corneal endothelial cell 
phenotype. 
4. Determine whether IDO2 is expressed on MCEC or whole corneas as 
determined by real time RT-PCR. 
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3.2 Results 
3.2.1 Upregulation of IDO mRNA in corneal endothelial cells post UVB irradiation 
A murine corneal  endothelial cell line (MCEC) was exposed to UVB irradiation at 
doses ranging from 0 to 1000 J/m2 as described previously (see section 2.2.4) (Harned 
et al., 2003). In order to validate real time RT-PCR results and generate a standard 
curve for the IDO plasmid template (pSMART-IDO), a series of consecutive 10-fold 
dilutions of an IDO plasmid template DNA ranging from 7.5x10-1 to 7.5x10-10 µg/ µl 
was generated and real time RT-PCR carried out. The amplification data revealed 
clear resolution of all dilutions from one another and the standard curve demonstrated 
an amplification efficiency of > 90% (Figure 10a). The dissociation curve revealed 
specific amplification of the IDO product (Figure 10b).  
Expression of IDO at the mRNA level (normalised to HPRT) was determined by real 
time PCR. Increasing UVB exposure resulted in upregulation of IDO in a dose 
dependent manner (Figure 11a and b). An IDO plasmid template with known IDO 
concentration (0.00075 µg/ µl) was used as the positive control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10- Validation of IDO real time RT-PCR 
A- In order to validate real time RT-PCR results and generate a standard curvve for an 
IDO plasmid template (pSMART IDO),  a series of consecutive 10-fold dilutions of 
pSMART-IDO ranging from 7.5x10-1 to 7.5x10-10 µg/ µl was generated and real time 
RT-PCR carried out. The amplification data and standard curve revealed a clear linear 
relationship between Ct value and IDO plasmid DNA concentration. B- The 
dissociation (melting) curve revealed a single peak confirming specific amplification 
of the IDO product. 
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Figure 11- IDO mRNA expression in UVB exposed MCEC samples.  
A- MCEC were exposed to UVB at doses ranging from 0-1000 J/m2, RNA was 
extracted and subsequently converted to cDNA and real time PCR carried out. The 
levels of IDO mRNA are normalised to HPRT and fold increase expressed relative to 
untreated samples. With increasing UVB exposure there is a corresponding increase 
in IDO mRNA expression. The positive control is a pSMART vector expressing IDO. 
Results are from one experiment, representative of three.  
 
3.2.2 UVB irradiation of MCEC did not upregulate IDO expression at the protein 
level. 
After demonstrating increased IDO expression in response to UVB irradiation at the 
mRNA level, it followed to examine whether this increase in expression could be 
translated to the protein level. Expression of the 45 kDa IDO protein in the lysates of 
MCEC exposed to UVB doses ranging from 0 to 1000 J/m2 was determined by 
western blotting 24 hours after UV exposure. The IDO protein expression was 
detected using an IDO specific antibody. The 45 kDa IDO protein was not detected in 
any of the samples except for the positive control, a CHO cell line stably transduced 
with IDO. Unexpectedly there was no IDO protein expression seen in MCEC 
stimulated with IFNγ. This suggests a lack of induction of IDO in MCEC (above 
threshold levels) by UVB irradiation (Figure 12).  
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Figure 12- IDO protein expression in UVB exposed MCEC samples 
IDO protein expression was assessed by immunoblot analysis, using an IDO specific 
antibody. Cell lysates from the different UVB treated cells (0J-1000J/m2) as well as 
MCEC stimulated with IFNγ (IFNγ) were prepared and analysed by western blotting 
for IDO expression. The blots were also analysed for β-actin as a housekeeping 
control. Results are from one experiment representative of three. UVB exposure did 
not induce IDO protein expression. The positive control was stably transduced CHO 
cell line expressing IDO (CHO IDO). 
 
 
3.2.3 UVB irradiation of MCEC did not result in any functional activity of IDO 
It may be that IDO is induced by UVB irradiation but at levels too low to be detected 
by western blotting. A functional assay was therefore used to measure IDO activity. 
The biological activity of IDO was evaluated by measuring levels of the tryptophan 
metabolite L-kynurenine in culture supernatant as described in section 2.5 using a 
colorimetric assay. Absorption of the resting solution was measured at 490 nm by a 
spectrophotometer. The assay was capable of detecting kynurenine concentrations as 
low as 3.13 µM. The values of kynurenine in conditioned medium were calculated by 
a standard curve with defined levels of kynurenine concentrations. There was very 
little kynurenine production in any UVB treated cell in comparison to untreated, 24 
hours post single dose of UVB exposure (Figure 13). In light of this result, it was 
determined whether or not time post UVB exposure had an impact on functional IDO 
activity. Cells were therefore exposed to UVB irradiation as above (0-1000J/m2) and 
supernatants removed ½ hr, 2 hr, 4 hr and 24 hr post UVB exposure. There was a lot 
of variability in results with no conclusive evidence of functional IDO activity (Figure 
14 a. and b.) The effect of repeated UVB exposure (twice daily dosing over three 
days) on functional IDO activity was also determined; again there was no conclusive 
evidence of functional IDO activity (Figure 15). The results of experiments 
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undertaken in the above two sections therefore demonstrated a lack of IDO protein 
production or a lack of function of the expressed IDO in MCEC in response to UVB 
irradiation. 
 
 
 
 
Figure 13 - Effect of UVB exposure on IDO activity 24 hrs post exposure 
Functional IDO activity in response to UVB exposure (0-1000J/ m2) was measured in 
vitro in terms of the ability of MCEC to metabolise tryptophan to kynurenine. 
Kynurenine concentrations were measured in supernatants using a colorimetric 
method. By using the standard curve, the level of kynurenine in treated samples could 
be calculated. The positive control are supernatants collected from an IDO transduced 
D17 cell line (D17-IDO) as well as IFNγ treated MCEC. As can be seen, there is very 
little kynurenine production in any UVB treated cells in comparison to untreated. Data 
represent mean ± SD of triplicate samples. Results are from one experiment 
representative of six. 
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Figure 14- Effect of UVB exposure on IDO activity at varying time points post 
exposure. 
Functional IDO activity in response to UVB exposure (0-1000J/m2) was measured in 
vitro in terms of the ability of MCEC to metabolise tryptophan to kynurenine at time 
points ranging from A- 2 hr, 4 hr and 24 hr and B- ½ hr, 2 hr and 24 hr post UVB 
exposure. Kynurenine concentrations were measured in supernatants using a 
colorimetric method. Data represent mean ± SD of triplicate samples. Results are 
from two experiments representative of six. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15- Effect of single and repeated doses of UVB exposure on IDO activity 
Functional IDO activity in response to single dose UVB exposure (0-1000J/m2) or 
repeated (twice daily dosage over three days) was measured in vitro in terms of the 
ability of MCEC to metabolise tryptophan to kynurenine. Kynurenine concentrations 
were measured in supernatants using a colorimetric method. Data represent mean ± 
SD of triplicate samples. Results are of one experiment representative of three. 
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3.2.4 Effect of UVB irradiation of MCEC on T cell proliferation 
In order to determine definitively the lack of function of IDO in UVB irradiated 
MCEC, cells that were exposed to UVB were used as stimulators in a mixed 
lymphocyte reaction (MLR) and proliferation assessed by thymidine incorporation. 
Previously it has been shown that MCEC can be used as stimulators in mixed 
lymphocyte reaction and that overexpression of IDO in MCEC either by lentiviral 
transduction or cytokine stimulation can inhibit CD4+ T cell proliferation in a simple 
(one stage) MLR (Beutelspacher et al., 2006).  
MCEC (BALB/c origin) were therefore exposed to UVB irradiation at doses ranging 
from 0 to 1000 J/m2 and subsequently co-cultured with allogeneic CD4+ T cells (C3H) 
at a ratio of 1:1 MCEC : T cells. Proliferation of CD4+ T cells was detected by 
thymidine incorporation on day 4 of the MLR (Figure 16). When MCEC were used as 
stimulators in an MLR, T cell proliferation was observed although it was minimal. 
Proliferation counts from the MLR demonstrate that UVB exposed MCEC did not 
inhibit further the proliferation of allogeneic CD4+ T cells in comparison to untreated 
(0). This further supported the findings from the kynurenine assays showing a lack of 
functional IDO.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16- Effect of UVB irradiation of MCEC on T cell proliferation 
Following single dose UVB exposure at doses ranging from 0-1000 J/m2. 1x105 
MCEC were cultured with allogeneic T cells (1x105 cells /well). As a control T cells 
were incubated with un-irradiated MCEC (bar labelled 0) or with no other cells. T cell 
proliferation was determined by 3H Thymidine incorporation on day 4. UVB 
irradiation of MCEC did not inhibit T cell proliferation. Data represent mean ± SD of 
triplicate samples. Results are of one experiment representative of three. 
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3.2.5 Effect of UVB irradiation on MCEC phenotype 
Previous studies have reported that UV treatment of corneal allografts resulted in a 
steep reduction in the incidence of immunological rejection of heterotopic corneal 
grafts in mice (Ray-Keil and Chandler, 1986) and orthotopic corneal allografts in 
rabbits (Dana et al., 1990). This has been attributed to the inactivation of highly 
immunogenic donor-derived passenger Langerhans’ cells by the UV irradiation 
thereby reducing the immunogenicity of the corneal allograft (Noonan and De Fabo, 
1992). 
It could be hypothesised that UV irradation of MCEC altered chemokine and adhesion 
molecule expression and hence reduced the immunogenicity of corneas in this way. It 
is known that MCEC have the ability to upregulate chemokine and adhesion molecule 
expression, and MHC class II expression in response to pro-inflammatory cytokines 
(Arancibia-Carcamo et al., 2004). 
MCEC were therefore exposed to UVB irradiation at a single dose of 300 J/m2 and the 
expression of ICOSL, ICAM, PDL1 and MHC class II analysed by flow cytometry. 
UVB irradiation did not alter the phenotype of MCEC (Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17- Effect of UVB irradiation on MCEC phenotype 
MCEC were exposed to UVB irradiation at a single dose of 300 J/m2 and 24 hours 
later the expression of ICOSL, ICAM, PDL1 and MHC class II analysed by flow 
cytometry. UV irradiation did not alter MCEC phenotype. Results are from one 
experiment representative of three. 
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3.2.6 Determination of corneal IDO2 expression 
The recent discovery of an isoform of IDO (IDO2) as mentioned in section 1.5.8, and 
the fact that IDO has shown to be expressed in murine corneas (Serbecic and 
Beutelspacher, 2006); led us to investigate whether or not murine corneas expressed 
IDO2. Expression of IDO2 at the mRNA level (normalised to HPRT) was determined 
in MCEC as well as whole corneas by real time RT-PCR. Metz et al. (2007) showed 
that mouse liver expressed high levels of IDO2 and therefore murine liver samples 
were used as positive controls. There was no IDO2 expression in MCEC or whole 
corneas whereas IDO expression was demonstrated (Figure 18).  
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Figure 18- Corneal IDO2 expression 
IDO and IDO2 mRNA expression in MCEC as well as whole corneas was 
determined. RNA was extracted from 1x106 MCEC (M), 6 whole BALB/c corneas 
(C) and liver (L) as a positive control, subsequently converted to cDNA and real time 
RT-PCR carried out. Water was used as a negative control (N). (A) The levels of 
IDO2 mRNA are normalised to those of HPRT mRNA and shown as the mean +/- SD 
of triplicate determinations. The separation of PCR products on a 1.5% agarose gel is 
also shown (B). 
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3.3 Discussion 
As mentioned previously, the first report of IDO in ocular tissue was in the lens, 
where Takikawa and co-authors demonstrated its role in protecting lens from UV 
damage (Takikawa et al., 2001). It is therefore likely that a physiological function of 
IDO is to prevent endothelial cells from UV-mediated cell injury, and there is data in 
the human that it can be upregulated in endothelial cells by UVB (Serbecic and 
Beutelspacher, 2006). UV treatment of corneal allografts has been shown to prolong 
graft survival in both a mouse and rabbit model (Ray-Keil and Chandler, 1986, Dana 
et al., 1990). It could therefore be hypothesised that the prolongation in corneal 
allograft survival observed in UVB treated corneas may be attributable to 
upregulation of IDO. The results from the work presented in this chapter have shown 
upregulation of IDO in response to UVB irradiation at the mRNA level, with 
increasing expression in a dose dependent manner. Expression of IDO at the protein 
or functional level however could not be demonstrated. It must be mentioned 
however, that there are limitations in the experiment carried out in section 3.2.4. 
These are due to the fact that MCEC alone are poor stimulators in a MLR owing to 
their low expression of MHC class II and hence in our experiments we were looking 
for inhibition of a low response which is difficult. Another method would have been 
to use anti-CD3/CD28 beads as stimulators and MCEC as inhibitors; here, we would 
have expected UVB irradiation of MCEC to increase inhibition of T cell proliferation 
and this could have been confirmed due to IDO upregulation by using the IDO 
inhibitor 1-MT.  
It is possible that the lack of functional activity observed maybe a result of post-
translational inactivation of IDO. IDO activity is regulated at both transcriptional and 
post-transcriptional levels (Braun et al., 2005). Braun et al. characterised the 
mechanism by which IDO is upregulated in monocyte derived DCs; showing that 
PGE2 induced mRNA expression of IDO, yet the enzyme remained inactive. It was 
only in response to a combined second signal via TNF receptor or Toll-like receptor 
(using TNFα, LPS or Staphylococcus aureus Cowan strain I) was bioactive IDO 
observed (Braun et al., 2005). 
In the case of UV irradiation, it is well known that cells subjected to UV irradiation 
actively repress DNA replication, transcription and mRNA translation. Although the 
effects of UV irradiation on DNA replication and transcription are well documented, 
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the mechanisms for translational repression have been poorly understood. Deng et al. 
recently described a mechanism for inhibition of translation by UV irradiation; 
demonstrating that UV irradiation elicits phosphorylation of the α-subunit of 
eukaryotic translation initiation factor 2 (eIF2α) by activating the GCN2 kinase. 
Phosphorylation of eIF2α results in cell cycle arrest through inhibition of mRNA 
translation of cell cyclins (Deng et al., 2002). Furthermore, UVB irradiation has been 
shown to activate nitric oxide synthase (NOS) and nitric oxide production (NO) (Liu 
and Wu, 2010). NO is a well known inhibitor of IDO; directly inhibiting the haem 
active site (Aitken et al., 2004) as well as promoting proteasome-mediated 
degradation of the IDO protein (Hucke et al., 2004). This may well explain the lack of 
IDO protein expression in the above experiments. As a result of this lack of 
demonstration of IDO protein and most importantly function in response to UV 
irradiation of MCEC it was deemed non-worthwhile to proceed with experiments 
investigating the effects of UV irradiation on corneal allograft survival. 
Although basal IDO expression has been demonstrated in murine corneas we 
have shown that its isoform IDO2 is not expressed in murine cornea, a finding not 
reported previously.  
 
3.3.1 Chapter Summary 
The work in this chapter has: 
• Demonstrated upregulation of IDO mRNA in response to UVB irradiation in a 
dose dependent manner. IDO protein expression however could not be 
detected. 
• Demonstrated a lack of function of any upregulated IDO as determined by L-
kynurenine production. 
• Demonstrated no alteration in MCEC phenotype in response to UVB 
irradiation. 
• Demonstrated a lack of IDO2 expression in MCEC and whole corneas. 
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CHAPTER 4: RESULTS 
MURINE CORNEAL TRANSPLANTATION MODEL 
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4.1 Introduction 
4.1.1 Animal models of experimental corneal transplantation  
Experimental corneal transplantation has been performed in various animal models 
and each animal species has its specific advantages and limitations. Rabbits, rats, and 
mice are the most commonly used models. Corneal allograft survival in these three 
species is markedly different and surgery becomes technically more difficult as the 
size of animal and its cornea decreases. Experimental corneal transplantation was first 
carried out in random bred rabbits in the 1940s and 1950s (Maumenee, 1951, 
Billingham et al., 1951). It was found that greater than 50% of corneal allografts 
placed into non-vascularised graft beds in rabbits survived indefinitely without the use 
of any immunosuppressive treatment (Maumenee, 1951, Chen et al., 1990). These 
studies established the avascular cornea as a main component of immune privilege. 
From the 1970s, inbred rats were used in experimental corneal transplantation 
(Williams and Coster, 1985, Lang et al., 1975, Gebhardt, 1981, Treseler and 
Sanfilippo, 1985). These investigations clarified the role of CD4+ and CD8+ T cells in 
corneal alloresponses and led to studies of the cellular and molecular events in corneal 
allograft rejection (Treseler et al., 1985, Treseler and Sanfilippo, 1986b, Treseler et 
al., 1986, Treseler and Sanfilippo, 1986a). Similar to the rabbit, approximatley 50% of 
rats receiving MHC mismatched corneal allografts undergo immune rejection whereas 
the remaining 50% survive without the use of immunosuppressive therapy (Peeler et 
al., 1988, Ross et al., 1991). A new model of corneal transplantation with clinico-
pathological features very similar to those observed in humans has recently been 
described in the outbred minature pig, but again corneal neovascularisation has to be 
induced prior to corneal transplantation to induce corneal graft rejection (Tavandzi et 
al., 2007). This will be particularly useful for assessing clinically applicable 
experimental immunosuppressive strategies.  
 
4.1.2 The mouse model of corneal transplantation 
Over the past decade the use of inbred strains of mice as donors and recipients of 
corneal allografts has been used increasingly by a number of investigators (She et al., 
1990a, Peeler et al., 1988, Joo et al., 1995, Sonoda et al., 1995, Plskova et al., 2004, 
Yamada et al., 1999a). The mouse has many advantages as an experimental animal for 
immunological studies. Whereas a large percentage of corneal allografts survive 
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without immunosuppression in rabbits and rats, the majority of grafts in mice are 
rejected (Joo et al., 1995, She et al., 1990a, Haskova et al., 2000, Ardjomand et al., 
1997). 
Mouse corneal transplantation has been successfully established in our laboratory for 
a number of years. The strain combination that was successfully used in our 
laboratory was adult female C3H/He (H2k) mice as allogeneic donors and female 
BALB/c (H2d) as recipients. Our experience is that even though the mouse cornea is 
avascular, exchange of corneas between strains of mice mismatched at the MHC 
genes such as C3H/He (H2k) and BALB/c (H2d) with multiple minor mismatches 
invariably leads to graft rejection; unless immunosuppression is used. In our 
experience this combination yielded a highly reproducible interval to rejection in 
almost all animals, with median graft survival (MST) of 12 days in unmodified 
recipients and minimal deviation (Ardjomand et al., 1997). 
The mouse cornea is approximately 3.5 mm in diameter and commonly 2-2.5 mm 
allografts are performed. It is necessary to hold grafts in place with a continuous 
nylon suture. The complexity of the operation and the ensuing surgical trauma 
ultimately leads to an intense, acute inflammatory response, which is followed by 
neovascularisation and culminates in immune graft failure (Figure 19).  
 
 
 
Figure 19- Photograph of a rejected corneal allograft in a BALB/c mouse. Fourteen 
days after transplantation the graft from a C3H/He donor is opaque and vascularised.  
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4.1.3 Chapter aims 
As the technique of mouse corneal transplantation was new to me, the aims of the 
work presented in this chapter were to: 
 
1. Set up the mouse model of corneal transplantation 
2. Confirm the syngeneic and allogeneic corneal graft survival in the C3H-
BALB/c strain combination 
3. Examine histopathology of normal cornea, syngeneic and allogeneic corneal 
grafts post-transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 124 
4.2 Results 
4.2.1 Mouse eyes 
The BALB/c mouse eye used as the recipient in this work has an axial length of 3.7 
mm and a corneal diameter of 3.5 mm (Zhang et al., 1996), significantly smaller 
dimensions than the human eye which has an average axial length of 23.0 mm and a 
corneal diameter of 12 mm. This appreciably makes surgery more technically 
demanding. The BALB/c mouse as a recipient however, has advantages over other 
strains, in that given it is an albino, the iris is thin and translucent with clearly visible 
vessels making corneal transplantation easier and also making the BALB/c mouse as 
the recipient of choice by most investigators. The mouse eye has a very shallow 
anterior chamber in comparison to the human eye due to the lens being proportionally 
larger (Figure 20 and 21). 
 
4.2.2 Histology of the mouse cornea 
Figure 22 is a histological slide showing a cryosection of a normal BALB/c cornea. 
This is made up of four layers: epithelium, stroma, Descemet’s membrane and 
endothelium. The outermost layer of the cornea is a stratified (5-7 cell layered), non-
keratinised and non-secreting epithelium- a tissue barrier essential for corneal 
integrity. The epithelium is composed of an outer layer of mostly differentiated 
superficial cells by two to three layers of intermediate wing cells. Underlying the 
basal cells is the basement membrane synthesised by the epithelial cells. In mouse, the 
epithelium comprises 30% of the cornea. Forming 70% of the cornea is the central 
connective tissue layer, the stroma, composed primarily of collagen fibrils, keratin 
sulphate and chondroitin sulphate proteoglycans. Synthesised by keratocytes, the 
collagens and proteoglycans form a highly ordered extracellular matrix. The posterior 
monolayered endothelium is separated from the stroma by a basal lamina, the 
Descemet’s membrane. Produced by the endothelium, the Descemet’s layer is a thick 
basal lamina that separates the endothelium from the stroma (Chakravarti, 2001). The 
cells of the endothelium are responsible for maintaining corneal transparency and in 
human, unlike mice are non-replicating. 
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Figure 20- Histological appearance of a normal human eye 
 
 
 
 
 
 
Figure 21- Histological appearance of a normal BALB/c mouse eye 
Cryosection from the eye of a BALB/c mouse counterstained with haematoxylin and 
eosin (original magnification x2). 
 
 
 
 
 
 
 
Image Courtsey of: 
http://biology.clc.uc.edu/fankhauser/Labs/Anatom
y_&_Physiology/A&P202/Special_Senses/Eye/H
istology_EYE.htm. Accessed 01.05.11, no 
copyright. 
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Figure 22- Histological appearance of a normal BALB/c cornea 
Cryosection from the cornea of a BALB/c counterstained with haematoxylin and 
eosin (original magnification x 40). 
 
4.2.3 Step-by-step corneal transplantation method  
Illustrated below are the steps required to perform corneal transplantation in mice. 
Preparation of donor 
 
1. The donor C3H mouse was killed by overdose of CO2. 
2. The eye was then enucleated. 
 
3. A 2.5 mm trephine was then used to mark the cornea. 
4. An anterior chamber paracentesis was performed using a diamond knife. 
Epithelium 
Stroma 
Endothelium 
Descemet’s 
membrane 
Keratocyte 
1 2 
3 4 
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5. The donor corneal button was excised using vannas scissors and retained in 
PBS until the recipient had been prepared for grafting. 
 
Preparation of recipient 
 
 
1. Preparation of the recipient required administration of a general anaesthetic by 
intra-peritoneal injection (150 µl of a mixture of 25% Hypnorm and 25% 
midazolam in 50% water).  
2. Topical atrophine sulphate 1% and phenylephrine 10% drops were instilled to 
ensure a fully dilated pupil. 
 
 
 
 
 
 
 
 
3. The cornea was marked using a 2.0 mm trephine 
4. The cornea was then excised using vannas scissors. 
5 
1 
1 
2 
3 4 
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5. The donor button was transferred to the recipient under a bubble of PBS. The 
bubble of PBS was maintained throughout the procedure to prevent the eye 
from drying and cataract formation. 
6. An initial fixation suture (11/0 nylon) was placed through the donor and 
recipient cornea. 
 
 
 
 
 
 
 
7. A continuous 11/0 nylon suture was used to fix the cornea in place with a 
minimum of 8 bites taken. The suture was then tied and trimmed. 
8. At the end of the procedure the eyelids were sutured closed with 7/0 vicryl to 
protect the corneas for the initial 48 hours. 
 
9. At that time and every 2 days thereafter the eye was examined by the 
operating microscope. Technically satisfactory grafts had corneal opacity 
grade 0 to 1 (see section 4.2.4) at all times until corneal suture removal on day 
7 (see Figure 23). All other graft recipients and those with intraocular 
haemorrhage or cataract were excluded from further analysis. 
 
 
 
 
 
5 6 
7 8 
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Figure 23- Orthotopic mouse corneal allograft at day 7 
Allogeneic corneal transplant showing a clear graft with a continuous 11/0 nylon 
suture in place. 
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4.2.4 Grading of corneal allografts 
Sonoda and Streilin devised the original scoring system for grading corneal allografts, 
describing in semi-quantitative terms the extent of corneal opacity and vascularisation 
and correlating observed graft appearances with histology (Sonoda and Streilein, 
1992). Over time, minor modifications have been made to the grading system. The 
grading we used is shown in Table 6 and illustrated in Figure 23. Corneal 
opacification is an indicator of disrupted corneal endothelial function and of graft 
endothelial injury. Grafts were considered rejected when they had an opacity score ≥ 
grade 3 (see Figure 24 red box). 
 
GRADE CLINICAL APPEARANCE 
0 Complete transparent cornea 
 
1 Minimal corneal opacity, but iris vessels 
clearly visible 
 
2 Moderate corneal opacity, iris vessels still 
visible 
 
3 Moderate corneal opacity, only pupil 
margin visible 
 
4 Complete corneal opacity, pupil not 
visible 
 
 
Table 6- Clinical scoring system for orthotopic corneal  allografts 
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Figure 24- Clinical scoring system for orthotopic corneal grafts 
Grading of corneal opacity: 0, complete transparent cornea; 1, minimal corneal 
opacity, but iris clearly visible; 2, moderate corneal opacity, iris vessels still visible; 3, 
moderate corneal opacity, only pupil margin visible; 4, complete corneal opacity, 
pupil not visible. Grafts with an opacity score ≥ grade 3 were considered to be 
rejected (red box). 
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4.2.5 Mouse corneal allograft survival: syngeneic versus allogeneic 
To become proficient in the technique of mouse corneal transplantation, syngeneic 
transplants were initially used as any failures would be as a result of surgical failure 
and this was also useful experimentally to confirm non-rejection of syngeneic grafts. 
Animals with grafts that remained clear at 60 days were deemed long term survivors 
and killed. To establish the median survival of allogeneic grafts, transplantation was 
carried out with the previously described strain combinations; inbred C3H female 
mice as donors and inbred BALB/c female mice as recipients. The two groups 
therefore consisted of syngeneic (BALB/c to BALB/c) and allogeneic C3H to 
BALB/c transplants. As expected the syngeneic grafts (n=8) remained clear 
throughout the 60 day observation period, whereas allogeneic donor grafts (n=8) 
rejected from day 9 with a median survival (MST) of 12 days. Actuarial graft survival 
in recipient groups is illustrated in Figure 25. 
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Figure 25- Kaplan-Meier survival of mouse syngeneic and allogeneic corneal 
transplants. 
Mouse corneal transplants were performed using female BALB/c as recipients 
receiving either a syngeneic (BALB/c) or allogeneic (C3H) donor corneas. Syngeneic 
(n=8) corneal graft survival showed long term graft acceptance with a median survival 
time (MST) of > 60 days compared to allogeneic (n=8) corneal graft survival that had 
a MST of 12 days.  
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4.2.6 Histology of syngeneic and allogeneic corneal transplants 
In order to confirm rejection, end-point histology was carried out on both syngeneic 
and allogeneic recipients. Whole eye balls were removed on the day of observed 
rejection in the allogeneic group and day 60 in the syngeneic group, snap frozen and 
stored at -80°C. Whole eye balls were used to maintain corneal integrity. 
Subsequently, 7 µM tissue sections were cut with a cryostat and counterstained with 
haematoxylin and eosin. The histological appearance of syngeneic transplants was 
similar to that of normal corneas with intact epithelium, stroma and endothelium 
(Figure 26a and b). The histological appearance of rejected grafts however, showed 
marked stromal thickening, with an inflammatory infiltrate and absence of the 
endothelium (Figure 25c and d). The appearances are consistent with reported 
literature (Ardjomand et al., 2003, Sonoda and Streilein, 1992). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 26- Histology of corneal transplants 
Whole eyes from a) normal cornea b) syngeneic and c) & d) allogeneic grafts, were 
removed on the day of observed rejection and day 60 post-transplantation. Tissues 
were cryosectioned and counterstained with haematoxylin and eosin. Representative 
histopathology sections are shown (original magnification x 10). The arrow indicates 
destroyed graft endothelium. The box demonstrates iris with cellular extravasate. 
 
a) b) 
c) d) 
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4.3 Discussion 
4.3.1 Development of the mouse model of corneal transplantation 
As mentioned previously, due to the small size of the mouse eye, corneal 
transplantation is surgically challenging. However with the availability of fine 11/0 
suture materials and advances in surgical instrument design it has become feasible to 
perform corneal transplantation in animals as small as mice (Plskova et al., 2002). 
There are several advantages to using the mouse model. 
1. The range of inbred, transgenic and gene-targeted strains of rodents available 
permitting more mechanistic studies. 
2. The availability of a large range of reagents for rodents. 
3. Large numbers of animals can be used with much smaller volumes of reagents 
required for systemic treatment than in a larger animal. 
As there are advantages, there are limitations to the use of the mouse model. The main 
disadvantage being the size of the mouse eye making surgery technically more 
demanding with a longer learning curve required to achieve adequate proficiency in 
the technique. Another limitation is the ability of mouse corneal endothelium to 
replicate unlike human corneal endothelium, although experimentally this did not 
pose a particular problem in our model as discussed later in section 4.3.3 and the 
clinical picture of rejection being different from that observed in humans. 
 
4.3.2 Grading of corneal transplantation 
Clinically and experimentally, rejection of corneal grafts is considered as 
opacification of the cornea. Various factors can contribute to opacification or reduced 
clarity of the cornea including new vessel ingrowth, cellular infiltration, thickening 
and irregularity of the cornea and oedema. Researchers using these rat and mouse 
corneal transplantation models therefore developed grading systems for corneal graft 
rejection which took into account each of these features and produced an aggregate 
score. An arbitary score level was then taken as clinical evidence of rejection (Plskova 
et al., 2002). However, Plskova et al. and others (Sonoda and Streilein, 1992) have 
shown in direct comparison studies that this more complex grading system correlates 
well with the single grading of the level of opacity as a measure of clinical graft 
rejection. As a result, opacity level is now used as the standard means for grading 
rejection (Plskova et al., 2002). The grading system used in our model of corneal 
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transplantation uses a single grading of opacification as a clinical measure of corneal 
graft rejection. 
 
4.3.3 Definition of irreversible graft rejection 
Graft rejection is considered irreversible when the corneal graft remains opaque 
despite treatment. Plskova et al. highlighted an interesting observation in mouse (fully 
MHC mismatched allograft combinations) corneal transplantation. That is, an early 
phase of rejection (8-21 days post graft) followed by recovery at a later stage, usually 
8 weeks post-grafting. This biphasic response greatly depended on the strain 
combination and on the host background. They suggested several possibilities for this, 
firstly that there is transient loss of donor endothelium which is followed by recovery 
presumably by repopulation by host endothelium (Plskova et al., 2002). However, it 
has been shown that using a green fluorescent protein transgenic (GFP-Tg) mouse that 
clear allografts retained donor endothelium while rejected allografts had no 
endothelium (Hori and Streilein, 2001). Secondly, that the donor endothelium can go 
through a period of dysfunction in response to inflammation, which eventually 
recovers (Plskova et al., 2002). In the strain combination used, we did not observe this 
biphasic response and consistently found allograft rejection (opacity grade ≥ 3) in 
100% of mice (Ardjomand et al., 2003). 
 
4.3.4 Allograft survival 
The results presented in this chapter found allograft rejection in 100% of mice with a 
MST of 12 days (range 9-14). This was inkeeping with the literature with 80-100% of 
mice rejecting between days 10-25 post-transplantation using fully mismatched 
allografts (He et al., 1994, He et al., 1996, Joo et al., 1995, Yamada and Streilein, 
1998, Niederkorn and Mellon, 1996, She et al., 1990b, He et al., 1991, Sonoda and 
Streilein, 1992). 
 
4.3.5 Histology of rejection 
Histological assessment of rejected allografts showed marked stromal thickening and 
oedema with a large inflammatory cell infiltrate. The salient finding in rejected 
allografts that has consistently been found in previous studies is the absence of the 
endothelium. This results in oedema, loss of corneal transparency and ultimately graft 
failure (Hori and Streilein, 2001). 
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4.3.6 Chapter summary 
The work in this chapter has: 
• Set up the mouse model of corneal transplantation 
• Confirmed syngeneic and allogeneic corneal graft survival in the C3H to 
BALB/c strain combination 
• Confirmed histological features of normal BALB/c cornea, syngeneic and 
rejected allogeneic transplants. 
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CHAPTER 5- RESULTS 
EFFECT OF TRYPTOPHAN METABOLITES ON 
CORNEAL ALLOGRAFT SURVIVAL  
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5.1 Introduction 
Previously it has been shown that ex-vivo lentiviral transduction of corneas with IDO 
significantly prolongs corneal allograft survival (Beutelspacher et al., 2006). While on 
the one hand this is explained by the accepted effect of IDO-induced tryptophan 
depletion in arresting replication of activated lymphocytes, it is also known that the 
metabolites resulting from tryptophan breakdown, including kyn, 3HK and 3HAA can 
themselves inhibit T cell activation and proliferation (Bauer et al., 2005). Little is 
known however about the effect of individual kynurenines on corneal allograft 
survival. The kynurenine molecule is well below the size of molecule that can 
penetrate (although other factors may also influence penetration) to the corneal 
stroma. Therefore, using these agents as a topical treatment might be a simpler 
effective approach to preventing graft rejection than gene-based therapy.  
 
 
5.1.1 Chapter aims 
The aims of the work presented in this chapter were to: 
 
1. To determine the in vitro effect of individual kynurenines on T cell 
proliferative responses as well as T cell viability and regulatory T cell 
development 
2. To determine the in vitro effect of individual kynurenines on DC function, 
phenotype and viability 
3. To determine the in vitro effect of individual kynurenines as well as IDO 
expression on MCEC phenotype and viability 
4. To determine the in vivo effect of both systemic and topical administration of 
3HK on murine corneal allograft survival 
5. To determine the in vivo effect of both systemic and topical administration of 
3HK on splenic and peripheral blood lymphocyte counts as well as draining 
lymph node (DLN) counts in topical treated animals. 
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5.2 Results 
5.2.1 Isolation of CD4+ T cells 
A principal aim of this study was to investigate the effects of kynurenines and other 
agents on CD4+ T cell responses. It was thus vital to ensure that pure populations of 
murine CD4+ T cells were isolated. CD4+ T cells were examined as corneal graft 
rejection is mediated predominantly by this subset (Tanaka et al., 2001). 
CD4+ T cells were first purified from the spleens of BALB/c mice by negative 
selection using magnetic beads. Purity of the CD4+ T cells was assessed by flow 
cytometry immediately after negative selection from the whole spleen cell population. 
Purified CD4+ T cells were analysed for cell surface expression of CD3, CD4, CD8, 
CD19 and CD16/CD32 (Figure 27). Greater than 90% of the negatively-selected cells 
expressed CD3 and CD4, consistent with a CD4+ T ‘helper’ cell phenotype, in 
addition to expressing negligible levels of the CD8 T cell marker, the B cell marker 
CD19 and the FcγR CD16/32. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27- Purification of murine spleen-derived CD4+ T cells. 
CD4+ T cells were purified from the spleens of BALB/c mice by negative selection 
using magnetic beads. Purity of the CD4+ T cells was assessed by flow cytometry 
immediately after negative selection from the whole spleen population. Purified CD4+ 
T cells were analysed for cell surface expression of CD3, CD4, CD8, CD19 and 
CD16/32. 
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5.2.2 T cell stimulation and expansion using anti CD3/CD28 beads 
T cell proliferation assays using anti-CD3/CD28 beads are well established in our 
laboratory and have been shown to provide a simple, rapid and reproducible method 
for polyclonal T cell stimulation and expansion (Trickett and Kwan, 2003). T cell 
stimulation was performed in 96 well plates and 1x105 T cells with equal numbers of 
beads were added to the wells. This gave a ratio of 1 bead: 1 cell (See section 2.12.3). 
T cell proliferation was detected on day 3 of the assay. CD4+ T cells demonstrated 
significant clonal proliferation after a 3 day culture on repeated experiments (Figure 
28). Advantages of this assay are its simplicity as well as providing an accurate 
method of assessing the effects of external agents solely on T cell proliferation. T cell 
proliferation assays that were subsequently performed throughout this investigation 
were harvested on day 3 subsequent to thymidine incorporation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28- Capacity of anti CD3/CD28 beads to stimulate CD4+ T cells. 
1x105 BALB/c CD4+ T cells were stimulated with anti CD3/CD28 beads at a ratio of 
1 bead: 1 cell in three separate experiments. T cell proliferation was detected by 
thymidine incorporation on day 3 of the assay. Data represents mean ± SD of 
triplicate samples from three different experiments.  
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5.2.3 The tryptophan metabolites 3HK and 3HAA inhibit murine T cell proliferation 
in vitro 
In order to confirm the effect of tryptophan metabolites on murine allogeneic T cell 
responses (Bauer et al., 2005), the metabolites were added at various concentrations to 
purified CD4+ T cells that were stimulated with anti-CD3/CD28 beads and 
proliferation determined using 3H thymidine incorporation. As shown in Figure 29a, 
addition of 3HK and 3HAA significantly inhibited CD4+ T cell proliferation in a 
dose-dependent manner with IC50 values of approximately 70 µM and 30 µM 
respectively, when compared to T-cells incubated in vehicle alone. A minimal effect 
with Kyn was observed and no effect was seen with QA. Similar data were obtained 
when the T cells were stimulated with allogeneic dendritic cells in a mixed 
lymphocyte response (Figure 29b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29a- Effect of kynurenines on T cell proliferation. 
 CD3/CD28 bead stimulated CD4+ T cells were incubated for 72 h in the presence of 
kynurenines (3HK, 3HAA, Kyn and QA) at concentrations varying from 0-100 µM. 
Proliferation was measured by 3H-Thymidine incorporation. The solid box represents 
the vehicle control and the open, the kynurenine. Data represents mean ± SD of 
triplicate cultures. Results shown are of one experiment representative of four. * 
p<0.005, versus control. 
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Figure 29b- Effect of kynurenines on T cell proliferation in a mixed lymphocyte 
reaction.  
Mature bone marrow derived DCs (C3H) were used to stimulate allogeneic CD4+ T 
cells (BALB/c) in a mixed lymphocyte reaction at a ratio of 1: 10 in the presence or 
absence of kynurenines. Proliferation was measured by 3H-thymidine incorporation on 
day 3 of the MLR. Data represents mean ± SD of triplicate cultures. Results shown 
are of one experiment, representative of four. * p<0.005, versus control. 
 
 
 
5.2.4 3HK and 3HAA induce CD4+ T cell death 
There are several possible mechanisms by which 3HK and 3HAA might influence T 
cell responses. These include the induction of T cell death, or the induction of T 
regulatory cells (Tregs). In order to investigate cell death CD4+ T cells were 
stimulated with anti-CD3/CD28 beads in the presence of the kynurenines (0-100 µM) 
for 24 h and cell death assessed by flow cytometry following staining with 7-AAD 
and annexin V. Both 3HK and 3HAA induced significant CD4+ T cell-mediated cell 
death in a dose-dependent manner whereas neither QA nor Kyn did (Figure 30a and 
b). Furthermore, as previously reported (Fallarino et al., 2002a), 3HAA was found to 
be more potent than 3HK; inducing apoptosis at concentrations as low as 25 µM in 
comparison to 100 µM for 3HK.  
 
 
0
5000
10000
15000
20000
25000
30000
0 3HK 3HAA QA Kyn
Kynurenine concentration 
3 H
-
th
ym
id
in
e
 
in
co
rp
o
ra
tio
n
 
(cp
m
) 
* * 
100 µM 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 143 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30- Effect of Kynurenines on T cell viability. 
CD3/CD28 bead activated CD4+ T cells were incubated with or without kynurenines 
for 72 h. Apoptosis and cell death were evaluated by flow cytometry following vital 
staining with Annexin V and 7-AAD (B). The bar graph summarises the percentage of 
cell death detected by Annexin V and 7-AAD staining using flow cytometry (A). Data 
represent mean ± SD of triplicate samples.  
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5.2.5 Tryptophan metabolites induce a T regulatory cell phenotype from the whole 
CD4+ T cell population 
Expression of FoxP3 correlates with suppressor activity in CD4+ T cells (Fontenot et 
al., 2005). Fallarino et al, demonstrated that naïve CD4+ FoxP3- T cells, which are 
resistant to kynurenine-induced apoptosis, can convert into CD4+FoxP3+ cells by a 
GCN2-dependent mechanism following incubation with kynurenines (Fallarino et al., 
2006a). We looked at the effect of the kynurenines on the number of FoxP3 positive 
cells from the whole CD4+ T cell population. CD4+ T cells were stimulated with anti-
CD3/CD28 beads in the presence of the kynurenines (0-100 µM) for 3 and 7 days. As 
shown in Figure 31a, there was no difference in the proportion of CD4+ cells 
expressing FoxP3 in the presence of any of the kynurenines after 3 days. However 
after 7 days, there was a significant increase in the proportion of CD4+ cells 
expressing FoxP3 in the presence of all of the kynurenines at the 10 µM concentration 
(Figure 31b), flow histograms of 3HK and 3HAA data are also shown (Figure 32). 
This suggests that lower concentrations of kynurenines are required to induce Tregs, 
in keeping with earlier reports (Fallarino et al., 2006a). Interestingly, at the 100 µM 
concentration there was a reduction in the percentage of FoxP3 expressing cells after 
both 3 and 7 days in the presence of 3HK and 3HAA, but not QA nor Kyn.  
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Figure 31- FoxP3 expression in CD4+ T cells cultured with kynurenines.   
CD4+ T cells were activated with anti-CD3/CD28 beads with or without kynurenines. 
At 3 days (A) and 7 days (B), cells were recovered and the percentage of CD4+ T cells 
that were FoxP3 positive was quantified by intracellular flow cytometry. Data 
represent mean ± SD of triplicate samples. * p≤0.005, experimental versus T cells 
alone. 
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Figure 32- FoxP3 expression in CD4+ T cells cultured with kynurenines.   
CD4+ T cells were activated with anti-CD3/CD28 beads with or without kynurenines. 
At 3 days (A) and 7 days (B), cells were recovered and the percentage of CD4+ T cells 
that were FoxP3 positive was quantified by intracellular flow cytometry. (Solid 
histograms = FoxP3, open = isotype control). Histograms are indicative of one 
experiment representative of three. 
 
 
 
 
 
 
 
 
3H
K 
3H
AA
 
0 µM 25 µM 50 µM 100 µM 
10 µM 100 µM 
3H
K 
0 µM 10 µM 100 µM 
3H
AA
 
0 µM 
0 µM 25 µM 50 µM 100 µM 
A 
B 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 147 
5.2.6 Tryptophan metabolites do not alter DC function or phenotype 
Given the observed effect of kynurenines on T cells, it was speculated that 
kynurenines could modify DC biology in a direct manner. The effect of the individual 
kynurenines on both immature and mature DC was assessed by co-incubation for 24 
h, followed by washing. The DCs were then used in mixed lymphocyte reactions to 
investigate their ability to stimulate CD4+ T cells; stained for CD80, CD86 and class 
II cell surface markers to identify phenotype; and viability assessed by flow cytometry 
following vital staining with 7-AAD. It was shown that incubation with kynurenines 
did not alter either the phenotype of immature or mature DCs (Figure 33A, B and 
Figure 34A, B), or alter their ability to stimulate CD4+ T cells (Fig 35A and B) and 
had no effect on their viability (Figure 36). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33- Effect of 3HK on the phenotype of both immature and mature bone 
marrow-derived dendritic cells. 
Bone marrow-derived dendritic cells from BALB/c mice were stimulated with LPS on 
day 7 of culture for 16 hours to induce maturation. Both unstimulated/immature (A) 
and LPS-stimulated/mature DCs (B) were subsequently co-cultured with 3HK at a 
concentration of 100 µM for 24 hrs, washed and cell surface expression of CD80, 
CD86 and MHC Class II analysed by flow cytometry (solid line represents 3HK, 
dashed line vehicle control and dotted line DC alone). Data is from one experiment 
representative of three. 
B 
A 
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Figure 34- Effect of kynurenines on the phenotype of both immature and mature bone 
marrow-derived dendritic cells. 
Bone marrow-derived dendritic cells from BALB/c mice were stimulated with LPS on 
day 7 of culture for 16 hours to induce maturation. Both unstimulated/immature (A) 
and LPS-stimulated/mature DCs (B) were subsequently co-cultured with the 
individual kynurenines at a concentration of 100 µM for 24 hrs, washed and cell 
surface expression of CD80, CD86 and MHC Class II analysed by flow cytometry. 
Data is from one experiment representative of three. 
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Figure 35- Effect of kynurenines on capacity of dendritic cells to stimulate allogeneic 
CD4+ T cells in a mixed lymphocyte response. 
Mature (A) and immature (B) bone marrow-derived (C3H/He) DCs were incubated 
with the individual kynurenines (open) as well as their vehicle controls (solid) at 
concentrations ranging from 0-100 µM for 24 h, subsequently washed and then used 
to stimulate allogeneic (BALB/c) CD4+ T cells (at a ratio of 1:10 DC : T cell ratio) in 
a mixed lymphocyte reaction and proliferation measured by 3H-thymidine 
incorporation on day 3. Data represents mean ± SD of triplicate cultures. Results 
shown are of one experiment representative of three. 
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Figure 36- Effect of kynurenines on DC viability 
Mature and immature bone marrow-derived (C3H/He) DCs were incubated with the 
individual kynurenines as well as their vehicle controls at a concentration of 100 µM 
for 24 h, subsequently washed and cell death evaluated by flow cytometry following 
vital staining with 7-AAD. 
 
 
5.2.7 Effect of IDO expression and kyurenines on corneal endothelial cell biology 
Clearly any strategies that aim at modulating or mimicking IDO activity have the 
potential of altering the behaviour of non-immunological cells. Having shown 
selective T cell toxicity in the presence of kynurenines, it was important to ensure that 
they did not alter the behaviour of corneal endothelial cells, the function of which is 
critical for maintenance of corneal transparency and particularly because of the 
potential of using these agents as a therapeutic strategy in preventing corneal graft 
rejection. 
 
5.2.7.1 Effect of kynurenines on MCEC viability 
The most likely consequence of IDO activity is death of cells. MCEC at a 
concentration of 1x105 were incubated with the individual kynurenines at a 
concentration of 100 µM for 24 hrs and subsequently assessed for apoptosis and cell 
death using Annexin V and 7-AAD staining as described previously. Minimal 
apoptosis was observed in the presence of any of the kynurenines (2.8-5.8%), 
therefore it could be concluded that there was no deleterious effect of kynurenine 
administration on the viability of MCEC (Figure 37). In previous work from the 
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laboratory, it has been shown that it is possible to induce apoptosis of corneal 
endothelial cells both in isolation and in intact corneas in a NO-dependent manner 
using combinations of cytokines (Sagoo et al., 2004). 
Recombinant murine pro-inflammatory cytokines TNFα, IL1-α and IFN-γ were added 
directly to cell cultures at final concentrations of 10 ng/ml and 100 ng/ml in 
combination together with the kynurenines and subsequently cultured for 48 h and 
then assessed for apoptosis using Annexin V staining.  
Using dose-response experiments in the presence or absence of kynurenines we 
investigated whether cells became more sensitive to apoptosis by this pathway. We 
found that in the presence of 3HK and 3HAA, there was no increase in apoptosis; 
however consistently in the presence of kynurenine and quinolinic acid there was 
(Figure 38 & 39). This suggests that 3HK and 3HAA do not sensitise cells to 
apoptosis. 
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Figure 37- Effect of kynurenines on MCEC viability 
(A) MCEC were incubated with the individual kynurenines as well as their vehicle 
controls at a concentration of 100 µM for 24 h, subsequently washed and cell death 
evaluated by flow cytometry following vital staining with Annexin V and 7-AAD. (B) 
The bar graph summarises the percentage of apoptosis detected by Annexin V 
staining as assessed using flow cytometry. 
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Figure 38- Effect of kynurenines on apoptosis of stressed MCEC 
MCEC were stressed by using a cocktail of cytokines- TNFα, IL1-α and IFNγ at 
concentrations of 10 and 100 ng/ml. These were added directly to cell cultures 
together with the kynurenines (100 µM) and left for 48 hrs. Apoptosis was evaluated 
by flow cytometry following vital staining with Annexin V. The control group 
consisted of MCEC with the cytokine cocktail but no added kynurenines. 
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Figure 39- Effect of kynurenines on apoptosis of stressed MCEC 
MCEC were stressed by using a cocktail of cytokines- TNFα, IL1-α and IFNγ at 
concentrations of 10 and 100 ng/ml. These were added directly to cell cultures 
together with the kynurenines (100 µM) and left for 48 hrs. Apoptosis was evaluated 
by flow cytometry following vital staining with Annexin V. The control group 
consisted of MCEC with the cytokine cocktail but no added kynurenines. This graph 
summarises the percentage of apoptosis detected by Annexin V staining as assessed 
using flow cytometry in figure 38. 
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5.2.7.2 Effect of IDO expression on MCEC viability 
5.2.7.2.1 Self-inactivating Lentivirus production using a three-plasmid co-transfection 
technique and highly efficient transduction of an immortalised cell line 
In order to assess the effect of IDO expression on MCEC viability, MCEC had to be 
transduced with an EIAV lentiviral vector expressing IDO as well as with a control 
vector expressing GFP. An EIAV lentiviral construct encoding murine IDO was 
generated previously in the laboratory and had been shown to efficiently transduce 
corneal endothelial cells (Beutelspacher et al., 2006) (Figure 40). The VSV-G-
pseudotyped, self-inactivating EIAV lentivirus was propagated by a three- plasmid 
co-transfection technique using pONY3.1, an EIAV/HIV gag/pol-expressing 
consrtuct, pRV67 (the EIAV VSV-G-expressing construct) and pSMART2G (the 
EIAV vector construct with the eGFP/ IDO expression cassette) (Figure 41a-d). The 
pSMART IDO construct would be used to generate the EIAV IDO lentivirus for long-
term, stable expression of the transgene after integration into the host cell genome. In 
addition to production of lentiviral vectors by transient transfection with three 
plasmids, safety has been further guaranteed by deleting genes not required for the 
generation of functional vector particles and making the vector self-inactivating 
(SIN). 
 
 
 
 
 
 
 
 
 
 
 
Figure 40- IDO EIAV Lentiviral construct (pSMART2G) 
An EIAV lentiviral construct encoding murine IDO was generated previously 
(plasmid shown). The gene for murine IDO was amplified from mature DCs by PCR 
and the plasmid pSMART2G cut with restriction enzymes, removing the eGFP gene 
originally present. A linker oligonucleotide was ligated into the plasmid using T4 
ligase. The gene for IDO was inserted between the PacI and NheI sites. 
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Figure 41- Self-inactivating EIAV Lentivirus production using a three-plasmid co-
transfection technique and highly efficient transduction of an immortalised cell line. 
The VSV-G-pseudotyped, self-inactivating/ third generation EIAV GFP lentivirus 
was propagated by a three-plasmid co-transfection technique using the following 
plasmids: a) pONY3.1 (EIAV/HIV gag/pol-expressing construct), b) pRV67 (EIAV 
VSV-G-expressing construct) and c) pSMART2G (EIAV vector construct with the 
eGFP expression cassette). d) D17 cells were transduced with EIAV GFP (generated 
using the three-plasmid co-transfection technique described above) at MOI 10 and 
transduction efficiency assessed by flouresence microscopy 72 hours later. 
Transduction efficiency was calculated by counting the number of green cells in a 
given area and expressed as a percentage of the total number of cells in this given 
area. 
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5.2.7.2.2 Lentivirus titration by real time (quantitative PCR) and fluorescence 
microscopy 
Consistency in the number of infectious units (or concentration of virus) used to 
transduce cells was achieved by titrating lentiviral stocks immediately after 
production. The number of infectious particles (or transducing units) per ml of virus 
stock was calculated after titration of viral stocks, and cells subsequently transduced 
at an identical multiplicity of infection (MOI). EIAV stocks were titred using a 
combination of fluorescence microscopy and quantitative (real-time) PCR. 
Fluorescence microscopy of EIAV GFP-transduced cells was used in conjunction 
with real-time PCR of mRNA (transgene transcripts) extracted from transduced cells 
to determine titres for EIAV IDO stocks. Real-time PCR was used as the pSMART 
IDO construct does not encode a reporter gene that allows for direct visualisation of 
transduced cells (the GFP sequence present in the pSMART2G construct was replaced 
by sequences encoding IDO to generate pSMART IDO). The real-time PCR was 
adapted from a method described in which a DNA sequence found in the woodchuck 
hepatitis postregulatory element (WPRE) was quantified using qPCR (Lizee et al., 
2003b). The WPRE sequence is known to enhance lentiviral transgene expression 
(Ramezani et al., 2000, Zufferey et al., 1999) and is included in the 3’ untranslated 
region (UTR) of many lentiviral vector plasmid constructs. Quantitative RT-PCR of a 
transcribed nucleotide sequence provides a useful tool for titring novel recombinant 
lentiviruses, particularly when it is difficult to quantify transgene expression at the 
protein level- the ultimate goal of viral transduction. Furthermore, it has been shown 
that titration of lentiviruses based on the determination of the number of integrated 
proviral DNA copies per cell by qPCR has limitations; it can overestimate the 
capacity of transduced cells to express the transgene, because a significant proportion 
of integrated provirus may not be transcribed (Lizee et al., 2003b). 
To calculate lentiviral titres, canine osteosarcoma (D17) cells were seeded on 24-well 
plates at 2x104 cells per well in 400 µl of medium. 40 µl of EIAV stock was added to 
the seeded wells in triplicate and serially diluted 10-fold (10-1 -10-7). The D17 cells 
were subsequently visualised by fluorescence microscopy 72 hours after transduction 
with the serial dilutions of EIAV GFP stocks. A graph of the number of foci of 
infection visualised per well at each of the dilutions (10-1 – 10-6) was generated with 
the Y axis (foci of infection) converted to a Log scale for linearisation of the curve 
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(Figure 42a and b). The graph was generated from values derived from the titration of 
EIAV GFP lentiviral stocks on three separate occasions. 
Ten-fold serial dilutions of the pSMART GFP plasmid were used to generate standard 
curves for WPRE qPCR (Figure 42c). Because the concentration of plasmid can be 
accurately measured by spectrophotometry, the standard curve can be used to 
calculate the number of copies of lentiviral molecules in a given sample. A similar 
curve was derived for the pSMART IDO plasmid. 
Similar to methods used for fluorescence microscopy, D17 cells transduced with 
EIAV IDO and EIAV GFP were harvested 72 hours post-transduction and total RNA 
extracted for real-time PCR analysis. Real-time PCR was used to quantify WPRE 
mRNA sequences in order to report a D17 cell lentivirus transduction event. A graph 
of WPRE copy numbers from the mRNA of EIAV transduced D17 at each dilution of 
EIAV GFP stock was generated with a line of best fit applied (Figure 42d). The same 
curve was derived for EIAV IDO transduced D17 cells. A line of best fit applied to 
the EIAV GFP standard curve (Figure 42b) was used to unite the WPRE copy number 
(of EIAV IDO transduced D17 cells) to a value of foci of infection for EIAV GFP 
transduced D17 cells (using the log 10 dilution as the connecting value). The number 
of infectious particles per ml of each lentiviral stock was then deduced from the 
estimated foci of infection value. The EIAV GFP curve (Figure 42b) was thus used as 
a standard to deduce the number of foci of infection from the real-time PCR data used 
to detect WPRE after transduction of cells with EIAV IDO, which lacks the reporter 
gene in its DNA construct. There are limitations to this approach, the most notable 
being that D17 cells are very easily transduced with 100% efficiency whereas other 
cell types in particular MCEC are more difficult to transduce. The maximum 
transduction efficiency achieved with MCEC was 50% using an MOI of 100. 
 
 
 
 
 
 
 
 
 
 
 
 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42- Lentivirus titration by Real-time (quantitative) PCR and fluorescence 
microscopy.  
EIAV stocks were titred using a combination of flourescence microscopy and 
quantitative (real-time) PCR of RNA extracted from transduced cells to determine 
titres for EIAV IDO stocks. (a-c) Canine osteosarcoma (D17) cells were seeded on 
24-well plates at 2x104 cells per well in 400 µl of medium. 40 µl of EIAV stock was 
added to the seeded wells in triplicate and serially diluted 10-fold (10-1 -10-7). The 
D17 cells were subsequently visualised by fluorescence microscopy 72 hours after 
transduction with the serial dilutions of EIAV GFP stocks. A graph of the number of 
foci of infection visualised per well at each of the dilutions (10-1 – 10-6) is shown a) 
with the Y axis in Log scale b). The graph was generated from values derived from 
the titration of EIAV GFP lentiviral stocks on three separate occasions. Ten-fold serial 
dilutions of the pSMART GFP plasmid were used to generate standard curves for 
WPRE qPCR. Because the concentration of plasmid can be accurately measured by 
spectrophotometry, the standard curve can be used to calculate the number of copies 
of lentiviral molecules in a given sample c). A similar curve was derived for the 
pSMART IDO plasmid. Similar to methods used for fluorescence microscopy, D17 
cells transduced with EIAV IDO and EIAV GFP were harvested 72 hours post-
transduction and RNA extracted for real-time PCR analysis. Real-time PCR analysis 
was used to quantify WPRE DNA sequences in order to report a D17 cell lentivirus 
transduction event. d) A graph of WPRE copy numbers from the mRNA of EIAV 
transduced D17 at each dilution of EIAV GFP stock was generated with a line of best 
fit applied. The same curve was derived for EIAV IDO transduced D17 cells. A line 
of best fit applied to the EIAV GFP standard curve b) was used to unite the WPRE 
copy number (of EIAV IDO transduced D17 cells) to a value of foci of infection for 
EIAV GFP transduced D17 cells (using the log 10 dilution as the connecting value). 
The number of infectious particles per ml of each lentiviral stock was then deduced 
from the estimated foci of infection value. 
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5.2.7.2.3 Confirmation of functional IDO activity 
In order to assess the effect of IDO on corneal endothelial cell biology it had to be 
assessed from the outset whether transduction of cells with EIAV IDO resulted in the 
expression of functional/active IDO (and thus the catabolism of tryptophan into 
kynurenines). As described in section 5.2.7.2.2, D17 cells were seeded on 24-well 
plates at 2x104 cells per well in 400 µl of medium. 40 µl of EIAV IDO stock (9.5x106 
TU/ ml) at an MOI of 10 was added to the seeded wells in triplicate and serially 
diluted 10-fold (10-1 -10-4). EIAV IDO (9.5x106 TU/ ml) at an MOI of 100 was added 
to 1x105 MCEC. L-tryptophan was added as a supplement to the culture media to a 
final concentration of 100 µM. IDO activity was assessed by an L-kynurenine assay 
on cell culture supernatants, removed 72 hours post-transduction. With decreasing 
EIAV IDO concentration, a dose dependent reduction in IDO activity in transduced 
D17 cells was observed (Figure 43). Functional/active IDO in MCEC transduced as 
described above was observed (Figure 43) and MCEC were subsequently transduced 
at an MOI of 100 throughout this investigation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 43- Expression of functional IDO in transduced cells 
D17 cells were seeded on 24-well plates at 2x104 cells per well in 400 µl of medium. 
40 µl of EIAV IDO stock (9.5x106 TU/ ml) at an MOI of 10 was added to the seeded 
wells in triplicate and serially diluted 10-fold (10-1 -10-4). EIAV IDO (9.5x106 TU/ 
ml) at an MOI of 100 was added to 1x105 MCEC. L-tryptophan was added as a 
supplement to the culture media to a final concentration of 100 µM. IDO activity was 
assessed by an L-kynurenine assay on cell culture supernatants, removed 72 hours 
post-transduction. Results shown are mean ± SD of triplicate cultures representative 
of three separate experiments. 
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5.2.7.2.4 Effect of IDO expression on MCEC viability 
MCEC were transduced with EIAV GFP and EIAV IDO at an MOI of 100. 72 hours 
post-transduction, MCEC were harvested and incubated with or without the cytokine 
cocktail described in section 5.2.7.1 to induce apoptosis, left for 48 hours and then 
assessed for apoptosis using Annexin V staining. IDO expression did not increase 
apoptosis of MCEC and did not sensitise cells to apoptosis, in fact it appeared 
protective (Figure 44). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44- Effect of IDO and GFP expression on MCEC viability 
MCEC virally transduced with EIAV IDO or GFP or nil were incubated with or 
without a cocktail of cytokines- TNFα, IL-1α and IFNγ at concentrations of 10 and 
100 ng/ml and left for 48 hrs. Apoptosis was evaluated by flow cytometry using 
Annexin V staining. 
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5.2.7.3 Effect of kynurenines and IDO expression on MCEC phenotype 
The effect of direct kynurenine administration and IDO expression on MCEC 
phenotype was investigated, looking specifically at ICOSL, ICAM-1, PDL-1 and 
MHC Class II expression. This is because MCEC have the ability to upregulate 
chemokine and adhesion molecule expression, and MHC class II expression in 
response to pro-inflammatory cytokines (Arancibia-Carcamo et al., 2004). No basal 
expression of ICOSL, ICAM-1 or MHC Class II was detected, though there was a 
strong basal expression of PDL-1. Upon incubation with 100 µM of each of the 
kynurenines for 24 hours, there was no effect on expression of any of the molecules 
investigated except for slight increase in ICAM-1 expression on incubation with QA. 
Furthermore, incubation with a cocktail of all the kynurenines showed no effect 
(Figure 45). IDO expression by viral transduction of MCEC did not alter phenotype 
(Figure 46). 
3HK KynQA3HAA
ICAM
ICOSL
Class II
PDL1
Isotype ctrl
QA induced upregulation
of ICAM
Basal PDL1 expression 
on MCEC
 
 
Figure 45- Effect of kynurenine administration on MCEC phenotype 
Effect of kynurenine administration on ICOSL, ICAM1, PDL1, and, MHC class II 
expression in MCEC as detected by flow cytometry. MCEC were incubated with each 
of the kynurenines as well as a cocktail at a concentration of 100 µM for 24 hrs and 
then stained with the appropriate antibody and analysed by flow cytometry. 
Histograms show profiles of the isotype control, MCEC alone, individual kynurenine 
treated MCEC and cocktail kynurenine treated MCEC. As can be seen there is no 
effect of the kynurenines on MCEC phenotype, except for QA which resulted in a 
consistent upregulation of ICAM1. MCEC showed basal expression of PDL1. Results 
shown are of one experiment representative of three. 
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Figure 46- Effect of IDO expression on MCEC phenotype 
MCEC were virally transduced with IDO or GFP and then stained for cell surface 
expression of ICOSL, ICAM-1, PDL-1 and MHC Class II and analysed by flow 
cytometry. Results shown are of one experiment representative of three. 
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5.2.8 Systemic administration of 3HK prolongs murine corneal allograft survival 
As kynurenines were not toxic to corneal endothelial cells and given the ability of 
3HK and 3HAA to suppress allogeneic T cell responses in vitro, we went on to 
determine whether administration of 3HK resulted in prolonged C3H corneal allograft 
survival in BALB/c recipients, in which strain combination there is full MHC and 
multiple minor mismatches. 3HK was administered at 560 mg/kg i.p. on a daily basis 
on day 1-7, day 7-14 or day 1-14 post-transplant. This dose was chosen as in 
preliminary experiments higher doses resulted in an observed lack of physical activity 
in treated animals. The ‘early’ (day 1-7) and ‘late’ (day 7-14) administration were 
chosen to compare the effect of 3HK on the induction and effector phases of the 
allogeneic response. Control animals were given the same volume of vehicle from day 
1-14. Median survival time (MST) of allogeneic C3H corneas was 12 days in 
untreated BALB/c recipients, while syngeneic corneas survived indefinitely and 
administration of the vehicle had no effect on survival (MST 11 days). 3HK 
administration resulted in significant prolongation of graft survival whether 
administered between days 1-7 (MST 18 days, p<0.036), days 7-14 (MST 19 days, 
p<0.0003) or day 1-14 (MST 18 days, p<0.0037). There was no significant difference 
between the different 3HK-treated groups (Figure 47). 
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Figure 47- Effect of systemic 3HK administration on corneal allograft survival 
BALB/c (H2d) mice received unilateral C3H (H2k) donor corneal allografts and i.p. 
injections of 3HK were administered at a dose of 560 mg/kg/day according to three 
different treatment regimes; on days 1-7, 1-14 and 7-14 post-transplantation. There 
was significant prolongation of graft survival in all treatment groups; n=7 (MST 18, 
18, 19 and p<0.036, p<0.0003, p<0.0037 respectively) in comparison to controls 
(MST 11 days). Indefinite survival was observed in untreated syngeneic grafts 
(BALB/c-BALB/c). 
 
 
5.2.9 Systemic administration of 3HK results in depletion of both splenic and 
peripheral blood lymphocytes 
Given the effect of 3HK on CD4+ T cell viability, it is possible that prolongation of 
graft survival is as a result of depletion of T cells. In animals that did not receive a 
graft, administration of 3HK for 14 days (following the same regimen) did not result 
in any significant change in the weight of the spleen (data not shown), but did result in 
a reduction in the number of splenic CD4+, CD8+ T cells and CD19+ B cells, albeit not 
statistically significant (Figure 48A); this was a consistent observation in repeated 
experiments. Systemic 3HK treatment did not induce regulatory T cell development 
as there was no alteration in the proportion of splenic CD4+ cells expressing FoxP3 
(Figure 48B). Furthermore, it was assessed whether or not 3HK treatment altered the 
function of CD4+ T cells by assesing their proliferative capacity following stimulation 
with CD3, CD28 beads.  3HK did not alter the proliferative capacity of CD4+ T cells 
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(Figure 48C). There was a significant reduction in the number of CD4+, CD8+ T cells 
and CD19+ B cells in peripheral blood (Figure 48D).  
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Figure 48- Splenic and peripheral blood analysis after daily i.p. administration of 
3HK.  
Animals (n=3) received systemic i.p. 3HK 560 mg/kg/day for 14 days consecutively, 
after which spleens were removed and:  (A) absolute counts of CD4, CD8 and CD19 
assessed using counting beads.  (B) The percentage of CD4+ T cells that were FoxP3 
positive was quantified by intracellular flow cytometry. (C) CD4+ T cells isolated and 
subsequently stimulated with CD3/CD28 beads and proliferation assessed by 3H-
Thymidine incorporation. (D) Peripheral blood from the tail vein was taken and 
absolute numbers of CD4, CD8 and CD19 cells assessed using counting beads. * 
p≤0.05, experimental versus vehicle control. Data represents mean ± SD of triplicate 
counts. Results shown are of one experiment representative of two. 
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5.2.10 Topical administration of 3HK results in prolongation of corneal allograft 
survival  
We went on to determine whether topical administration might prolong graft survival. 
3HK (0.165 mg in 30 µl) was administered twice daily on days 3-14 post-transplant. 
Control animals were given the same volume of vehicle. Treated animals had a 
significant prolongation in graft survival (MST=15 days, p<0.0001) compared to 
untreated or vehicle alone (MST= 12, 11 days). In addition a minority of animals 
(3/15) showed long term survival (> 60 days) (Figure 49).  
The corneal grafts of mice that had received topical 3HK treatment as well as controls 
were excised after the onset of rejection (n=8/group) and RNA extracted. Corneal 
FoxP3 mRNA expression was subsequently assessed by quantitative, real time-RT-
PCR. There was a marked upregulation of FoxP3 expression in 3HK versus vehicle 
control treated corneas (Figure 50). 
In mice that did not receive a graft, topical administration of 3HK did not alter the 
splenic or peripheral blood lymphocyte count (Figure 51A and B) but did result in a 
moderate albeit insignificant generalised reduction in the lymphocyte count of the 
draining lymph node (Figure 51C). The draining lymph nodes assessed were the deep 
cervical and submandibular nodes which have previously been shown to be the ocular 
draining nodes (Plskova et al., 2004).  There was minimal difference in the proportion 
of CD4+ cells expressing Fox P3 in the draining lymph node (Figure 51D).  
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Figure 49- Effect of daily topical administration of 3HK on murine corneal allograft 
survival.  
BALB/c (H2d) recipients of unilateral C3H (H2k) donor corneal allografts were 
treated with topical 3HK or vehicle in the operated eye twice daily on days 3-14 post-
operatively. There was a significant prolongation of graft survival in the 3HK treated 
group; n=15 (MST 15 days, p<0.0001) in comparison to controls (MST 12 days). 
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Figure 50- FoxP3 mRNA expression in rejected corneal grafts. 
The corneal grafts of mice that had received topical 3HK treatment as well as controls 
were excised after the onset of rejection (n=8/group) and RNA extracted. Corneal 
FoxP3 mRNA expression was subsequently assessed by quantitative, real time RT-
PCR. A- Bar graph showing corneal FoxP3 mRNA expression normalised to HPRT 
as assessed using qReal-time PCR. B- 1.5% Agarose gel of PCR products. 
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Figure 51- Splenic, peripheral blood and draining lymph node analysis after daily 
topical administration of 3HK. 
Animals (n=3) received topical 3HK for 12 days consecutively, after which spleens 
were removed (A), peripheral blood taken (B), and lymphocytes from the draining 
lymph node collected (C) and absolute counts of CD4, CD8 and CD19 assessed using 
counting beads. The percentage of CD4+ T cells that were FoxP3 positive from the 
draining lymph node was quantified by intracellular flow cytometry (D). Data 
represents mean ± SD of triplicate counts.* p≤0.01, treatment versus vehicle control. 
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5.3 Discussion 
Ever since it was reported that IDO can prevent rejection of the foetus during 
pregnancy in mice (Munn et al., 1998); there has been considerable interest in 
elucidating the role of this enzyme in immunoregulation. In the context of 
transplantation, tryptophan catabolism has been shown to suppress alloimmune 
responses. IDO-expressing DCs suppress allogeneic T cell proliferation in vitro via 
tryptophan metabolites (Terness et al., 2002) and the metabolites themselves have 
been shown to inhibit allogeneic T cell responses both in vitro and in vivo (Bauer et 
al., 2005). There has however been no investigation as to how tryptophan metabolites 
mediate their in vivo effect. In this study, we have investigated whether the tryptophan 
metabolites given either locally or systemically can modulate corneal allograft 
survival.  
We confirmed that 3HK and 3HAA suppressed CD4+ T cell proliferation in vitro, 
related to death of the T cells. Previously, Fallarino et al. (Fallarino et al., 2006b, 
Fallarino et al., 2006a) showed a large  increase in the proportion of naïve CD4+ 
FoxP3 expressing cells in the presence of the kynurenines (70% vs 2% controls), we 
showed a moderate increase (8% vs 2% controls) from the whole CD4+ T cell 
population.  This may relate to differences in the populations studied, it is recognised 
that naïve T cells are more resistant to kynurenine-induced apoptosis than effector 
CD4+ T cells (Fallarino et al., 2002a). We found a reduction of FoxP3 expression in 
CD4+ T cells at the higher concentrations of 3HK and 3HAA after 3 and 7 days 
incubation. This could be due to the fact that T regs are more sensitive or it may be an 
indirect effect as for example, it has been shown that CD4+CD25+ FoxP3+ T cells are 
extremely sensitive to two common cell metabolites that are released from necrotic 
cells; NAD and ATP (Aswad et al., 2005). However, given the kinetics of T reg 
development, they will not contribute significantly to the inhibition of T cell 
proliferation seen in vitro, where the major mechanism of action is death of the 
responding cells. 
Consistent with previous reports, we demonstrated that DCs are resistant to 
kynurenine-induced apoptosis (Terness et al., 2002, Fallarino et al., 2002a). Taking 
this further, we have shown that the function and phenotype of DCs is not altered in 
the presence of kynurenines. It is interesting to speculate why DCs are resistant to 
kynurenines: it may be the result of cell-specific uptake mechanisms or differential 
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expression of enzymatic breakdown pathways (Moffett and Namboodiri, 2003, 
Frumento et al., 2002). It is known that DCs metabolise tryptophan through the 
kynurenine pathway as demonstrated by immunohistochemical staining of the 
presence of quinolinic acid, the penultimate product of the kynurenine pathway (Hill 
et al., 2007). Furthermore, it has been shown that 3HAA induced T cell death is as a 
result of inhibition of NF-κB activation upon T cell receptor engagement by 
specifically targeting PDK1 (inhibiting its phosphorylation and therefore activation) 
(Hayashi et al., 2007). The same authors showed that the induction of apoptosis is 
specific to CD4+ T cells as 3HAA did not inhibit NFκB activation or induce cell death 
upon Toll-like receptor 4 stimulation in dendritic cells (Hayashi et al., 2007). We also 
demonstrated that there were no toxic effects of either IDO or kynurenines on corneal 
endothelial cells, in keeping with findings demonstrating IDO to be part of the ocular 
immune privilege (Chen et al., 2006a). Furthermore, it has been recently demonstrated 
that a tryptophan / kynurenine transporter protein exchange mechanism (LAT1) is 
upregulated by inflammatory cytokines in human corneal endothelial cells. This 
transporter would allow rapid delivery of the cytotoxic tryptophan catabolites to the 
local corneal environment, dampening down T cell responses (Serbecic et al., 2009), 
again suggesting a probable role for kynurenines in corneal immune privilege. 
 Earlier reports on the effect of subcutaneous administration of 3HAA and Kyn in a 
model of skin transplantation indicated a short prolongation of graft survival (two 
days) (Bauer et al., 2005). For the first time we demonstrate that both systemic and 
topical administration of 3HK resulted in prolongation of corneal graft survival. In the 
systemic group, we administered 3HK i.p. in three different regimes. Although we 
observed a longer median graft survival in the day 7-14 treated group, there was no 
statistical difference between the three treatment regimes. Despite concern about 
administration of 3HK in vivo owing to its neurotoxic potential (Freese et al., 1990, 
Moroni, 1999), we did not observe any major effect at the doses we administered. 
Furthermore, the systemic doses administered (60 mg/L) are only 20 times higher than 
the serum concentration of Kyn in rats or humans (3 mg/L) (Chavele et al., 2010). The 
longest survival of individual grafts (>50 days) was observed in the topical group in 
comparison to 30 days in the systemic group. Direct application of drops to the graft 
recipient eye, offer a more targeted treatment reducing possible systemic adverse 
effects.  
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To determine the effect of 3HK on lymphocyte counts we examined mice that had had 
systemic administration of 3HK for 14 days, finding a moderate although not 
statistically significant reduction in the CD4+, CD8+ and B lymphocyte population of 
the spleen but a significant reduction in peripheral blood. This loss of lymphocytes 
could be as a result of cell death; consistent with our in vitro findings, or due to a 
redistribution of circulating lymphocytes to the bone marrow and/or transient arrest of 
recirculation as has been observed with corticosteroid treatment (Yu et al., 1974, 
Fauci, 1975).  
While there is a small decrease in cell number, it is not clear that such a small 
decrease would be responsible for the prolongation of graft survival. However, the 
topical administration of 3HK resulted in a significant upregulation of corneal FoxP3 
mRNA expression in comparison to controls suggesting, therefore, that regulatory 
pathways may be involved. Although significant prolongation in graft survival was 
observed in both the topical and systemic treated groups following a treatment 
duration of fourteen days post transplantation, longer duration treatment might have 
resulted in longer term acceptance of grafts as in other reported treatment studies in 
this mouse model (Zhang et al., 2000).  
In conclusion, our data show that 3HK and 3HAA induce mouse T cell suppression in 
vitro, primarily as a result of death of the T cells, and 3HK prolongs corneal allograft 
survival whether administered by topical or systemic routes. These data show that 
these molecules may be responsible in part for the effect of IDO in preventing 
allograft rejection (though they cannot determine the relative importance of 
kynurenine production as compared to tryptophan reduction). In addition we have 
demonstrated the potential for using kynurenine or kynurenine-like molecules to 
prevent graft rejection. 
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5.3.1 Chapter Summary 
The work in this chapter has demonstrated: 
• That of the four kynurenines, 3HK and 3HAA inhibit T cell proliferation and 
promote death of T cells in vitro. 
• Kynurenines induce T regulatory cells. 
• Kynurenines do not alter DC phenotype or function in vitro. 
• Kynurenines are not toxic to corneal endothelial cells and do not alter their 
phenotype. 
• Systemic and topical 3HK administration prolongs corneal graft survival. 
• Systemic 3HK administration results in reduction in splenic and peripheral 
blood generalised lymphocyte counts. 
• Systemic 3HK administration does not alter function of CD4+ T cells. 
• Topical 3HK administration results in local T regulatory cell development as 
well as reduction in draining LN lymphocyte counts. 
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CHAPTER 6- RESULTS 
EFFECT OF N-(3,4-DIMETHOXYCINNAMONYL) 
ANTHRANILIC ACID (TRANILAST) ON CORNEAL 
ALLOGRAFT SURVIVAL  
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6.1 Introduction 
Tranilast, an anti-inflammatory drug, has several mechanisms of action and is 
currently approved for use in Japan as an anti-allergic drug. 
As mentioned previously in section 1.5.10.1, Tranilast is a synthetic anthranilic acid 
derivative that shares the anthranilic acid core with both 3-HAA and 3-HK. Platten et 
al. have shown it to suppress antigen specific T cell proliferation and IFNγ and TNFα 
production and to increase production of IL-4 and Il-10 in a manner similar to the 
structurally related kynurenines (Platten et al., 2005). They also showed Tranilast to 
reverse paralysis in mice with established experimental autoimmune 
encephalomyelitis at least partly by inhibiting the activation of myelin-specific T cells 
(Platten et al., 2005). Similarily, Tranilast has been shown to ameliorate the clinical 
and histological manifestations of arthritis in a mouse model of collagen induced 
arthritis, a T cell mediated disease that displays many pathological, genetic and 
immunological similarities to human rheumatoid arthritis (Inglis et al., 2007). 
In summary, Tranilast has anti-inflammatory, antiproliferative as well as 
immunomodulatory effects. The exact mechanism for Tranilast’s immunosuppressive 
activities remains unknown and its possible role in preventing allograft rejection has 
not been previously investigated.  
 
6.1.1 Chapter aims: 
The aims of the work presented in this chapter were to: 
 
1) Confirm the inhibitory effect of Tranilast on T cell proliferation 
2) Determine the effect of Tranilast on T cell viability and regulatory cell 
development 
3) To determine the effect of systemic Tranilast administration on allograft 
survival 
4) To investigate possible mechanisms of action for the observed 
immunosuppressive properties of Tranilast. 
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6.2 Results 
6.2.1 Tranilast inhibits murine T cell proliferation in vitro 
Prior to analysing the effect of Tranilast on allograft survival, its inhibitory effect on T 
cell proliferation had to be confirmed. Tranilast was added at various concentrations 
to purified CD4+ T cells that were stimulated with anti-CD3/CD28 beads and 
proliferation determined using 3H thymidine incorporation. As shown in Figure 52, 
addition of Tranilast significantly inhibited CD4+ T cell proliferation in a dose-
dependent manner when compared to T cells incubated with vehicle alone. 
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Figure 52- Effect of Tranilast on CD4+ T cell proliferation 
CD3/CD28 bead stimulated CD4+ T cells were incubated for 72 h in the presence of 
Tranilast at concentrations varying from 0-200 µM. Proliferation was measured by 
3H-Thymidine incorporation. Data represents mean ± SD of triplicate cultures. Results 
shown are of one experiment representative of three. * p<0.005, versus control. 
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6.2.2 Tranilast does not induce T cell death 
In contrast to the kynurenines which inhibited T cell proliferation as a result of T cell 
death as discussed in section 5.2.4; Tranilast did not induce T cell death. CD4+ T cells 
were stimulated with anti-CD3/CD28 beads in the presence of varying concentrations 
of Tranilast (0-200 µM) as well as vehicle control for 72 h and cell death assessed by 
flow cytometry following staining with 7-AAD and annexin V. Tranilast did not 
induce T cell death in comparison to controls and increasing the concentration of 
Tranilast had no influence on T cell viability (Figure 53). This suggests that although 
structurally similar to kynurenines, Tranilast has a different underlying molecular 
mechanism of action.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53- Effect of Tranilast on T cell viability 
CD3/CD28 bead activated CD4+ T cells were incubated with or without Tranilast and 
with or without vehicle for 72 h. Cytotoxicity was evaluated by flow cytometry 
following vital staining with 7AAD. Results shown are of one experiment, 
representative of three. The bar graph summarises the percentage of cell death 
detected by Annexin V and 7-AAD staining as assessed using flow cytometry. Data 
represent mean ± SD of triplicate samples. 
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6.2.3 Tranilast can induce T reg development from the whole CD4+ T cell population 
Having established that Tranilast inhibits CD4+ T cell proliferation and that this 
inhibition is not as a result of T cell death, we went on to investigate the effect of 
Tranilast on regulatory T cell development. We looked at the effect of Tranilast on the 
number of FoxP3 positive cells from the whole CD4+ T cell population.  
CD4+ T cells were stimulated with anti-CD3/CD28 beads in the presence or absence 
of Tranilast at varying concentrations for 7 days. As shown in Figure 54, there was 
only a slight although statistically insignificant increase in the percentage of FoxP3 
expressing cells at low concentrations of Tranilast (10 µM) but a significant drop at 
higher concentrations. Interestingly however, when we looked at the relative 
percentage of CD4 cells expressing FoxP3 there was a statistically significant increase 
in the presence of a low concentration of Tranilast in comparison to vehicle alone 
(Figure 55).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 54- FoxP3 expression in CD4+ T cells cultured with Tranilast. 
CD4+ T cells were activated with anti-CD3/CD28 beads with or without Tranilast for 
7 days, cells were recovered and the percentage of CD4+ T cells that were FoxP3 
positive was quantified by intracellular flow cytometry. Results shown are of one 
experiment, representative of three. The bar graph summarises the percentage of 
FoxP3 expressing cells as assessed using flow cytometry. Data represent mean ± SD 
of triplicate samples. 
CD
4 
FoxP3 
Effect of Tranilast on Treg development
0
1
2
3
4
5
6
7
8
9
0 10 100 200
Concentration (uM)
Pe
rc
en
ta
ge
 
Fo
x
P3
 
e
x
pr
es
s
in
g 
ce
lls
Tranilast
Ctrl
0 
Tranilast 
10 µM 
100 µM 200 µM 
100 µM 200 µM 
Vehicle 
10 µM 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 180 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55- Relative FoxP3 expression in CD4+ T cells cultured with Tranilast. 
CD4+ T cells were activated with anti-CD3/CD28 beads with or without Tranilast for 
7 days, cells were recovered and the relative percentage of CD4+ T cells that were 
FoxP3 positive to the was quantified by intracellular flow cytometry. Data represent 
mean ± SD of triplicate samples. * p<0.005, versus control. Results are from one 
experiment representative of three. 
 
6.2.4 Cell cycle arrest in T cells cultured with Tranilast 
Experimental work carried out so far indicates Tranilast to inhibit T cell proliferation 
not as a result of cell death but possibly through regulatory mechanisms. We have 
shown an increase in Treg development in response to low concentrations of Tranilast 
but this does not explain the significant inhibition observed at the higher 
concentrations of Tranilast where in fact, a reduction in the percentage of Tregs was 
observed. As mentioned in section 1.5.7.1, Tranilast has previously been shown to 
inhibit vascular smooth muscle proliferation and hence inhibit allograft vasculopathy 
in association with enhanced p21 expression on neointimal cells (Izawa et al., 2001). 
The protein product of the Waf1/Cip1 gene, p21, is identified as a universal inhibitor 
for cyclin-dependent kinases (Xiong et al., 1993, Harper et al., 1993), which are 
essential for cell progression through the G1-S check point. Platten et al. 2005, 
demonstrated suppression of T cell proliferation in response to Tranilast and observed 
that this was associated with a G1-S phase arrest in CD4+ T cells rather than through 
cytotoxic effects. We postulated that the Tranilast induced inhibition of T cell 
proliferation was as a result of G1-S phase cell cycle arrest secondary to upregulation 
of specific cell cycle inhibitors in particular p21. 
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The definition of tolerance and anergy; is the inability of T cells to produce 
interleukin (IL)-2 and proliferate after stimulation with competent APCs (Schwartz, 
1997). Anergy of T cells is induced by ligation of the TcR by antigen alone and is 
overcome by co-stimulation or IL-2. Given the potential clinical importance of the 
induction and maintenance of tolerance, many investigators have examined the 
biochemical events that define the anergic state. The most direct model of anergy 
induction proposes that the central gap is the failure to activate mediators of the cell 
cycle for progression from the G1 to S phase (Rudd, 2006). 
It has been observed in the murine system that the induction of anergy (or its 
stimulus) results in a considerable and sustained increase in T cells in the G1 phase of 
the cell cycle, whereas productive stimulation causes induced cells to enter G1 after 
12-16 hours, enter S phase by 18-24 hours and reach G2-M after 48-72 hours 
(Boussiotis et al., 2000, Gilbert and Weigle, 1993). 
 
The cell division cycle is under tight regulatory control with many factors that 
promote or inhibit different stages of the cell cycle (Figure 56a). Cyclin dependent 
kinases (Cdks) are fundamental to the cell cycle and their actions are positively 
regulated by binding to the cyclins. In resting cells, due to the abundance of cyclin-
Cdk2 inhibitors such as p21Cip1, G1 Cdks are relatively inactive ensuring that cell 
cycling is not activated without a proper signal. The inhibitor p21Cip1 (which belongs 
to the Cip/Kip family of Cdk inhibitors) binds and inhibits cyclin E-Cdk2 complexes 
in late G1 phase. The irreversible progression of a cell to S phase entry occurs at the 
G1 restriction point and is characterised by activation of cdk2 and synthesis of cyclin 
E (Sherr and Roberts, 1995). Cyclins E and A sequentially activate Cdk2 near the start 
of S phase, a process thought to be responsible for initiating DNA replication. 
Activated cyclin E-Cdk2 acts in synergy with D cyclins and their associated Cdk4 and 
Cdk6 molecules to phosphorylate Rb. Increased levels of p21 can bind and inactivate 
cyclin D-Cdk4, 6 and cyclin E-Cdk2 complexes, resulting in hypophosphorylation of 
pRB and subsequent cell cycle arrest (Harper et al., 1995). 
p21 can also inhibit cellular proliferation through at least another two different 
mechanisms. p21 is a potent inhibitor of the proliferating-cell nuclear antigen 
(PCNA), which functions as the variable inhibitor of DNA polymerase delta, the 
principal replicative DNA polymerase. PCNA expression is low in resting T cells, 
whereas upon activation, PCNA expression increases 1000-fold during mid G1 phase 
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(Moore et al., 1987). Lorens et al. have shown p21 to inhibit the cell cycle in both G1 
and G2 phases in Jurkat T cells as a result of its inhibition of PCNA (Lorens et al., 
2000). 
The third mechanism by which p21 can block the cell cycle is via inhibition of c-Jun 
N-terminal kinase (JNK). In vitro studies have shown p21 to interact with JNK and 
inhibit JNK activity in various cells, including fibroblasts and T cells (Shim et al., 
1996, Xue et al., 2003, Patel et al., 1998). JNK is a member of the mitogen-activated 
protein kinase (MAPK) signalling pathway that is activated by antigen stimulation in 
T cells. Stimulation of the MAPK pathway in T cells normally leads to the activation 
of transcription factors such as activation protein 1 (AP-1), with a corresponding 
increase in IL-2 transcription. Dagtas et al. showed that p21 interacted with members 
of the MAPK pathway, specifically p-JNK and p-c-jun, resulting in an inhibition in 
proliferation and IL-2 secretion in anergic Th1 cells (Selma Dagtas and Gilbert, 
2010). 
The role of the cell cycle inhibitors p15 and p21 was investigated in CD4+ T cells 
incubated with varying concentrations of Tranilast. CD4+ T cells were stimulated with 
anti-CD3/CD28 beads in the presence or absence of Tranilast at varying 
concentrations for 72 hours. Expression of p15 and p21 at the mRNA level 
(normalised to HPRT) was determined by real time PCR. Tranilast resulted in an 
upregulation of p21 and p15 expression in comparison to vehicle alone and increasing 
Tranilast concentration resulted in a dose dependent increase in expression of the cell 
cycle inhibitors (Figure 56b and c). 
The expression of cyclin E by CD4+ T cells incubated with Tranilast was also 
investigated. Increasing Tranilast concentration resulted in a dose-dependent 
reduction in cyclin E protein expression (Figure 56d). Hence, T cells incubated with 
Tranilast fail to progress through the restriction point into late G1 and are thus 
arrested at earlier stages of the G1 phase. 
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Figure 56 continues on next page 
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Figure 56- Cell cycle arrest in CD4+ T cells cultured with Tranilast. 
(A) Control of cell-cycle progression from G1 to S transition. Following stimulation, 
cyclins D and Cdk2 or CDK6 are induced and coupled, initiating the G1/S transition. 
Cyclin E and Cdk2 drive the cell into S phase, and progression of the cycle proceeds. 
Cyclin A assembles with Cdk2 during late G1 and early S phase. The rest of the cell-
cycle is controlled by cyclins A, B and D and their associated kinases. G1 to S 
transition is negatively regulated by the INK4 and the Cip/Kip families of Cdk 
inhibitors. 
p21(B) and p15 (C) mRNA expression in Tranilast treated CD4+ T cells. CD4+ T cells 
were stimulated with anti-CD3/CD28 beads in the presence or absence of Tranilast at 
varying concentrations for 72 hours, cells were washed, RNA extracted and 
subsequently converted to cDNA and real time PCR carried out. The levels of p15 and 
p21 mRNA are normalised to those of HPRT mRNA and shown as the mean +/- SD 
of triplicate determinations. The separation of PCR products on a 1.5% agarose gel is 
also shown, L=Ladder.  
(D) Expression of the 52 kDa Cyclin E protein in the lysates of CD4+ T cells 
incubated with Tranilast and vehicle alone (relative to T cell expression of the 42 kDa 
β-actin protein) was determined by western blotting on day 3 of culture.  
Results shown are from one experiment, representative of three.  
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6.2.5 Cell cycle arrest in CD4+ T cells cultured with Tranilast is associated with 
reduced IL-2 production 
As mentioned earlier in section 6.2.4, anergy of helper T cells is induced by ligation 
of the T cell receptor by antigen alone and is prevented by co-stimulation or IL-2. 
Having shown that Tranilast inhibits T cell proliferation as a result of cell cycle arrest 
in the G1-S phase, the levels of IL-2 in supernatants of T cells cultured with Tranilast 
was analysed. CD4+ T cells were stimulated with anti-CD3/CD28 beads in the 
presence or absence of Tranilast at varying concentrations for 72 hours. Culture 
supernatants from the assays were harvested for detection of the IL-2 cytokine by 
ELISA. Relative to concentrations of IL-2 in the culture supernatants of CD4+ T cells 
incubated with vehicle alone, there was a significant dose dependent reduction in IL-2 
levels in Tranilast-treated CD4+ T cells (Figure 57). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57- Production of IL-2 in Tranilast treated T cell assays. 
CD4+ T cells were stimulated with anti-CD3/CD28 beads in the presence or absence 
of Tranilast at varying concentrations for 72 hours. Culture supernatants from the 
assays were harvested for detection of the IL-2 cytokine by ELISA. Data represent 
mean ± SD of triplicate samples, * p<0.05, versus control. Results shown are of one 
experiment representative of two. 
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6.2.6 Tranilast does not induce donor alloantigen-specific tolerance in vivo 
As mentioned in section 6.2.4, tolerance and anergy, are defined as the inability of T 
cells to produce IL-2 and expand after stimulation with competent antigen-presenting 
cells. Although anergy induced through blockade of co-stimulation has been studied 
in vitro, in vivo models of allogeneic organ and bone marrow transplantation provide 
evidence that induction of alloantigen-specific anergy results in long-term graft 
acceptance (Larsen et al., 1996, Kirk et al., 1997, Ardjomand et al., 2003). For a 
tolerogenic therapy to be effective in transplantation medicine, it is critical that 
allogeneic cells rendered anergic do not die but have the capacity to regulate the 
activity of alloreactive T cells. We have already demonstrated T cell anergy in 
response to Tranilast treatment and shown that low concentrations of Tranilast are 
associated with a slight increase in regulatory cell development. We therefore 
addressed the question as to whether Tranilast could induce donor alloantigen specific 
tolerance in vivo.  
In order to demonstrate the induction of donor allospecificity, T cells that 
encountered alloreactive DCs in vivo after injection of allogeneic DC populations into 
mice (that were treated with or without Tranilast) were subsequently ‘rechallenged’ in 
vitro with both donor-derived and third-party DCs as detailed below. 
 
6.2.6.1 Optimisation of rechallenge assays for the detection of in vivo generated 
allogeneic T cell responses 
Rechallenge assays were optimised from established protocols in the laboratory 
designed to investigate the induction of anergy in vivo. Thus, for the detection of an 
allogeneic T cell response following a primary challenge in vivo, 8x106 C3H/He LPS 
stimulated splenocytes were injected intravenously into BALB/c mice. After 10 days, 
spleen-purified CD4+ T cells from the injected mice were rechallenged in vitro (at a 
1:5 DC: T cell ratio) with donor C3H/He LPS stimulated splenocytes (Figure 58a) or 
third-party C57BL/6 LPS stimulated splenocytes (Figure 58b), and proliferation 
assessed by thymidine incorporation on days 3, 5 and 7. The rechallenge assay used 
after a primary challenge of CD4+ T cells in vivo was optimised such that rechallenge 
of CD4+ T cells with donor-derived DCs resulted in the kinetics of a secondary 
(memory) response with optimal T cell proliferation on day 3, whereas rechallenge 
with third party C57BL/6 DCs resulted in the kinetics of a primary response with 
optimal T cell proliferation on day 5. 
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Figure 58- Optimisation of rechallenge assays for the detection of in vivo-generated 
allogeneic T cell responses. 
Two-stage DC : T cell MLRs (rechallenge assays) were used to detect donor-specific 
allogeneic T cell responses following a primary in vivo-generated T cell response. For 
the detection of an allogeneic T cell response following a primary challenge in vivo, 
8x106 C3H/He DCs were injected intravenously into BALB/c mice. After 10 days, 
spleen-purified CD4+ T cells from the injected mice were rechallenged in vitro (at a 
1:5 DC: T cell ratio) with (A) donor C3H/He DCs or (B) third party C57BL/6 DCs 
and proliferation assessed by thymidine incorporation on days 3, 5 and 7. The 
rechallenge assay used after a primary challenge of CD4+ T cells in vivo was 
optimised such that rechallenge of CD4+ T cells with donor-derived DCs resulted in 
the kinetics of a secondary (memory) response with optimal T cell proliferation on 
day 3, whereas rechallenge with third party C57BL/6 DCs resulted in the kinetics of a 
primary response with optimal T cell proliferation on day 5. Data represent mean ± 
SD of triplicate samples. Results shown are of one experiment representative of three. 
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6.2.6.2 Tranilast fails to induce donor alloantigen-specific T cell anergy in vivo 
We investigated whether treatment with Tranilast induced donor allospecific anergy 
in CD4+ T cells in vivo. BALB/c mice were treated with or without Tranilast (400 
mg/kg/day) or with vehicle control for a total of 5 days (one day prior to splenocyte 
injection and 4 days thereafter). 8x106 LPS stimulated C3H/He splenocytes were 
injected intravenously into the BALB/c mice. After 10 days, spleen-purified CD4+ T 
cells from the injected mice were rechallenged in vitro (at a 1:5 DC : T cell ratio) with 
donor C3H/He LPS stimulated splenocytes (Figure 59a) or third party C57BL/6 LPS 
stimulated splenocytes (Figure 59b) and proliferation assessed by thymidine 
incorporation on days 3, 5 and 7. Although an inhibition in T cell proliferation was 
observed in Tranilast treated animals and two out of the three treated animals 
exhibited the kinetics of a memory response on donor rechallenge (Figure 59a); the 
overall proliferation counts were greater than the vehicle control treated animals. 
Moreover, animals who were treated with Tranilast alone (T alone) and had had no 
primary challenge exhibited greater T cell proliferation than animals who had 
received no treatment (No injection). It is difficult to ascertain whether this effect is 
real or just experimental variation. It does suggest however that Tranilast treatment 
did not induce donor-allospecific T cell anergy in this study, although it is possible 
that the dose and duration of Tranilast used was insufficient to induce tolerance.  
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Figure 59- Tranilast fails to induce donor-alloantigen specific T cell anergy in vivo. 
BALB/c mice were treated with (3 separate mice T1-T3) Tranilast (400 mg/kg/day) or 
with vehicle control for a total of 5 days (one day prior to splenocyte injection and 4 
days thereafter). 8x106 LPS stimulated C3H/He splenocytes were injected 
intravenously into the BALB/c mice (non-injected mice were also used as controls). 
After 10 days, spleen-purified CD4+ T cells from the injected mice were rechallenged 
in vitro (at a 1:5 DC : T cell ratio) with (A) donor C3H/He LPS stimulated 
splenocytes or (B) third party C57BL/6 LPS stimulated splenocytes and proliferation 
assessed by thymidine incorporation on days 3, 5 and 7. Data represent mean ± SD of 
triplicate samples. 
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6.2.7 Systemic administration of Tranilast results in prolongation of corneal allograft 
survival 
Given the ability of Tranilast to inhibit allogeneic T cell responses in vitro we went on 
to determine whether systemic administration of Tranilast resulted in prolonged C3H 
corneal allograft survival in BALB/c recipients. Tranilast was administered at 400 
mg/kg i.p. on a daily basis on days 1-16 post-transplant. This dose was based on 
previous published studies (Inglis et al., 2007). Control animals were given the same 
volume of vehicle on days 1-16 post-transplant (n=10/group). Tranilast administration 
resulted in significant prolongation in graft survival in comparison to controls (MST 
24 days vs 12 days, p<0.0001, Figure 60). As well as delaying the onset of rejection, a 
delay in vascularisation (new blood vessel growth) of the grafted corneas was 
observed in the Tranilast treated group (Figure 61a-d- for illustrative purposes).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60- Effect of systemic Tranilast administration on corneal allograft survival. 
BALB/c (H2d) mice received unilateral C3H (H2k) donor corneal allografts and i.p. 
injections of Tranilast were administered at a dose of 400 mg/kg/day on days 1-16 
post-transplantation (n=10/group). There was significant prolongation of graft 
survival in the Tranilast treated group (MST 23.5 days, p<0.0001) in comparison to 
controls (MST 11.5 days).  
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Figure 61- Tranilast treatment delays onset of allograft rejection as well as delaying 
the onset of neovascularisation of recipient and donor cornea. 
Systemic Tranilast treatment (A&B) resulted in a delay in the onset of rejection as 
well as a delay in vascularisation (new blood vessel growth-arrows) in comparison to 
controls (C&D). 
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6.2.8 Systemic administration of Tranilast results in prolongation of skin allograft 
survival 
The markedly significant prolongation in corneal allograft survival observed after 
Tranilast treatment led us to investigate whether this effect would be observed in other 
transplant models. As mentioned in section 1.3, corneal allograft rejection is 
predominantly mediated by the indirect pathway of allorecognition owing largely to 
paucity of passenger class II+ APC in donor cornea. Skin allograft rejection however, 
is mediated by the direct pathway due to the abundance of APCs in the skin as well as 
the strong MHC expression and represents a more aggressive transplant model. We 
used a fully MHC mismatched with multiple minor mismatch donor-recipient strain 
combination, C57BL/6 male donors to BALB/c male recipients, which have a similar 
rejection kinetic to the C3H/He to BALB/c corneal transplant model (a fast rejecting 
donor-recipient strain combination, with a MST of ~12 days). Animals were treated 
with Tranilast at a dose of 400 mg/kg/day i.p. on days 1-15 and days 1-30 post-
transplant to compare the effect of short as well as long term treatment on allograft 
survival. Control animals were given the same volume of vehicle on days 1-15 post-
transplant (n=5/group). 
Systemic Tranilast administration resulted in a significant prolongation in skin 
allograft survival in both the short and long term treatment groups (MST= 17 and 21 
days respectively) in comparison to controls (MST= 13 days, p<0.03, Figure 62). 
There was however no significant difference between short- and long-term treatment 
on skin allograft survival.  
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Figure 62- Effect of systemic Tranilast administration on skin allograft survival. 
Skin transplants were carried out in C57BL/6 male donors to BALB/c male recipients, 
a strain combination, which has a similar rejection kinetic to the C3H/He to BALB/c 
corneal transplant strain combination. Animals were treated with Tranilast at a dose of 
400 mg/kg/day i.p. on days 1-15 and days 1-30 post-transplant to compare the effect 
of short as well as long term treatment on allograft survival. Control animals were 
given the same volume of vehicle on days 1-15 post-transplant (n=5/group). 
Systemic Tranilast administration resulted in a significant prolongation in skin 
allograft survival in both the short and long term treatment groups (MST= 17, p<0.03 
and 21 days, p<0.0001 respectively) in comparison to controls (MST= 13 days). 
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6.3 Discussion 
Tranilast (3,4-DAA), a natural anthranilic acid derivative, is currently licensed for use 
as an anti-allergy drug in humans in Japan (Komatsu et al., 1988b). Initially, it was 
found to inhibit mast cell degranulation and the antigen-induced release of histamine 
(Azuma et al., 1976) and hence its development for the treatment of allergic diseases. 
Its safety has been established in greater than fifteen years of clinical use.  
Recently it has been shown to be effective in a mouse model of EAE (Platten et al., 
2005) and CIA (Inglis et al., 2007), both studies demonstrating its potent 
immunosuppressive effects on T cell proliferation in a manner similar to that of the 
structurally related kynurenines. Having shown the effectiveness of kynurenines in 
prolonging allograft survival, the aim of this study was to assess whether Tranilast 
would be effective in preventing allograft rejection. 
We confirmed that similar to the kynurenines, Tranilast inhibited T cell proliferation 
but not through cytotoxic effects; rather possibly through immunoregulatory 
mechanisms by demonstrating a minor increase in the percentage of CD4 cells 
expressing FoxP3 in the presence of a low concentration of Tranilast. Higher 
concentrations of Tranilast inhibited T cell proliferation by inducing cell cycle arrest. 
Previously, it has been shown that the Tranilast induced T cell cycle arrest is at the 
G1-S phase (Platten et al., 2005). We confirmed that this is indeed the case by 
demonstrating a novel action in the upregulation of p21 and p15, cell cycle specific 
inhibitors that bind and inhibit cyclin E-Cdk2 complexes in late G1 phase.  
The irreversible progression of a cell to S phase entry occurs at the G1 restriction 
point and is characterised by activation of cdk2 and synthesis of cyclin E (Sherr and 
Roberts, 1995). We demonstrated a decrease in cyclin E protein expression with 
increasing Tranilast concentration, further supporting the cell cycle arrest to be at the 
G1-S phase. 
Reports on p21 and its role in cell cycle arrest are well documented with three 
different mechanisms identified: 
1) Increased levels of p21 can bind and inactivate cyclin D-Cdk4, 6 and cyclin E-
Cdk2 complexes, resulting in hypophosphorylation of pRB and subsequent 
cell cycle arrest (Harper et al., 1995). 
2) p21 is a potent inhibitor of PCNA, which can inhibit DNA polymerase delta, 
the principal replicative DNA polymerase. Inhibition of PCNA by p21 has 
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been reported to inhibit the cell cycle in both G1 and G2 phases in Jurkat T 
cells (Lorens et al., 2000). 
3) p21 can block the cell cycle via inhibition of JNK. Dagtas et al. showed that 
p21 interacted with members of the MAPK pathway, specifically p-JNK and 
p-c-jun, resulting in an inhibition in proliferation and IL-2 secretion in anergic 
Th1 cells (Selma Dagtas and Gilbert, 2010). 
Another striking observation not reported previously is the dose-dependent decrease 
in the pro-inflammatory cytokine IL-2 that was observed following Tranilast 
treatment. This allowed us to define a novel mechanism of action of Tranilast-induced 
T cell anergy most likely working through triggering of the MAPK pathway as 
described in point 3 above. 
Having elucidated a novel mechanism for the in vitro Tranilast induced T cell anergy, 
we showed a significant prolongation in both corneal and skin allograft survival 
following systemic administration. In vivo tolerance however was not achieved and 
may have been as a result of the short duration of Tranilast treatment. In corneal 
transplant recipients it was evident that continued therapy with Tranilast was 
associated with continued graft acceptance, rejection only occurring on cessation of 
therapy, although we did not look at long term treatment. This was not observed with 
the skin transplants however and may be a manifestation of the higher responder 
transplant model. The use of Tranilast in other disease models such as CIA showed 
that disease severity increased upon cessation of therapy, indicating that continued 
Tranilast treatment is necessary for therapeutic effect (Inglis et al., 2007). 
We know from previous published studies that the systemic doses of Tranilast used in 
this study (400 mg/kg/day) are equivalent to the doses which are known to be safe and 
effective in humans (Inglis et al., 2007). 
In conclusion, we have shown that Tranilast- a drug already in routine clinical use- is 
highly effective in prolonging allograft survival. We have confirmed that it inhibits T 
cell proliferation through cell cycle arrest and elucidated a novel mechanism for the in 
vitro Tranilast-induced T cell anergy. Its oral bioavailability and safe therapeutic 
profile make it an excellent novel candidate for the prevention of rejection. 
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6.3.1 Chapter Summary: 
The work in this chapter has demonstrated: 
• Tranilast inhibits T cell proliferation. 
• Tranilast does not induce T cell death and is associated with an increase in 
the percentage of CD4+ T cells expressing FoxP3 at low Tranilast 
concentration. Higher Tranilast concentration induces T cell cycle arrest. 
• Systemic Tranilast administration results in a significant prolongation in 
allograft survival. 
• A novel mechanism of action of Tranilast induced T cell anergy. 
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7.1 Introduction 
Recently, Th17 cells have been shown to be implicated in allograft rejection of solid 
organs, (see section 1.4.7.5.). There has only been one report in the literature which 
demonstrated a pathogenic role of IL-17 at the early stage of corneal allograft 
rejection. The authors demonstrated significantly enhanced Th17 expression in 
inflamed transplants and draining lymph nodes early on in allocorneal rejection, while 
upregulation of Th1 producing IFNγ was seen in the late phase. Furthermore, they 
showed that IL-17 deficiency led to a delay in the onset of allogeneic rejection, but 
did not affect the overall survival time of transplants (Chen et al., 2009).  
Conversely, Cunnusamy et al. recently showed that depletion of IL-17A significantly 
increased corneal allograft rejection rates and that inhibition of the Th17 lineage 
promoted the emergence of a Th2 cell subset that independently mediated allograft 
rejection. They provide evidence that IL-17A may in fact contribute to ocular immune 
privilege, demonstrating high IL-17A expression from CD4+ T cells taken from mice 
who had accepted their corneal allografts (Cunnusamy et al., 2010).  
As described in section 1.4.7.3, the AhR has been shown to be expressed in high 
levels in Th17 cells. Environmental pollutants such as dioxin are the most extensively 
characterised classes of AhR ligands, however, the fact that the AhR is highly 
conserved in evolution supports the idea of there being other more naturally occurring 
ligands that drive its functions (Nguyen and Bradfield, 2008). An example of such a 
ligand is the tryptophan photo-product 6-formylin-dolo (3,2-b) carabazole (FICZ) 
(Veldhoen et al., 2009). In fact tryptophan can be converted by a variety of 
mechanisms into AhR ligands and inducers of AhR-dependent gene expression 
(Denison and Nagy, 2003). 
Veldhoen et al. have shown that AhR activation as well as promoting the expression 
of IL-22, enhances Th17 cell development and increases cytokine production 
(Veldhoen et al., 2009). Furthermore, in vivo studies using a model of experimental 
autoimmune encephalomyelitis have shown premature onset of disease and more 
severe pathology, as well as a reduction in the number of Th17 cells, in Ahr null mice 
in comparison to wild type (Veldhoen et al., 2008). Despite AhR not being an 
essential requirment for Th17 differentiation, its activation promotes further 
functional differentiation in these cells.  
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Interestingly, it has been shown that FICZ, an endogenous AhR ligand mentioned 
above affects Th17 differentiation. FICZ has been shown to markedly increase the 
number of Th17 cells and their production of cytokines through activation of the AhR 
(Veldhoen et al., 2008, Veldhoen et al., 2009). 
 
 Based on the above information, we postulated that kynurenines and Tranilast 
could act as AhR agonists and induce AhR signalling transduction pathways, which 
could increase IL-17 expression and that this could provide another plausible 
explanation for the prolongation in allograft survival observed after both kynurenine 
and Tranilast treatment. 
 
7.1.1 Chapter aims: 
The aims of the work presented in this chapter were to: 
 
1) Investigate IL-17 expression in cornea. 
2) Determine if kynurenines and Tranilast could act as AhR agonists and induce 
AhR signalling transduction pathways. 
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7.2 Results 
7.2.1 Corneal IL-17 expression is upregulated in corneal allograft rejection 
In order to determine the likelihood of a role of IL-17 in corneal allograft rejection, 
we examined IL-17 mRNA expression in rejected corneas. Murine corneal allografts 
were excised after the onset of rejection (n=8/group), corneas from non-operated mice 
were used as controls, and RNA extracted. IL-17A mRNA expression in cornea was 
subsequently assessed by quantitative, real time-RT-PCR. There was a doubling of 
expression of IL-17A as well as of RORγt (a Th17 transcription factor) in rejected 
versus control corneas (Figure 63a,b), a finding which was reproducible on repeated 
experiments. Direct immunohistochemistry for Il-17A expression of corneal cryostat 
sections was also compared in rejected and non-operated corneas: there was an 
apparent increase in intracellular IL-17A expression in corneal epithelium in rejected 
vs. non-operated corneas although we had no positive control for comparison (Figure 
63c). A finding of interest, not previously reported, was basal expression of IL-17A in 
non-operated corneas from BALB/c strain mice, exactly which resident cells would be 
producing this remains unclear. In order to establish definitively whether or not 
resting corneas expressed IL-17, corneal IL-17A expression between IL-17 KO and 
wild type (WT) mice was compared. As the IL-17 KO was only available on a 
C57BL/6 background, expression was compared with a C57BL/6 IL-17 WT. 
Expression was assessed at the mRNA level by real time-RT-PCR, by direct 
immunohistochemistry and by flow cytometry of corneal cells (Figure 64a-c). In this 
strain we found i) no IL-17 mRNA expression in the corneas from the WT or the KO 
mice, ii) no difference in the pattern of immunohistochemical staining of IL-17A 
between the WT and KO mice and iii) flow cytometric analysis of IL-17A expression 
in corneal cells from WT and KO mice showed no IL-17A expression. Corneal IL-
17A mRNA expression in the C3H strain of mouse was also assessed and no basal IL-
17 expression was found (data not shown).  The evidence therefore points to a lack of 
IL-17A expression in unmodified corneas tested other than the BALB/c strain.  
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Figure 63- IL-17A expression in cornea 
(A) IL-17A mRNA expression in rejected vs non-operated corneas. Mouse corneal 
allografts were excised after onset of rejection (n=8/group), corneas from non-
operated mice (Normal) were used as controls, and RNA extracted. Intracorneal IL-
17A and RORγt mRNA expression was subsequently assessed by quantitative, real 
time-RT-PCR. (B) Separation of IL-17A PCR products on 1.5% agarose gel (DNA 
Hyperladder IV used and RNA from Th17 cells was used as a positive control for IL-
17A expression). 
(C) Whole eyes from normal cornea and rejected allografts were enucleated on the 
day of observed rejection and snap frozen in OCT compound. Tissues were 
cryosectioned and stained with FITC-coupled monoclonal anti-mouse IL-17A 
antibody as well as its isotype control. The slides were counterstained with DAPI and 
visualised under a fluorescent microscope. Original magnification (x10). 
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Figure 64- Corneal IL-17A expression in IL-17 KO vs WT mice 
(A) Corneal IL-17A mRNA expression- 4 corneas from both C57BL/6 IL-17A WT 
and KO mice were excised, RNA extracted and corneal IL-17A mRNA expression 
subsequently assessed by quantitative, real time-RT-PCR, the PCR products were 
separated on a 1.5% agarose gel (DNA Hyperladder IV used).  
(B) Whole eyes from IL-17 KO and WT mice were enucleated and snap frozen in 
OCT compound. Tissues were cryosectioned and stained with FITC-coupled 
monoclonal anti-mouse IL-17A antibody and its isotype control and visualised under 
a fluorescent microscope. Original magnification (x10). 
(C) Corneal buttons from 3 IL17 WT and KO mice were treated with Collagenase D 
and a single cell suspension prepared. Cells were subsequently stimulated with PMA, 
Ionomycin and Brefeldin A for 3.5 hours prior to intracellular IL-17A staining and 
analysed by flow cytometry.  
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7.2.2 Kynurenines and Tranilast act as AhR agonists, inducing AhR signalling 
transduction pathways 
Recent data emphasising the role of AhR activation in the development of Th17 cells 
as well as demonstrating the tryptophan photoproduct, FICZ being a potent enhancer 
of Th17 differentiation (Veldhoen et al., 2009) led us to assess whether kynurenines 
or Tranilast could act as AhR agonists, inducing AhR signalling pathways.  
The structure and signalling pathway of the AhR was recently reviewed (Stevens et 
al., 2009). The AhR belongs to the Per-Arnt-Sim (PAS) superfamily of proteins. It is a 
ligand-activated transcription factor and structural analysis shows it to consist of three 
components: an N-terminal basic helix loop helix (bHLH) domain, a C-terminal 
variable domain and a central PAS domain with two degenerate repeats. The central 
PAS domain of the AhR is responsible for heterodimerisation with a structurally 
related protein known as the aryl hydrocarbon receptor nuclear translocator (ARNT), 
DNA recognition, ligand binding and chaperone interactions. The N-terminal, bHLH 
domain is involved in DNA binding and support of dimerisation. The C-terminal 
domain is highly variable and accounts for differences in receptor molecular weight 
within and across species. This region also contains a transcriptionally active portion 
and domains involved in receptor transformation. When unbound, the AhR exists in 
complex with its chaperones heat shock protein 90 (Hsp 90), P23 and aryl 
hydrocarbon receptor associated 9 protein (ARA9) within the cytoplasm. Hsp90 is 
responsible for both holding the receptor in a form able to bind ligand and preventing 
nuclear translocation of the AhR. P23 as a cochaperone stabilises the AhR-Hsp90 
interaction, while the ARA9 protein improves AhR signalling by increasing the 
amount of properly folded AhR in the cytoplasm. Once bound with agonist, the AhR-
chaperone complex translocates to the nucleus and binds the ARNT protein. The 
AhR:ARNT heterodimer initiates the transcription of genes from dioxin-responsive 
enhancer elements (DREs) within the genome. These primary targets are commonly 
referred to as the ‘AhR gene battery’. The list of members of the AhR gene battery 
continues to expand but includes those that encode xenobiotic metabolising enzymes, 
such as cytochromes P450 (CYP1A1), CYP1A2, CYP1B1 and UDP 
glucoronsyltransferase 1 family polypeptide A6 (UGT1A6). Collectively these 
enzymes are well known for their important roles in the clearance of toxins (Stevens 
et al., 2009). 
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Therefore, in order to assess whether kynurenines or Tranilast utilised the AhR 
signalling transduction pathway, naïve CD4+ T cells isolated by FACS sorting using a 
MoFlo sorter of lymph node cell suspensions for CD44lo CD25- CD62Lhigh and CD4+ 
were polarised under Th17 conditions in the presence or absence of 10 µM of 
Tranilast or 3HK. Cells were collected at the following time points, 0, 18, 24 and 36 
hrs and mRNA expression of AhR, ARNT, CYP1A1 and IL-17A assessed using real 
time RT-PCR. In order to ensure that the correct Th17 polarising conditions were 
used, naïve CD4+ T cells polarised under Th17 conditions in IMDM for 7 days were 
then stimulated with PMA, Ionomycin and Brefeldin A for 4 hours on day 7 after 
initiation of cultures and intracellular staining for IL-17, IFNγ and FoxP3 performed. 
The conditions used, polarised the naïve CD4+ T cells to a Th17 phenotype with no 
differentiation into a Th1 or Treg phenotype (Figure 65). 
It was evident that naïve CD4+ T cells did not express AhR or the remainder of the 
components of the AhR signalling pathway (Figure 66a) but when polarised under 
Th17 conditions expression of AhR was maximal after 18 hrs (Figure 66a) and 
dropped after 24 hrs (Figure 66b). ARNT expression was maximal after 24 hours 
(Figure 66b) and no IL-17 expression was seen at any of the time points. In the 
presence of 3HK or Tranilast, a similar kinetic of AhR and ARNT expression was 
observed but what was most interesting was the IL-17 expression noted at the 36 hour 
time point in both the presence of 3HK and Tranilast (Figure 66g). This suggested that 
3HK and indeed Tranilast could act as agonists of the AhR, utilising the AhR 
signalling transduction pathway and that similar to FICZ they were also potent 
enhancers of Th17 differentiation.  
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Figure 65- Th17 polarisation of Naïve CD4+ T cells. 
Naïve CD4+ T cells isolated by FACS sorting using a FACSaria sorter of lymph node 
cell suspensions for CD44lo CD25- CD62Lhigh and CD4+ were polarised under Th17 
conditions in IMDM for 7 days. Cells were then stimulated with PMA, Ionomycin 
and Brefeldin A for 4 hours on day 7 after initiation of cultures and intracellular 
staining for IL-17, IFNγ and FoxP3 performed. Representative dot plots of three 
independent experiments are shown. 
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Figure 66- 3HK and Tranilast act as AhR agonists utilising the AhR signalling 
pathway. 
Naïve CD4+ T cells isolated by FACS sorting using a MoFlo sorter of lymph node cell 
suspensions for CD44lo CD25- CD62Lhigh and CD4+ were polarised under Th17 
conditions in the presence or absence (-) of 10 µM of Tranilast (T) or 3HK. Cells 
were collected at the following time points, 0 (A) (naïve CD4+ T cells, N), 18 (A), 24 
(B-D) and 36 hrs (E-G) and mRNA expression of AhR, ARNT, CYP1A1 and IL-17A 
assessed using real time RT-PCR. The PCR products separated on a 1.5% agarose gel 
for each time point and condition is shown under the corresponding dissociation 
curve. Results are of one experiment representative of four independent experiments. 
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7.3 Discussion 
The recent finding by Cunnusamy et al. showing increased rejection of corneal 
allografts following depletion of IL-17A and the suggestion that IL-17A has a 
probable role in ocular immune privilege (Cunnusamy et al., 2010) led us to 
investigate whether or not corneas exhibited basal IL-17 expression. We found no 
constitutive corneal IL-17A mRNA expression with the exception of the BALB/c 
mouse strain. This observed lack of basal corneal IL-17 expression is not in keeping 
with the suggested direct role of IL-17 in ocular immune privilege. However a 
functional role in immune privilege may be explained by IL-17 production by 
activated immune cells which are not present in resting corneas. 
IL-17 is produced not only by adaptive, but also by innate immune cells such as NKT 
cells (Rachitskaya et al., 2008). These are unique cells of the innate immune system 
that express both NK lineage markers, such as NK1.1 and CD49b/DX5 in mice and 
CD56 in humans, with a TCR (Godfrey et al., 2004) and are characterised by their 
ability to rapidly produce immunoregulatory cytokines, such as IL-4 and IFNγ, upon 
engagement of their TCR (Bendelac et al., 2007). Rachitskaya and colleagues recently 
showed that NKT cells are responsible for an early, rapid, IL-6 independent IL-17 
response and that this is due to their constitutive expression of IL23R and RORγt, 
similar to memory T cells but unlike NK and naïve T cells (Rachitskaya et al., 2008). 
NKT cells have a reported role as participants in the process of eye-induced tolerance 
(Sonoda and Stein-Streilein, 2002b), contributing to ocular immune privilege and 
therefore the connection between NKT cells, IL-17 and ocular immune privilege still 
remains possibile. 
A role for AhR signalling in the functioning of the immune system is becoming 
increasingly evident as previously discussed. AhR null animals have been shown to 
have altered lymphocyte numbers in the spleen as well as enlarged spleens (Schmidt 
et al., 1996, Fernandez-Salguero et al., 1995) and have been shown to be more 
susceptible to Listeria infection (Ward et al., 2007). A role for AhR signalling in 
Tregs has been reported by at least four independent laboratories (Quintana et al., 
2008, Marshall et al., 2008, Hauben et al., 2008, Kimura et al., 2008) and a role for 
AhR activation in the development of Th17 cells as well as a tryptophan photoproduct 
being a potent activator of Th17 differentiation has recently been reported (Veldhoen 
et al., 2008). Our preliminary results show 3HK and Tranilast to be AhR agonists 
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utilising the AhR signalling pathway. Most interestingly, 3HK and Tranilast treated 
naïve CD4+ T cells showed increased IL-17 expression in comparison to naïve CD4+ 
T cells alone, indicating, similar to FICZ, their role as potent enhancers of Th17 
differentiation. Whether or not the increased IL-17 expression could explain the 
observed prolongation in allograft survival in response to both 3HK and Tranilast 
treatment remains to be investigated. Our results however are preliminary: a more 
definitive method of investigating the effects of 3HK and Tranilast on Th17 
differentiation would be to incubate naïve CD4+ T cells for longer (such as 8 days) 
under Th17 polarising conditions in their presence or absence, and then assessing IL-
17 expression by intracellular staining using flow cytometry. Financial restrictions 
and time limitation did not allow for this. 
Interestingly, in support of the preliminary findings above are the results of a recent 
study by Mezrich et al. showing kynurenine and to a lesser extent 3HK to be a potent 
AhR agonist, but inducing the generation of FoxP3+ Tregs, rather than effector Th17 
cells, in an AhR-dependent manner (Mezrich et al., 2010). Although the concept of 
one AhR agonist diverting T cells towards regulators and another, generating effectors 
is unusual, multiple studies have confirmed the importance of the AhR in Th17 
development as mentioned previously in section 7.1. It appears therefore, that AhR 
activation with different ligands can lead to entirely different outcomes depending on 
the surrounding milieu. Not only this, but Nguyen etal. demonstrated only recently 
that the AhR has a kynurenine-dependent immunoregulatory role in DCs by showing 
that in a T cell: BMDC co-culture system; Ahr -/- BMDCs inhibited the development 
of Tregs from naïve CD4+ T cells but with the addition of synthetic L-kynurenine, 
naïve T cells differentiated into Tregs (Nguyen et al., 2010).  
Another explanation for our observed Th17 induction via the AhR following 3HK and 
Tranilast treatment may be due to the fact that we performed assays in media rich in 
aromatic amino acids (IMDM) rather than in a low tryptophan media as used by 
Mezrich and colleagues (Mezrich et al., 2010). It has been shown that media richer in 
aromatic amino acids, which give rise to AhR agonists, supports higher Th17 
expansion than medium with low amino acid content (Veldhoen et al., 2009). The 
presence of other AhR agonists may shift the balance toward an effector response 
rather than toward generation of regulatory cells. 
These findings open an interesting avenue for further research particularly because we 
did not look at Treg induction in this set of experiments. Furthermore, this provides 
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another possible explanation for the prolongation of allograft survival in response to 
both 3HK and Tranilast observed in our models. The hypothesis of Tranilast inducing 
its immunoregulatory effects via the AhR has not been previously investigated or 
reported. 
 
 
 
 
7.3.1 Chapter Summary: 
The work in this chapter has demonstrated: 
• Lack of basal corneal IL-17A expression 
• 3HK and Tranilast to be agonists of AhR, utilising the AhR signalling 
pathway and increasing IL-17 expression. 
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CHAPTER 8- GENERAL DISCUSSION  
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8.1 Introduction 
Topical steroids are the mainstay of treatment in preventing or treating corneal graft 
rejection but are not without their associated sight-threatening side effects. More 
importantly, they can fail to prevent or reverse allograft rejection in a proportion of 
patients. Some corneal transplant recipients perceived at high risk of allograft 
rejection are reliant for prolonged graft survival on systemic immunosuppression, the 
adverse effects of which cannot be justified in many patients in whom vision is 
normal in the contralateral eye (Reis et al., 1999, George and Larkin, 2004, Chatel and 
Larkin, 2010). Consequently there is a need for more specific immunomodulatory 
interventions that would allow the opportunity of a corneal transplant in those high 
rejection risk patients in whom it is currently considered unjustified or denied. 
Moreover, systemic immunosuppression is not successful as rejection prophylaxis in 
all corneal transplant recipients, even at the doses used following solid organ 
transplantation (Chatel & Larkin 2010). The effect of transplant antigen matching 
(HLA –A, -B and –DR) has been under investigation in corneal recipients since the 
1970s without the convincing benefit in outcomes evident in renal transplantation.  
Alternative investigative interventions have been studied in experimental models of 
corneal transplantation for many years. One recent body of work summarised 
previously (section 1.4.8) is ex vivo transduction of the donor cornea with gene 
sequences, which has been demonstrated to be feasible using adenoviral, lentiviral, 
herpes and adeno-associated viral vectors in a range of different species (George et 
al., 2000, King et al., 2000, Larkin et al., 1996, Gong et al., 2006, Xie et al., 2003). 
However, while viral vectors are highly efficient, they can be immunogenic and pro-
inflammatory, and in at least one study vector controls have shortened graft survival 
when compared with untreated corneal grafts. Furthermore, the oncogenic potential of 
viral vectors and the recent cases of leukaemia have blunted the enthusiasm of many 
for viral vector-mediated gene therapy (Yanez-Munoz et al., 2006). Therefore, there 
remains a need for alternative strategies and approaches to introduce 
immunomodulatory agents. 
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8.2 Summary of Major Findings 
In this project I have shown that kynurenines, in particular 3HK, have an 
immunoregulatory role, specifically suppressing the T cell response as a result of T 
cell death. Whether administered systemically or topically, kynurenines result in 
prolongation in graft survival and explain in part one mechanism by which IDO 
prolongs graft survival. More importantly, I have shown that they are not pathogenic 
to corneal endothelial cells. I have shown that a synthetic, commercially available 
tryptophan analogue, Tranilast, is effective in prolonging allograft survival; this effect 
results from its inhibition of T cell proliferation through cell cycle arrest and I have 
characterised a novel potential mechanism for Tranilast induced T cell anergy. The 
importance of the fact that this agent is commercially available and in clinical use in 
allergic disease is that there would be few regulatory hurdles to its introduction in 
transplantation in the event that it were found in large animal or other preclinical 
studies to be effective in delaying rejection. In addition, I have shown that contrary to 
published data, UVB irradiation of cornea upregulates IDO at the mRNA level but not 
at the protein or functional level and demonstrated that murine corneas do not basally 
express the IDO isoform IDO-2.  Prelimanary findings indicate murine corneas to lack 
basal expression of IL-17 and that both kynurenines and Tranilast can act as agonists 
of the AhR, utilising the AhR signalling pathway and increasing IL-17 expression. 
 
8.3 Discussion of the Major Findings 
8.3.1 The effect of kynurenines on corneal graft survival 
One of the major aims in transplantation immunology is the induction of donor-
specific transplantation unresponsiveness (tolerance) in the recipient, where a short-
term immunomodulatory treatment would induce indefinite graft survival.  
There has been speculation on the role of IDO and kynurenines in T cell regulation. 
Of particular interest is whether IDO+ DCs can induce the expression of the enzyme 
in neighbouring IDO- DCs via induction of Tregs as a mechanism of infectious 
tolerance (Mellor et al. 2004), or whether kynurenines can directly induce a regulatory 
T cell phenotype from naïve CD4+ T cells (Munn et al., 2004b, Fallarino et al., 
2006a). Data generated both in vitro and in vivo during the course of this project has 
demonstrated the ability of kynurenines to specifically suppress T cell responses as 
well as prolong allograft survival. This supression of T cell proliferation was as a 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 217 
result of T cell death rather than via a regulatory phenomenon. Although 3HK 
resulted in modest induction of Tregs in vitro, this was not translated in vivo, where 
there was no difference between splenic CD4+ FoxP3 expression and splenic CD4+ T 
cell function after systemic 3HK treatment in comparison to controls. In the context of 
allotransplantation, a moderate prolongation in allograft survival was observed after 
both systemic and topical 3HK treatment but not long term graft acceptance; the 
exception was a small number of topical 3HK-treated grafts, which could be 
explained by the finding of increased FoxP3 expression locally in topical 3HK-treated 
grafts versus controls. These findings are in keeping with other work carried out in 
our laboratory by Khan et al (manuscript in submission) who demonstrated that IDO-
transduced DCs fail to induce and/or expand T reg populations both in vitro and in 
vivo; this being in contrast to DCs expressing the intracellular fusion protein CTLA4-
KDEL (resulting in intracellular retention of CD80/86). Furthermore, they showed 
indefinite survival of corneal allografts in mice injected with CTLA4-KDEL DCs, 
consistent with a tolerance induction mechanism mediated by the induction of Tregs, 
whereas only a moderate prolongation of corneal allograft survival was observed in 
mice injected with IDO DCs, consistent with a deletional mechanism resulting from 
the apoptosis of alloreactive T cells after localised tryptophan depletion. 
Current literature investigating the effects of IDO expression and kynurenines on 
allograft survival corroborates with our findings with moderate prolongation in graft 
survival being demonstrated but not tolerance. 
One explanation regarding the lack of in vivo donor-specific T reg induction by 
kynurenines reported in this thesis is that Tregs are generated at tryptophan 
concentrations within a narrow range - see section 5.2.5. The concentrations used in 
the in vivo studies may have been higher than the concentrations used in studies that 
have reported the generation of Tregs after the incubation of T cells with tryptophan 
catabolites. 
It is important to note that the C3H/He (H2k) → BALB/c (H2d) donor-recipient strain 
combination used in this study is a high-responder allogeneic combination, with 
median corneal graft survival in untreated graft recipients of 12 days. Moreover it is a 
robust rejection model in that almost all donor corneas are rejected at 12±1 days post-
transplantation. In contrast, reported survival times in BALB/c recipients of C57BL/6 
(H2b) donor corneas (the most common donor-strain combination reported in the 
literature) is 5 weeks (Yamagami et al., 2002). Irrespective of the reasons behind this 
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observed difference in survival between different MHC mismatch combinations, 
experimentation in a high-responder combination is a useful strategy for evaluating 
immunomodulation with great therapeutic potential in patients at high rejection risk 
(Watson et al., 2006). 
 
8.3.2 The effect of Tranilast on allograft survival 
The use of Tranilast in transplantation has not been previously reported. As mentioned 
in section 1.5.7.1, Tranilast which is prepared from the constituents of the leaves of 
the nandina plant (Ogawa et al., 2010) is currently licensed for human use as an anti-
allergy agent in Japan because of its anti-inflammatory effects; inhibiting mast cell 
degranulation and histamine release (Azuma et al., 1976). It has however, also been 
shown to inhibit vascular smooth muscle proliferation and hence inhibit allograft 
vasculopathy in association with enhanced p21 expression on neointimal cells (Izawa 
et al., 2001). The protein product of the Waf1/Cip1 gene, p21, is identified as a 
universal inhibitor for cyclin-dependent kinases (Xiong et al., 1993, Harper et al., 
1993), which are essential for cell progression through the G1-S check point. In this 
research, we took this further and showed that this Tranilast induced upregulation of 
p21 was responsible for arrest of T cells at the G1-S phase and rendered T cells 
anergic through inhibition of IL-2 release, allowing us to characterise a novel 
mechanism of Tranilast induced T cell anergy. 
Following on from this, we showed a significant prolongation in both corneal and skin 
allograft survival following systemic Tranilast administration. Whether or not this was 
due to the induction of Tregs remains to be investigated, as at the doses administered 
we did not induce tolerance although we did observe Treg induction in vitro at low 
Tranilast concentration. Tranilast inducing Treg development is a novel finding in 
itself and warrants further investigation and as is discussed later in section 8.3.3 this 
maybe mediated through activation of the AhR. 
Having demonstrated that Tranilast - a drug already in routine clinical use - is 
effective in prolonging allograft survival makes it an excellent novel candidate for the 
prevention of rejection, particularly because a topical preparation of Tranilast exists 
and has recently been shown to be effective in the management of dry eye secondary 
to chronic GVHD (Ogawa et al., 2010). A phase II clinical trial (NCT00882024) 
looking at the efficacy of Tranilast in the treatment of active Rheumatoid arthritis has 
just been completed and its results are awaited. 
Sarah Zaher, Section of Immunobiology, Department of Medicine, Imperial College London 219 
8.3.3 Kynurenines, the Aryl hydrocarbon receptor and Th17 cells 
A role for AhR signalling in the functioning of the immune system is becoming 
increasingly evident as previously discussed. AhR null animals have been shown to 
have altered lymphocyte numbers in the spleen as well as enlarged spleens (Schmidt 
et al., 1996, Fernandez-Salguero et al., 1995) and have been shown to be more 
susceptible to Listeria infection (Ward et al., 2007). A role for AhR signalling in 
Tregs has been reported by at least four independent laboratories (Quintana et al., 
2008, Marshall et al., 2008, Hauben et al., 2008, Kimura et al., 2008) and a role for 
AhR activation in the development of Th17 cells as well as a tryptophan photoproduct 
(FICZ) being a potent activator of Th17 differentiation has recently been reported 
(Veldhoen et al., 2008). Data from others and ourselves show kynurenines to directly 
induce Tregs but the mechanism for this was not clear (Fallarino et al., 2006a, Zaher 
et al., 2011). Preliminary work presented in this study shows 3HK and Tranilast to be 
AhR agonists utilising the AhR signalling pathway and we know that the AhR has 
been shown to be required for optimal Treg differentiation.  Recent data has now 
emerged supporting our findings where it has been shown that kynurenine and to a 
lesser extent 3HK to be potent AhR agonists, but inducing the generation of FoxP3+ 
Tregs, rather than effector Th17 cells, in an AhR-dependent manner (Mezrich et al., 
2010).  
The question as to why different ligands of the AhR produce different effects, e.g. 
FICZ enhancing Th17 differentiation (Veldhoen et al., 2008) and L-kyn enhancing 
Treg differentiation (Mezrich et al., 2010) is an interesting one and Mezrich et al. 
hypothesised that this maybe due to the fact that kynurenine itself maybe 
enzymatically modified by the cytochrome P450 enzymes that are induced by the 
AhR whereas FICZ may not. The product of this modification may then directly lead 
to FoxP3 induction as opposed to a direct effect of the kynurenine itself. This may 
well be true for Tranilast as well. 
These findings bring together nicely all parts of the research carried out in this thesis 
and provide a plausible explanation for the observed prolongation in graft survival 
after both 3HK and Tranilast treatment as well as accounting for the direct induction 
of Tregs seen following both 3HK and Tranilast treatment in vitro. It opens an 
interesting avenue of research, particularly because the possibility of Tranilast 
mediating its immunreglatory effects via AhR signalling has never been previously 
investigated or reported. 
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Moreover, what is most intriguing is that the AhR is also reported to contribute to 
normal physiological processes during cell growth and differentiation (Schmidt and 
Bradfield, 1996). In cultured cells, several studies suggest that the activation of the 
AhR is involved in cell cycle arrest in the absence or presence of exogenous agonists. 
Kolluri et al. have shown that AhR activation with TCDD delays cell-cycle 
progression through the G1 phase by increasing p27Kip1 mRNA (Kolluri et al., 1999). 
Han et al. have shown that AhR activation with laminar fluid shear stress induces cell 
cycle arrest in vascular endothelial cells by increasing p21 mRNA and protein 
(Akimoto et al., 2000, Han et al., 2008). Work presented in this thesis indicating 
Tranilast to be an AhR agonist, utilising the AhR signalling pathway and inducing T 
cell cycle arrest as a result of upregulation of the cell cycle inhibitors p21 and p15, 
could possibly indicate a role for AhR in Tranilast-induced cell cycle arrest.  
 
8.4 Future strategies 
8.4.1 Future possibilities with kynurenines in corneal transplantation 
Although we did not observe longterm graft acceptance after either topical or 
systemic 3HK treatment, one wonders whether combination and prolonged therapy 
would have been more promising. 
Also one wonders whether combination therapy with genetic modulation of DCs to 
overexpress IDO combined with exogenous systemic 3HK treatment may have been 
more effective in inducing graft tolerance. Dai et al. recently showed that a single IV 
injection of 3HAA together with allogeneic DCs seven days before cardiac grafting 
markedly prolonged graft survival (Dai and Zhu, 2009). 
Kynurenines have also been used effectively in the treatment of experimental models 
of allergic airway inflammation (Taher et al., 2008) as well as a mouse model of 
collagen induced arthritis (CIA) (Criado et al., 2009). This suggests that kynurenines 
may have a wider therapeutic role in ophthalmology, other than corneal 
transplantation, e.g. in the treatment of ocular inflammatory disorders such as uveitis, 
a T cell mediated process, which can be associated with significant ocular morbidity. 
The kynurenine molecule (208 Da) is well below the size of molecule that can 
penetrate to the corneal stroma (Brereton et al., 2005). This therefore makes it 
attractive as a potential topical treatment. 
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8.4.2 Future possibilities with Tranilast 
Having shown that Tranilast is effective in prolonging allograft survival is very 
promising not only in the field of corneal transplantation but allotransplantation as a 
whole given our additional findings of prolonged graft survival in a skin transplant 
model. Investigating its efficacy in treatment of ocular inflammatory disorders is also 
warranted particularly as there has been one study demonstrating amelioration of 
experimental uveoretinitis by a single injection of dioxin, an established AhR agonist 
(Zhang et al., 2010). This provides real impetus to take Tranilast into larger animal or 
preclinical studies, particularly as it is already commercially available and in clinical 
use in allergic disease. 
Findings from this thesis characterising a novel mechanism for Tranilast induced T 
cell anergy and indicating a possibility that this maybe due to tranilast induced p21 
upegulation blocking the cell cycle through inhibition of JNK (Selma Dagtas and 
Gilbert, 2010) warrants further investigation.  
Our preliminary data showing Tranilast to be an AhR agonist and potentially 
mediating its immunoregulatory effects via the AhR pathway again warrants further 
investigation to help elucidate further its molecular mechanism of action. 
 
8.4.3 Evolving understanding of the AhR pathway and its ligands 
There is emerging evidence including the findings from this thesis that helps to 
explain the direct effects of kynurenines on Treg and Th17 development via the AhR 
pathway. The ability of different AhR ligands to produce different effects is intriguing 
and requires further investigation to help elucidate the exact molecular responses 
elicited after binding of different agoinsts to the AhR.  
Emerging evidence of the AhR playing a key role in the differentiation of T cells is 
supported by findings from this thesis and as this pathway is further characterised, it 
will enhance our understanding of T cell differentiation and yield new strategies of 
modulating the balance between regulatory and effector responses using ligands of the 
AhR. 
 
8.4.4 Conclusion 
Collectively, the data represented in this thesis helps to explain the effects of IDO and 
kynurenines in prolonging corneal allograft survival. The role of the AhR in T cell 
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differentiation and the fact that it is generally believed that T cell differentiation 
depends on the interaction between DCs and T cells, with IDO playing a role in this 
(Grohmann et al., 2002) helps to shed light on the direct mechanism of IDO which has 
been controversial. The identification of a commercially available drug effective in 
prolonging corneal allograft survival may prove a useful adjunct or alternative to 
topical corticosteroids that can be transferred from the laboratory to clinical practice. 
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3-Hydroxykynurenine Suppresses CD4 T-Cell
Proliferation, Induces T-Regulatory-Cell Development,
and Prolongs Corneal Allograft Survival
Sarah S. Zaher,1 Conrad Germain,1 Hongmei Fu,1 Daniel F. P. Larkin,1,2
and Andrew J. T. George1,2
PURPOSE. IDO (indoleamine 2,3-dioxygenase) modulates the
immune response by depletion of the essential amino acid
tryptophan, and IDO overexpression has been shown to pro-
long corneal allograft survival. This study was conducted to
examine the effect of kynurenines, the products of tryptophan
breakdown and known to act directly on T lymphocytes, on
corneal graft survival.
METHODS. The effects of kynurenines on T-cell proliferation and
death, T-regulatory-cell development, and dendritic cell func-
tion, phenotype, and viability were analyzed in vitro. The effect
of topical and systemic administration of 3-hydroxykynurenine
(3HK) on orthotopic murine corneal allograft survival was
examined.
RESULTS. T-lymphocyte proliferation was inhibited by two of
the four different kynurenines: 3HK and 3-hydroxyanthranilic
acid (3HAA). This effect was accompanied by significant T-cell
death. Neither 3HK nor 3HAA altered dendritic cell function,
nor did they induce apoptosis or pathogenicity to corneal
endothelial cells. Administration of systemic and topical 3HK
to mice receiving a fully mismatched corneal graft resulted in
significant prolongation of graft survival (median survival of
control grafts, 12 days; of treated, 19 and 15 days, respectively;
P  0.0003). While systemic administration of 3HK was asso-
ciated with a significant depletion of CD4 T, CD8 T, and B
lymphocytes in peripheral blood, no depletion was found after
topical administration.
CONCLUSIONS. The production of kynurenines, in particular 3HK
and 3HAA, may be one mechanism (in addition to tryptophan
depletion) by which IDO prolongs graft survival. These mole-
cules have potential as specific agents for preventing allograft
rejection in patients at high rejection risk. (Invest Ophthalmol
Vis Sci. 2011;52:2640–2648) DOI:10.1167/iovs.10-5793
Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting en-zyme in the catabolism of tryptophan and is mainly ex-
pressed by antigen-presenting cells and in the placenta.1,2 It is
present at low levels in healthy individuals, but production
markedly increases during infection or inflammation, being
induced by cytokines, lipopolysaccharide (LPS), or other
agents.3–6 Early literature documents the ability of IDO to
inhibit the proliferation of microbes and tumor cells in vitro
through consumption of the essential amino acid tryptophan.7
In 1998, Munn et al.8 proposed a further role for IDO, suggest-
ing that IDO-dependent suppression of T-cell responses might
function as a natural immunoregulatory mechanism, based on
data showing that IDO regulates maternal T-cell immunity
during pregnancy. So far, physiological IDO activity has been
implicated as an effector mechanism for the immunosuppres-
sive reagent CTLA4-Ig fusion protein,9 in T-cell tolerance to
tumors,2,10–12 in dysfunctional self-tolerance in nonobese dia-
betic (NOD) mice,13 as a protective negative regulator in au-
toimmune disorders,14–16 and as an inhibitor in an induced
model of asthma.17
While it is clear that IDO suppresses T-cell responses, the
exact mechanism has not been fully elucidated. T cells are
particularly sensitive to tryptophan deprivation.18 At low tryp-
tophan concentrations, cell cycle progression is arrested at
mid-G1 phase. Restoration of tryptophan to arrested cells,
along with a second round of T-cell receptor signaling, reverses
the state of nonreactivity and induces cell cycle progression.
These and other observations led to the hypothesis that the
main mechanism by which IDO inhibits T-cell proliferation is
the depletion of tryptophan. However, it is also known that
the kynurenines resulting from tryptophan catabolism,
which include L-kynurenine (Kyn), 3-hydroxykynurenine
(3HK), 3-hydroxyanthranilic acid (3HAA), and quinolinic
acid (QA), can themselves inhibit T-cell activation and pro-
liferation.19,20 Kynurenines have proapoptotic properties
particularly for activated cells and Th1 lymphocytes,21,22
and the molecular mechanisms of apoptosis have been char-
acterized in murine thymocytes.21 In monocyte/macrophage
cell lines, 3HAA can also induce apoptosis by production of
hydrogen peroxide.23
The combined effect of tryptophan degradation and increas-
ing concentration of kynurenines has been shown to be re-
sponsible for GCN2 kinase–mediated downregulation of the
TCR-chain in CD8 cells, reducing their cytotoxic effector
function.24 In addition, long-term tryptophan depletion with
increased production of tryptophan metabolites promotes con-
version of naïve CD4CD25 T cells into a regulatory pheno-
type.24 There has only been one report on the effect of local
administration of 3HAA and Kyn in a model of skin transplan-
tation, in which prolongation of graft survival by 2 days was
found.25
Having previously shown that IDO can be expressed in the
cornea during inflammation, including allograft rejection and
that overexpression of IDO in murine corneas prolongs allo-
graft survival,26 we examined whether kynurenines can mod-
ulate the allogeneic response to a corneal transplant. In this
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study, we show that systemic 3HK administration results in
prolonged corneal graft survival and is associated with a deple-
tion of the circulating lymphocyte count in peripheral blood.
The kynurenine molecule (208 Da) is well below the size of
molecule that can penetrate to the corneal stroma.27 There-
fore, using these agents as a topical treatment may be a sim-
pler, more effective approach to preventing graft rejection
than gene-based therapy. In this study, we demonstrate that
topical 3HK administration also results in prolonged corneal
graft survival and is associated with moderate depletion of the
lymphocyte count in the draining lymph node (DLN).
MATERIALS AND METHODS
Murine Corneal Endothelial Cells
A murine corneal endothelial cell (MCEC) line, a kind gift from Jerry
Niederkorn, (University of Texas Southwestern Medical Center, Dallas,
TX), was maintained in DMEM supplemented with 100 U/mL penicil-
lin-streptomycin, nonessential amino acids (Invitrogen-Gibco, Paisley,
UK) and 10% heat-inactivated fetal bovine serum (Invitrogen-Gibco).
Generation and Culture of Murine Bone Marrow–
Derived Dendritic Cells
The hind limbs, tibia, and femur, were collected in PBS and the BM
cavities flushed out to obtain a single cell suspension. The cells were
pelleted and red blood cells were lysed with red blood cell (RBC) lysis
solution (Flowgen, Nottingham, UK). The cells were pelleted and put
in RPMI 1640 medium supplemented with 10% FCS, 100 U/mL peni-
cillin, 100 g/mL streptomycin, 2 mM L-glutamine, and 50 M -mer-
captoethanol (Invitrogen) in the presence of a 1:30 dilution of culture
medium obtained from a GM-CSF-producing hybridoma.28 DCs were
cultured at 37°C with 5% CO2 until day 7. The DC culture medium was
replaced with fresh GM-CSF-containing medium on day 3, and half of
the culture medium was replaced with fresh GM-CSF-containing me-
dium on day 6. To generate mature DCs, the cultures were stimulated
for 16 hours with 1 g/mL LPS (Sigma-Aldrich, Dorset, UK) on day 7.
DC and MCEC Phenotyping
Immature DCs taken at day 7, mature DCs at day 8, and MCECs were
incubated with the individual kynurenines at a concentration of 100
M for 24 hours. Kyn, 3HK, and 3HAA (Sigma-Aldrich) were dissolved
in 1 M HCl as a carrier and QA (Sigma-Aldrich) dissolved in 1 M NaOH.
After the cells were washed, they were incubated with 1 g/L
unconjugated rat anti-mouse and with MHC class II (BD Biosciences-
Pharmingen, Oxford, UK), CD80, and CD86 (Invitrogen-Caltag) for
DCs; MHC class II, ICOS-L, PDL-1, and ICAM-1 (all BD-Biosciences) for
MCECs; and rat anti-mouse IgG2a (R&D Systems, Abingdon, UK) as an
isotype control for both, for 30 minutes. After three washes, the cells
were incubated with goat anti-rat PE-conjugated secondary antibody
(BD Biosciences-Pharmingen) for 30 minutes. Staining was analyzed on
a flow cytometer (FACSCalibur; BD Biosciences).
T-Cell Proliferation Assays
Splenocytes from BALB/c mice were treated with a mixture of anti-
CD45R/B220, anti-CD8, and anti-MHC class II supernatants (RA3–3A1,
M5/114, 53.6.7, and 2.4G2) for 30 minutes. After antibody treatment,
the cells were washed and incubated with goat anti-mouse IgG and
goat anti-rat IgG-coated beads (Dynal, Bromborough, UK) for 30 min-
utes, and bound cells were removed with a magnet (CD4 T-cell purity
85%–90%). Responder CD4 T cells (1  105 cells/well) were stimu-
lated with anti-mouse CD3 and CD28 beads (mouse CD3/CD28 T-cell
expander; 1 bead/cell; Dynabeads; Dynal) or allogeneic BM-derived
C3H (H-2k) DCs at a ratio of 10:1 (1  105 CD4 T cells: 1  104 DCs)
in the presence of tryptophan metabolites in 96-well plates for 3 days.
Proliferation was measured by a 16-hour pulse with [3H]thymidine
(Amersham, Buckinghamshire, UK).
Tryptophan Metabolites
The main metabolites resulting from IDO-induced degradation of tryp-
tophan are generally known as kynurenines and comprise N-formyl-
kynurenine, kynurenine (Kyn), 3-hydroxykynurenine (3HK), 3-hy-
droxyanthranilic acid (3HAA), and quinolinic acid (QA). To determine
the inhibitory concentration, we tested the tryptophan metabolites in
a titration series. Kyn, 3HK, 3HAA, and QA (Sigma-Aldrich) with a
purity 98% were dissolved in RPMI 1640 medium (Invitrogen-Gibco)
and added to the cell cultures in different concentrations ranging from
0 to 100 M (pH of final cell culture medium, 7.5–8.5).
Detection of Cell Death
CD4 T cells (1  105 cells/well) were stimulated with CD3/CD28
beads (1 bead/cell) in the presence of Kyn, 3HK, 3HAA, or QA (100 M
concentration) individually for 3 days and MCECs for 24 hours. The
Cells were then stained with FITC-labeled annexin V and 7-AAD (BD
Biosciences), according to the manufacturer’s instructions.
Detection of Regulatory T-Cells
CD4 T cells were activated by CD3/CD28 beads, in low tryptophan (5
M)–containing medium in combination with 3HK, 3HAA, Kyn, or QA
(0–100 M) for 3 to 7 days. The cells were stained with an APC
anti-mouse/rat FoxP3 staining kit (eBioscience, Gloucestershire, UK)
after permeabilization and analyzed by flow cytometry.
Calculation of Absolute Cell Counts from Spleen,
Peripheral Blood, and DLN
Splenocytes, PBMCs, and lymphocytes (from the DLN) taken from
mice after systemic and topical 3HK administration (or controls) were
stained with rat anti-mouse CD4-FITC, CD8-peridinin chlorophyll pro-
tein (PerCP), and CD19-phycoerythrin (PE) (AbCam, Cambridge, UK).
For absolute cell counts, cell counting beads (Perfect-count Micro-
spheres; Cytognos SL, Salamanca, Spain) were used according to the
manufacturer’s instructions.
RNA Extraction, Reverse Transcription, and
Quantitative PCR
Corneal tissue was ground using the beads and reagent supplied in a kit
(Fast RNA Pro Green Kit; QBiogene, Carlsbad, CA). RNA extraction and
quantification were performed as previously described.29 Quantitative
PCR was performed as previously described,26 and FoxP3 mRNA was
performed with the paired primers 5-CACCCAGGAAAGACAG-
CAACC-3 (forward) and 5-GCAAGAGCTCTTGTCCATTGA-3 (re-
verse) spanning 314 bp of the FoxP3 gene. Transcripts were normal-
ized to levels of hypoxanthine phosphoribosyl transferase (HPRT)
mRNA. Quantification of HPRT mRNA was performed using the paired
primers 5-GTAATGATCCAGTCAACGGGGGAC-3 (forward) and 5-
CCAGCAAGCTTGCAACCTTAACCA-3 (reverse).
Corneal Transplantation
Orthotopic corneal transplantation of fully mismatched C3H strain
or syngeneic BALB/c donor corneas was undertaken in inbred
BALB/c (6–10-week-old) mouse recipients (Harlan Olac UK, Bices-
ter, UK). The animals were maintained in a specific pathogen-free
facility and treated in accordance with the U.K. government regu-
lations for care of experimental animals and with the ARVO State-
ment for the Use of Animals in Ophthalmic and Vision Research.
Transplantation was performed in the right eye of all animals as
originally described,30 with minor modifications.31 Corneal graft
transparency was graded on a scale of 0 to 4 as described.31
Rejection was diagnosed when the opacity score reached or ex-
ceeded 3 in a previously transparent cornea.
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Kynurenine Treatment of Graft Recipients
Stock 3HK was dissolved in PBS and administered intraperitoneally (IP)
560 mg/kg on a daily basis on days 1 to 7, days 7 to 14, or days 1 to 14
after surgery. Control animals were given the same volume of vehicle
from days 1 to 14. For topical application, a total dose of 3HK of 0.165
mg was dissolved in 30 L 0.9% NaCl eye drops (final pH 2.5–3.0) and
administered twice daily on days 3 to 14 after surgery after removal of
the protective eyelid suture. This was the highest tolerated topical
dose, having been tested on nonsurgical eyes of BALB/c mice for 5
days. This dose is a molar equivalent and is based on one third of the
total dose used in systemic administration. Control animals were given
the same volume of vehicle.
Statistical Analyses
The mean of triplicate values and associated standard deviations were
calculated for all T-cell proliferation data. Statistically significant differ-
ences were calculated with a two-tailed t-test. Differences in graft
survival were analyzed with a log rank test and plotted according to the
Kaplan-Meier method. P 0.05 was regarded as statistically significant.
RESULTS
The Tryptophan Metabolites 3HK and 3HAA
Inhibit Murine T-Cell Proliferation In Vitro
To confirm the effect of tryptophan metabolites on murine
allogeneic T-cell responses, we added the metabolites at vari-
ous concentrations to purified CD4 T cells that were stimu-
lated with anti-CD3/CD28 beads and proliferation determined
using 3H thymidine incorporation. CD4 T cells were exam-
ined as corneal graft rejection is mediated predominantly by
this subset.32 As shown in Figure 1, addition of 3HK and 3HAA
significantly inhibited CD4 T-cell proliferation in a dose-de-
pendent manner with IC50 of approximately 70 and 30 M,
respectively, when compared with T cells incubated in vehicle
alone. A minimal effect with Kyn was observed, and no
effect was seen with QA. Similar data were obtained when
the T cells were stimulated with allogeneic dendritic cells in
a mixed lymphocyte response (Supplementary Fig. S1,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.10-
5793/-/DCSupplemental).
3HK and 3HAA Induce CD4 T-Cell Death
There are several possible mechanisms by which 3HK and
3HAA may influence T-cell responses. These include the induc-
tion of T-cell death or the induction of T regulatory cells
(Tregs). To investigate cell death, we stimulated CD4 T cells
with anti-CD3/CD28 beads in the presence of the kynurenines
(0–100 M) for 24 hours and cell death assessed by flow
cytometry after staining with 7-AAD and annexin V. Both 3HK
and 3HAA induced significant CD4 T-cell-mediated cell death
in a dose-dependent manner, whereas neither QA nor Kyn did
(Fig. 2). Furthermore, as previously reported,21 we found 3HAA
to be more potent than 3HK; inducing apoptosis at concentra-
tions as low as 25 M compared with 100 M for 3HK.
FIGURE 1. Effect of kynurenines on
T-cell proliferation. CD3/CD28 bead–
stimulated CD4 T cells were incu-
bated for 72 hours in the presence of
kynurenines (3HK, 3HAA, Kyn, and
QA) at concentrations varying from 0
to 100 M. Proliferation was measured
by 3H-thymidine incorporation. (f)
Vehicle control; () kynurenine. The
data represent the mean  SD of trip-
licate cultures. Results shown are rep-
resentative of four experiments. *P 
0.005, versus the control.
FIGURE 2. Effect of kynurenines on T-cell death. CD3/CD28 bead
activated CD4 T cells were incubated with or without kynurenines
for 72 hours. Cytotoxicity was evaluated by flow cytometry after
vital staining with 7AAD. Data represent the mean  SD of triplicate
samples. Results shown are representative of three experiments.
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Tryptophan Metabolites Induce a T-Regulatory-
Cell Phenotype from the Whole CD4
T-Cell Population
Expression of FoxP3 correlates with suppressor activity in
CD4 T cells.33 Fallarino et al.34 demonstrated that naïve CD4
FoxP3 T cells, which are resistant to kynurenine-induced
apoptosis, can convert into CD4FoxP3 cells by a GCN2-
dependent mechanism after incubation with kynurenines.34
We looked at the effect of the kynurenines on the number of
FoxP3 cells from the whole CD4 T-cell population. CD4 T
cells were stimulated with anti-CD3/CD28 beads in the pres-
ence of the kynurenines (10–100 M) for 3 and 7 days. As
shown in Figure 3A, there was no difference in the proportion
of CD4 cells expressing FoxP3 in the presence of any of the
kynurenines after 3 days. However, after 7 days (Fig. 3B), there
was a significant increase in the proportion of CD4 cells
expressing FoxP3 in the presence of all the kynurenines at the
10-M concentration, flow histograms of 3HK and 3HAA data
are also shown (Supplementary Fig. S2, http://www.iovs.org/
lookup/suppl/doi:10.1167/iovs.10-5793/-/DCSupplemental).
This suggests that lower concentrations of kynurenines are
necessary to induce T-regulatory cells (Tregs), in keeping with
earlier reports.34 Of note, at the 100-M concentration, there
was a reduction in the percentage of FoxP3-expressing cells
after both 3 and 7 days in the presence of 3HK and 3HAA, but
not QA or Kyn. The possible reasons for this are discussed
below.
Tryptophan Metabolites Do Not Alter DC
Function or Phenotype
We speculated that kynurenines could modify DC biology in an
autocrine manner. We assessed the effect of the individual
kynurenines on both immature and mature DCs by co-incuba-
tion for 24 hours, followed by washing. The DCs were then
used in mixed lymphocyte reactions to investigate their ability
to stimulate CD4 T cells; stained for CD80, CD86, and class II
cell surface markers to identify phenotype; and assessed for
viability by flow cytometry after vital staining with 7-AAD. We
showed that incubation with kynurenines did not alter the
phenotype of either immature or mature DCs (data shown for
3HK only; Fig. 4A), did not alter their ability to stimulate CD4
T cells (Figs. 4B, 4C), and had no effect on their viability (data
not shown). Similarly, kynurenines were not pathogenic to
corneal endothelial cells and did not alter phenotype or viabil-
ity (Supplementary Figs. S3, S4, http://www.iovs.org/lookup/
suppl/doi:10.1167/iovs.10-5793/-/DCSupplemental).
Systemic Administration of 3HK Prolongs Murine
Corneal Allograft Survival
Given the ability of 3HK and 3HAA to suppress allogeneic
T-cell responses in vitro, we went on to determine whether
administration of 3HK resulted in prolonged C3H corneal allo-
graft survival in BALB/c recipients, in which strain combination
there is full MHC and multiple minor mismatches. 3HK was
administered at 560 mg/kg IP on a daily basis on days 1 to 7,
days 7 to 14, or days 1 to 14. This dose was chosen, as in
preliminary experiments higher doses resulted in an observed
lack of activity in treated animals. The early (days 1–7) and late
(days 7–14) administration were chosen, to compare the effect
of 3HK on the induction and effector phases of the allogeneic
response. Control animals were given the same volume of
vehicle from days 1 to 14. Median survival time (MST) of
allogeneic C3H corneas was 12 days in untreated BALB/c re-
cipients, whereas syngeneic corneas survived indefinitely and
administration of the vehicle had no effect on survival (MST, 11
days). 3HK administration resulted in significant prolongation of
graft survival whether administered between days 1 to 7 (MST, 18
days; P 0.036), days 7 to 14 (MST 19 days; P 0.0003), or days
1 to 14 (MST 18 days; P  0.0037). There was no significant
difference between the 3HK-treated groups (Fig. 5).
Systemic Administration of 3HK Depletes Both
Splenic and Peripheral Blood Lymphocytes
To determine whether 3HK alters the number of lymphocytes,
we administered 3HK for 14 days (according to the same
regimen) to animals that did not receive a graft. This treatment
did not result in any significant change in the weight of the
spleen (data not shown), but did result in a statistically insig-
nificant reduction in the number of splenic CD4 and CD8 T
cells and CD19 B cells (Fig. 6A); this was a consistent obser-
vation in repeated experiments. There was no alteration in the
proportion of splenic CD4 cells expressing FoxP3 (Fig. 6B).
Furthermore, it did not alter the proliferative capacity of CD4
T cells after stimulation with CD3/CD28 beads (Fig. 6C). There
was a significant reduction in the number of CD4 and CD8
T cells and CD19 B cells in peripheral blood (Fig. 6D).
Topical Administration of 3HK Results in
Prolongation of Corneal Allograft Survival
We went on to determine whether topical administration
might prolong graft survival. 3HK (0.165 mg) was administered
FIGURE 3. FoxP3 expression in CD4 T cells cultured with kynure-
nines. CD4 T cells were activated with CD3/CD28 beads, with or
without kynurenines. At 3 (A) and 7 (B) days, the cells were recovered
and the percentage of CD4 T cells that were FoxP3 was quantified
by intracellular flow cytometry. Data represent the mean  SD of
triplicate samples. *P  0.005, experimental versus T cells alone.
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twice daily on days 3 to 14 after transplantation. Control
animals were given the same volume of vehicle. Treated ani-
mals had a significant prolongation in graft survival (MST, 15
days; P  0.0001) compared with untreated or vehicle alone
(MST, 12; 11 days). In addition, a minority of animals (3/15)
showed long-term survival (50 days; Fig. 7).
The corneal grafts of mice that had received topical 3HK
treatment, as well as those of the controls, were excised after
the onset of rejection (n  8/group), and RNA was extracted.
Corneal FoxP3 mRNA expression was subsequently assessed
by quantitative real-time RT-PCR. There was a marked upregu-
lation of FoxP3 expression in 3HK versus vehicle control–
treated corneas (Fig. 8).
In mice that did not receive a graft, topical administration of
3HK did not alter the splenic or peripheral blood lymphocyte
count (Figs. 9A, 9B), but did result in a moderate, albeit insig-
nificant generalized reduction in the lymphocyte count of the
DLNs (Fig. 9C). The DLNs assessed were the deep cervical and
submandibular nodes, which have been shown to be the ocu-
lar DLNs.35 There was minimal difference in the proportion of
CD4 cells expressing Fox P3 in the DLNs (Fig. 9D).
DISCUSSION
Ever since it was reported that IDO can prevent rejection of
the fetus during pregnancy in mice,8 there has been consider-
able interest in elucidating the role of this enzyme in immuno-
regulation. In the context of transplantation, tryptophan catab-
olism has been shown to suppress alloimmune responses.
IDO-expressing DCs suppress allogeneic T-cell proliferation in
vitro via tryptophan metabolites,19 and the latter inhibit allo-
geneic T-cell responses both in vitro and in vivo.25 There has
been no investigation, however, as to how tryptophan metab-
olites exert their in vivo effect. In this study, we have investi-
gated whether the tryptophan metabolites given either locally
or systemically can modulate corneal allograft survival.
We confirmed that 3HK and 3HAA suppressed CD4 T-cell
proliferation in vitro, related to death of the T cells rather than
FIGURE 4. Effect of kynurenines on function and phenotype of DCs. (A) Mature and immature bone marrow–derived DCs were incubated with
3HK at a concentration of 100 M for 24 hours, and expression of CD80, CD86, and MHC class II expression was quantified by flow cytometry
(solid line: 3HK; dashed line: vehicle control; dotted line: DCs alone). The isotype control is represented by the solid profile. Mature (B) and
immature (C) bone marrow-derived DCs were incubated with the individual kynurenines () as well as their vehicle controls (f) at concentrations
ranging from 0 to 100 M for 24 hours, subsequently washed, and then used to stimulate allogeneic CD4 T cells in a mixed lymphocyte reaction
and proliferation measured by [3H]thymidine incorporation. Data represent the mean  SD of triplicate cultures. Results shown are representative
of three experiments.
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Treg development. Previously, Fallarino et al.24,34 showed a
large increase in the proportion of naïve CD4 FoxP3 express-
ing cells in the presence of the kynurenines (70% vs. 2%
controls), we showed only a moderate increase (8% vs. 2%
controls) in the whole CD4 T-cell population. This result may
relate to differences in the populations studied. It is recognized
that naïve T cells are more resistant to kynurenine-induced
apoptosis than are effector CD4 T cells.21 We found a reduc-
tion in FoxP3 expression in CD4 T cells at the higher con-
centrations of 3HK and 3HAA after 3 and 7 days of incubation.
This decrease could be because Tregs are more sensitive or it
may be an indirect effect as, for example, it has been shown
that CD4CD25 FoxP3 T cells are extremely sensitive to
two common cell metabolites that are released from necrotic
cells: NAD and ATP.36 However, given the kinetics of Treg
development, they will not contribute significantly to the inhi-
bition of T-cell proliferation seen in vitro, where the major
mechanism of action is the death of the responding cells.
Consistent with previous reports, we demonstrated that
DCs are resistant to kynurenine-induced apoptosis.19,21 Taking
this further, we showed that the function and phenotype of
DCs is not altered in the presence of kynurenines. It is inter-
esting to speculate why DCs are resistant to kynurenines. It
may be the result of cell-specific uptake mechanisms or differ-
ential expression of enzymatic breakdown pathways.20,37 It is
known that DCs metabolize tryptophan through the kynure-
nine pathway, as demonstrated by immunohistochemical stain-
ing of the presence of quinolinic acid, the penultimate product
of the kynurenine pathway.38 Furthermore, it has been shown
that 3HAA-induced T-cell death is as a result of inhibition of
NF-B activation on T-cell receptor engagement by specifically
targeting PDK1.39 The same investigators showed that the
induction of apoptosis is specific to CD4 T cells, as 3HAA did
not inhibit NF-B activation or induce cell death on Toll-like
receptor-4 stimulation in dendritic cells.39 We also demon-
strated that there were no toxic effects of either IDO or
FIGURE 5. Effect of systemic administration of 3HK on murine corneal
allograft survival. BALB/c (H2d) mice received unilateral C3H (H2k)
donor corneal allografts, and IP injections of 3HK were administered at
a dose of 560 mg/kg/d according to three different treatment regimens:
on days 1 to 7, 1 to 14, and 7 to 14 after transplantation. There was
significant prolongation of graft survival in all treatment groups; n  7
(MST, 18, 18, and 19; P  0.036, P  0.0003, and P  0.0037,
respectively) in comparison to the controls (MST, 11 days). Indefinite
survival was observed in the untreated syngeneic grafts (BALB/c-BALB/c).
FIGURE 6. Splenic and peripheral
blood analysis after daily IP administra-
tion of 3HK. Animals (n  3) received
systemic IP 3HK 560 mg/kg/d for 14
days consecutively, after which the
spleens were removed and (A) abso-
lute counts of CD4, CD8, and CD19
assessed by using counting beads.
(B) The cells were stained intracellu-
larly for Fox P3. (C) CD4 T cells iso-
lated and subsequently stimulated
with CD3/CD28 beads and prolifera-
tion assessed by 3H-thymidine incorpo-
ration. (D) Peripheral blood was taken
from the tail vein, and the absolute
number of CD4, CD8, and CD19 cells
was assessed by using counting beads.
*P 0.05, experimental versus vehicle
control. Data represent themean SD
of triplicate counts. Results shown are
representative of two experiments.
FIGURE 7. Effect of daily topical administration of 3HK on murine
corneal allograft survival. BALB/c (H2d) recipients of unilateral C3H
(H2k) donor corneal allografts were treated with topical 3HK or vehi-
cle in the surgical eye twice daily on days 3 to 14 after surgery. There
was a significant prolongation of graft survival in the 3HK treated
group; n  15 (MST, 15 days; P  0.0001) in comparison to controls
(MST, 11 days).
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kynurenines on corneal endothelial cells, in keeping with find-
ings demonstrating IDO to be part of the ocular immune
privilege.26,40 Furthermore, it has been recently demonstrated
that a tryptophan/kynurenine transporter protein exchange
mechanism (LAT1) is upregulated by inflammatory cytokines in
human corneal endothelial cells. This transporter would allow
rapid delivery of the cytotoxic tryptophan catabolites to the
local corneal environment, dampening T-cell responses,41
again suggesting a probable role for kynurenines in corneal
immune privilege.
Earlier reports on the effect of SC administration of 3HAA
and Kyn in a model of skin transplantation indicated a short
prolongation of graft survival.25 For the first time we dem-
onstrate that both systemic and topical administration of
3HK resulted in prolongation of graft survival. In the sys-
temic group, we administered 3HK IP in three different
regimens. Although we observed a longer median graft sur-
vival in the day 7- to 14-treated group, there was no signif-
icant difference between the three treatment regimens. De-
spite concern about administration of 3HK in vivo owing to
its neurotoxic potential,42,43 we did not observe any major
effect at the doses we administered. Furthermore, the sys-
temic doses administered (60 mg/L) are only 20 times higher
than the serum concentration of Kyn in rats or humans (3
mg/L).44 The longest survival of individual grafts (50 days)
was observed in the topical group in comparison to 30 days
in the systemic group. Direct application of drops to the
graft-recipient eye offer a more targeted treatment, reducing
possible systemic adverse effects.
To determine the effect of 3HK on lymphocyte counts we
examined mice that had had systemic administration of 3HK
for 14 days, finding a moderate although not statistically
significant reduction in the CD4, CD8 and B-lymphocyte
population of the spleen but a significant reduction in pe-
ripheral blood. This loss of lymphocytes could be as a result
of cell death, consistent with our in vitro findings, or due to
a redistribution of circulating lymphocytes to the bone mar-
row and/or transient arrest of recirculation, as has been
observed with corticosteroid treatment.45,46
While there is a small decrease in the number of cells, it is
not clear that such a small decrease would be responsible for
the prolongation of graft survival. However, the topical admin-
istration of 3HK resulted in a significant upregulation of cor-
neal FoxP3 mRNA expression in comparison to controls, sug-
gesting that regulatory pathways may therefore be involved.
Although significant prolongation in graft survival was ob-
served in both the topically and systemically treated groups
after a treatment duration of 14 days after transplantation,
longer duration treatment might have resulted in longer term
acceptance of grafts, as in other reported treatment studies in
this mouse model.47
FIGURE 8. FoxP3 mRNA expression in rejected corneal grafts. The
corneal grafts of mice that were not operated on (No Op) and those
that had received an allograft together with topical vehicle control
(VC) or 3HK treatment were excised after the onset of rejection (n 
8/group) and RNA extracted. Corneal FoxP3 mRNA expression was
subsequently assessed by quantitative, real-time RT-PCR. (A) Bar graph
showing corneal FoxP3 mRNA expression normalized to HPRT, as
assessed using qRT-PCR. Data represents mean  SD of triplicate
samples. (B) Separation of PCR products on 1.5% agarose gel. (1, VC;
2, 3HK; 3, Op-no treatment; 4, No Op).
FIGURE 9. Splenic, peripheral blood,
and draining lymph node analysis af-
ter daily topical administration of
3HK. Animals (n  3) received topi-
cal 3HK for 12 consecutive days, af-
ter which the spleens were removed
(A), peripheral blood was taken
(B), and lymphocytes from the DLNs
collected and absolute counts of
CD4, CD8, and CD19 assessed by us-
ing counting beads (C). Lymphocytes
from the DLNs were also stained in-
tracellularly for FoxP3 (D). Data rep-
resent the mean  SD of triplicate
counts.*P  0.01, treatment versus
vehicle control.
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In conclusion, our data show that 3HK and 3HAA induce
mouse T-cell suppression in vitro, primarily as a result of death
of the T cells, and that 3HK prolongs corneal allograft survival
whether administered by topical or systemic routes. These data
show that these molecules may be responsible in part for the
effect of IDO in preventing allograft rejection (although they
cannot determine the relative importance of kynurenine pro-
duction compared with tryptophan reduction). In addition, we
have demonstrated the potential for using kynurenine or
kynurenine-like molecules to prevent graft rejection.
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